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Abstract
Seamless phase II/III clinical trials are attractive in development of new drugs because
they accelerate the drug development process. Seamless phase II/III trials are carried out in
two stages. After stage 1 (phase II stage), an interim analysis is performed and a decision
is made on whether to proceed to stage 2 (phase III stage). If the decision is to continue
with further testing, some dose selection procedure is used to determine the set of doses to
be tested in stage 2. Methodology exists for the analysis of such trials that allows complete
flexibility of the choice of doses that continue to the second stage. There is very little work,
however, on optimizing the selection of the doses. This is a challenging problem as it
requires incorporation of the dose-response relationship, of the observed safety profile and
of the planned analysis method. In this thesis we propose a dose-selection procedure for
binary outcomes in adaptive seamless phase II/III clinical trials that incorporates the dose-
response relationship, and explicitly incorporates both efficacy and toxicity. The choice of
the doses to continue to stage 2 is made by comparing the predictive power of the potential
sets of doses which might continue to stage 2.
x
Chapter 1
Introduction
In drug development, clinical trials are categorized into three phases. Phase I is the stage
where the drug is first tested in human beings and the objective is to determine the safety of
the new drug. Phase I trials are small and several dose levels are generally tested. If a safe
dose (or dose range) is identified, the drug is then tested for efficacy in a small clinical trial.
Such a trial is referred to as a phase II clinical trial and like phase I, often more than one
dose level is tested. At the end of the phase II trial, a decision has to be made on the basis
of efficacy and safety data regarding which dose(s) proceeds to the next stage of testing.
The last stage of drug testing in human beings before submission for regulatory approval
is the phase III clinical trial which is a large confirmatory trial for efficacy. A review of
the statistical models used in design and analyses of data at each of the three phases of a
clinical trial is given in Chapter 3. Chapter 2 outlines the statistical tools needed in the
review of the statistical models used in each of the phases of a clinical trial.
In order to reduce the time before approval of a new drug, there has been interest in
combining different phases of a clinical trial. Trials which combine phase II and phase III
into a single trial with a phase II stage and phase III stage are referred to as (seamless) phase
II/III trials. Such trials are conducted in two stages. In stage 1 (phase II stage) of phase
1
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II/III trials, several hypotheses, such as comparing how the drug works in different sub-
populations or which doses are more efficacious than control treatment are tested. Based
on stage 1 data, subpopulation(s) or dose(s) which show promising results continue to
stage 2 (phase III stage) for further testing. At the end of stage 2, data from both stage 1
and stage 2 are used for the final confirmatory analysis. Although such phase II/III trials
save development time, they introduce statistical complexity associated with controlling
the type I error while testing multiple hypotheses and combining evidence from the two
phases. In Chapter 4 we describe how to address these issues.
In addition to the issues associated with testing phase II/III clinical trials, another
challenge raised by these trials is how to make the choice of the subpopulation(s) or the
dose(s) to continue to stage 2 after stage 1. This is the question considered in this thesis. In
Chapter 5, we develop a new method for dose selection in seamless phase II/III allowing
for the final analysis that incorporates the dose response relationship, the prior knowledge
and the stage 1 data. The dose selection procedure is evaluated using simulation studies in
Chapter 6.
The method for dose selection developed in Chapter 5 assumes that: (1) in both
stages binary outcomes are primary endpoints, (2) there is no uncertainty on the dose-
response relationship, and (3) the seamless phase II/III is monitored only once and there
are no opportunities for stopping early either for futility or for overwhelming evidence
of efficacy. In Chapter 7, we describe how in future work, we intend to address these
limitations. We end the thesis by discussing the main features of the new dose selection
procedure and stating the conclusions in Chapter 8.
Chapter 2
Statistical background
In this chapter we give background on some of the statistical tools that will be needed in the
rest of this thesis. The work in this thesis is based on binary outcomes, that is, occurrence
or non-occurrence of an event such as toxicity or a therapeutic effect. Hence statistical
tools reviewed in this chapter are demonstrated using binary outcomes. After describing
the technique of transformation of random variables in Section 2.1, we will describe how
to make Bayesian inference for a binary outcome parameter in Section 2.2. The chapter
ends by describing Bayesian decision theoretic techniques in Section 2.3.
2.1 Transformation of random variables
In this thesis, we will occasionally need to determine the distribution of a random vector
when we know the distribution of another random vector with which there is one-to-one
transformation. To do this, we will use the technique of transformation of random variables
that is described in several statistics text books such as in Chapter 11 of Roussas (2007).
In the rest of this section, we briefly review this technique. Let fX1,...,Xn(x1, ..., xn) be the
value of the joint probability density of the continuous random vector X = (X1, ..., Xn)′.
3
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Suppose the transformations y1 = φ1(x1, ..., xn), ..., yn = φn(x1, ..., xn) are respectively
partially differentiable with respect to x1, ..., xn and represent one-to-one transformations
for all values within the range of X for which fX1,...,Xn(x1, ..., xn) 6= 0, then for these val-
ues of (x1, ..., xn), the equations y1 = φ1(x1, ..., xn), ..., yn = φn(x1, ..., xn) are uniquely
solved for x1, ..., xn to give x1 = ψ1(y1, ..., yn), ...., xn = ψn(y1, ..., yn) and for the cor-
responding values of (y1, ..., yn), the joint probability density of Y = (φ1(X1, ..., Xn), ...,
φn(X1, ..., Xn))
′ is given by
fY1,...,Yn(y1, ..., yn) = fX1,...,Xn(ψ1(y1, ..., yn), ..., ψn(y1, ..., yn))|J |, (2.1)
where |J | is the determinant of the Jacobian of the transformation J given by
J =
∣∣∣∣∣∣∣∣∣
dψ1
dy1
... dψ1
dyn
.
dψn
dy1
... dψn
dyn
∣∣∣∣∣∣∣∣∣
.
For all the other values of (y1, ..., yn), fY1,...,Yn(y1, ..., yn) = 0.
2.2 Review of Bayesian principle
As mentioned above, we will mostly focus on clinical trials with binary outcomes. Exam-
ples of binary outcomes in clinical trials are (1) after treatment is administered to a patient,
the patient is successfully treated or not, and (2) after treatment is administered to a patient,
the patient experiences an adverse (or toxic effect) or not. In this chapter, we will use the
first example. We will assume successful treatment (success) after treatment is a Bernoulli
process that occurs with probability p, that is, the probability of success is p. The number
of successfully treated patients (sn) generated using the Bernoulli process after n subjects
have been entered in the trial will have a binomial distribution with parameters n and p,
that is Sn is Bin(n, p). The objective of the clinical trial is to make inference on p.
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A common feature of phase I and phase II trials is that they are small studies. This
means that the incorporation of information from outside the trial is particularly attractive.
This can be achieved by using the Bayesian principle in order to learn from previous ex-
perience. In this section, we demonstrate how to make Bayesian inference for a parameter
of interest such as the binomial parameter p. In contrast to the frequentist setting where p
is assumed to be fixed, in Bayesian statistics p itself is considered to be a random variable
whose distribution is continually updated as more data are collected. After data x are col-
lected, the updated distribution of p is referred to as the posterior distribution of p given x,
with the density that will be denoted by pi(p|x). The Bayesian principle is centered around
Bayes’ theorem. If p is the parameter of interest and data x are collected, Bayes’ theorem
is expressed as
pi(p|x) = l(p|x) · pi0(p)∫
l(p|x) · pi0(p)dp, (2.2)
where l(p|x) is the likelihood function of p given the data x and pi0(p) is the density of
the prior distribution of p before data x are observed. For binary outcomes, data can be
summarised by the number of successfully treated patients (sn) and the number of patients
entered in the trial (n) so that we may write l(p|sn, n) for l(p|x). Inference on p or a
function of p is then made using the posterior distribution. For example, the posterior mean
can be used to estimate the probability of success p.
When a prior distribution chosen for some parameter leads to a posterior distribution
of the same form as the prior distribution, the prior distribution is said to be a conjugate
prior. Conjugate priors are advantageous because they may lead to integrals which can
be evaluated using analytical methods. In general numerical integration techniques are
required to make inference using the posterior distribution. Expression (2.2) assumes a
single parameter p but this could be replaced by a vector. Gelman et al. (2004) describe
making inference for several models. In this chapter, we will focus on obtaining the prior
distribution for the probability of success based on a single treatment and for parameters in
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a logistic regression model.
2.2.1 Eliciting beta prior distribution for a Bernoulli parameter
The beta prior distribution is a conjugate prior for a Bernoulli process parameter such as
the probability of success p. The beta prior distribution for the binomial data parameter is
proposed in some clinical trial designs that will be reviewed in the next chapter and is also
used for research work outlined in the remainder of this thesis. For a Bernoulli process, the
likelihood function of p, the probability of success, after n patients have been treated and
sn successes have been observed is given by
l(p|sn, n) =
(
n
sn
)
psn(1− p)n−sn (sn = 0, 1, ..., n).
If we assume that p has a beta prior distribution with parameters a > 0 and b > 0, that is,
pi0(p) = Beta(p; a, b) =
pa−1(1− p)b−1
B(a, b)
, 0 < p < 1,
where B(a, b) is the beta function, then using equation (2.2), the posterior distribution of p
given (sn, n) is given by
pi(p|sn, n) = l(p|sn, n) · Beta(p; a, b)∫ {l(p|sn, n) · Beta(p; a, b)} dp
∝ pa+sn−1(1− p)b+n−sn−1
which is of beta form Beta(a+sn, b+n−sn). Hence a beta prior distribution is a conjugate
prior for a Bernoulli parameter.
The prior information is elicited from investigators and quantified into a relevant
distribution. For a beta prior distribution, the elicited information is quantified into a
beta distribution by using the elicited information to determine the parameters a and b in
Beta(p; a, b). For the rest of this subsection, we describe how this may be done. In addition
to being a conjugate prior for the binomial distribution parameter, a beta distribution has a
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number of attractive properties which make it appealing to use it as a prior distribution for a
binomial data parameter p. The domain of p in Beta(p; a, b) is [0, 1] which makes it sensible
to use a beta distribution as a prior for a binomial distribution parameter which itself has its
domain [0, 1]. As shown above, if a binomial distribution parameter p is assumed to have
a beta distribution Beta(p; a, b), the posterior distribution of p is Beta(a + sn, b+ n− sn),
where sn is the number of successfully treated patients after n patients have been admin-
istered a treatment. The mean of a random variable p that is Beta(a + sn, b + n − sn)
is
a + sn
a+ b+ n
. (2.3)
If a = b = 0, then expression (2.3) gives the proportion of successfully treated patients after
n patients have been entered in the trial. Thus the parameters of the beta prior distribution,
that is a and b, may be thought of as pseudo-data elicited such that the prior belief is
that if a + b patients were treated, a will be successfully treated so that the proportion
of successfully treated patients is a/(a + b). This proportion is then updated when data
(sn, n) are collected to give expression (2.3). Figure 2.1 shows beta densities with different
parameter values. The legends give the parameter values of the beta densities. For a beta
density with parameter vector (a, b) = (0.5, 10), most mass is at values of p close to 0
while for a beta density with parameter vector (a, b) = (10, 0.5), most mass is at values of
p close to 1. For a beta density with parameter vector (a, b) = (0.5, 0.5), probability mass
is concentrated at values of p close to 0 and 1. When p is Beta(1,1), the density is flat so
that this corresponds to Uniform[0,1]. When both parameters values are greater than 1, the
densities have a mode between 0 and 1. For example when p is Beta(2,8), p = 0.1 is the
mode. When a > 1 and b > 1 the mode is
a− 1
a + b− 2
so that when a→∞ or b→∞, the mean is approximately equal to the mode. Hence from
Figure 2.1, if the investigators do not have prior knowledge on p, the flat prior distribution
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Figure 2.1: Beta densities with different parameter values. The legends give the values of
the parameters.
is Beta(1,1) and prior densities with parameter value(s) less than 1 should be used with
care.
In addition to the mean value of the parameter of interest, the parameter values
chosen for its prior distribution should reflect the level of uncertainty (variance) associated
with the parameter of interest. The variance of p which is Beta(a, b) is given by
ab
(a+ b)2(a+ b+ 1)
,
so that different sets of a and b can result in the same mean but different variance. The
variance of the probability of success p in the density curve is exhibited by the spread of
the curve. Large values of variance (small values of a and b) lead to flat densities reflecting
limited knowledge while small values of variance (large values of a and b) lead to curves
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with high peaks at the mode reflecting more certainty on the true value of p. Accordingly,
Lindley and Phillips (1976) suggest referring to curves of the beta densities plotted for
different values of a and b during the elicitation process. In their paper, they give a good
discussion using an example of how to elicit and quantify a beta distribution. Figure 2.2
shows curves for different values of a and b but with the same mean (0.2). As the values of
a and b increase the peaks are higher and the mode moves closer to the mean 0.2. Thall and
Simon (1994) refer to Lindley and Phillips (1976) for the elicitation and quantification of
the beta distribution but they also introduce the idea of the width of the 90% interval (W90)
running from the 5% to 95% percentiles. An investigator is asked to provide the width of
an interval within which he/she is 90% confident p lies. A search is then carried out to
determine values of a and b such that the mean of p is a/(a+ b) and the difference between
the 95th quantile and the 5th quantile is equal to the specified value. The shorter the width
the more informative is the prior distribution since the density curves will be more peaked.
2.2.2 Prior distribution for dose-response parameters
The example given above is applicable when inference is made for the probability of suc-
cess at a single treatment dose. When more than one dose of the same drug are tested,
some dose-response curve may be assumed and if the Bayesian principle is used to make
inference, it is necessary to give the joint prior distribution of the parameters of the dose-
response curve. Prior distributions for generalized linear models parameters were proposed
by Bedrick et al. (1996). The form of prior distribution for generalized linear models pa-
rameters proposed by Bedrick et al. (1996) generalizes the prior distribution proposed by
Tsutakawa (1975). This form of prior distributions is used in one of the phase II design
reviewed in the next chapter and will also be adopted in the dose selection procedure that
we propose in Chapter 5. Rather than describe the theory given by Bedrick et al. (1996),
we will demonstrate with the models which we are interested in. Whitehead (2006) has
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Figure 2.2: Beta curves with same mean (0.2) but different parameter values
reviewed this form of prior distribution and some of the notation used in this section is
adopted from his review.
Let p(d) denote the probability of success at dose level d. Further suppose that given
dose, successes are independent binary outcomes with probability p(d) and that p(d) can
be modeled by a generalized linear model. Then probabilities of success are related to the
dose levels through the formula
g(p(d)) = α + β f(d),
where g(.) is a link function that links the probability of success (p(d)) to the linear pre-
dictor α + β f(d), where α is the intercept parameter, β is the slope parameter and f(.)
is some transformation of the dose such as natural log of the dose so that f(d) = log(d).
Agresti (2002) describes link functions which can be used for binary outcomes such as the
logit, probit and complementary log-log link functions. We will use the logit link which
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links the probability of success to the linear predictor as follows
g(p(d)) = logit(p(d)) = log
(
p(d)
1− p(d)
)
= α+ β f(d). (2.4)
Using the proposal of Bedrick et al. (1996), rather than directly elicit prior distri-
butions for the parameter vector (α, β), prior distributions for the probabilities of success
are elicited at some dose levels. Because the dose-response curve (2.4) is defined by two
parameters (α and β), prior distributions for probabilities of success are elicited at two dose
levels. Assuming these prior distributions are independent, the joint distribution of the two
probabilities of success is obtained and hence the joint distribution of the linear predictor
parameters (α, β) using transformation of random variables. If there were three parameters
in the linear predictor, prior distributions for probabilities of success would be elicited at
three dose levels and so on. For the dose-response curve (2.4), suppose the prior distribu-
tions for probabilities of success are elicited at dose levels di, i = −1, 0. These dose levels
do not have to be among the experimental dose levels. In this thesis, we will assume beta
prior distributions Beta(pi; ai, bi), i = −1, 0 at dose i can be elicited as described above
where pi denotes the probability of success at dose i and ai and bi may be interpreted as
pseudo-data elicited as described above. Assuming the elicited beta prior distributions at
the two doses are independent, then the joint prior distribution of p(d−1) and p(d0) is given
by
0∏
i=−1
p
(ai−1)
i (1− pi)(bi−1)
B(ai, bi)
.
To obtain the joint prior distribution of α and β which we denote by pi0(α, β), the
technique of transformation of random variables described in Section 2.1 is used. In equa-
tion (2.1), let n = 2, X1 = p(d−1), X2 = p(d0), y1 = α, y2 = β. Assuming the logit link
(2.4),
ψ1(α, β) = p(d−1) = p−1 =
exp(α + β f(d−1))
1 + exp(α+ β f(d−1))
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and
ψ2(α, β) = p(d0) = p0 =
exp(α + β f(d0))
1 + exp(α + β f(d0))
,
so that using equation (2.1),
pi0(α, β) =
0∏
i=−1
p
(ai−1)
i (1− pi)(bi−1)
B(ai, bi)
|J |, (2.5)
where pi, (i = −1, 0) are functions of α and β as defined above. The partial derivatives
are
dψi
dα
= pi(1− pi) and dψi
dβ
= pi(1− pi)g(di) i = −1, 0
so that
|J | = |g(d−1)− g(d0)|
0∏
i=−1
(pi)(1− pi)
which when substituted in equation (2.5) gives
pi0(α, β) = |g(d−1)− g(d0)|
0∏
i=−1
paii (1− pi)bi
B(ai, bi)
.
The transformation of the dose that we are going to use in this thesis is the natural log.
Hence the joint prior density of α and β is given by,
pi0(α, β) =
0∏
i=−1
paii (1− pi)bi
B(ai, bi)
∣∣∣∣log
(
d−1
d0
)∣∣∣∣ . (2.6)
Suppose that a new drug is tested at k doses. Let the number of treatment successes and
treatment failures at dose di (i = 1, ..., k) be denoted by ai and bi respectively. The likeli-
hood function of (α, β) given the observed data is
l(α, β|x) =
k∏
i=1
(
ni
ai
)
paii (1− pi)bi ,
2.3. BAYESIAN DECISION THEORY 13
where ni = ai + bi is the number of patients allocated to dose di so that updating the
distribution of (α, β) given by equation (2.6) with these data using equation (2.2), the joint
posterior density for α and β is
pi(α, β|x) ∝
k∏
i=−1
paii (1− pi)bi , (2.7)
where
pi =
exp(α + β log di)
1 + exp(α + β log di)
, i = −1, 0, 1, ..., k.
The form of the posterior distribution given by equation (2.7) has the same form as the prior
distribution given by equation (2.6) so that this prior is a conjugate prior for (α, β). Eliciting
the prior distribution for (α, β) as described in this section may also have the advantage of
being easier and more intuitive since it involves elicitation of the probabilities of success
at several doses from investigators rather than direct elicitation of the joint probability of
(α, β).
2.3 Bayesian decision theory
Bayesian decision procedures are most common and seem appropriate in early clinical
trials. For example, Stallard (1998) points out that the outcome of a phase II study is a
decision of whether to continue with further evaluation or to abandon the therapy due to
lack of efficacy or high toxicity or cost and hence argues for Bayesian decision techniques.
Decision theory involves defining gain functions for different actions (or decisions) that
can be taken and comparing the expected gain from each action. The best decision is the
one with the highest expected gain. Rather than think of the gain, it is also possible to think
of losses and hence take the decision with the least expected loss. Lindley (1985) gives a
good introduction to the basic concepts in decision theory.
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Before giving gain functions for complex decision problems, we first consider the
simplest decision making problem where there are only two decisions to choose from and
only two states of nature can occur. Table 2.1 summarizes this simple problem for a drug
company with a capital base of £m from which it can choose whether or not to invest £c
in a clinical trial to test efficacy of a new drug. Decision 1 is “to invest” (d1) and decision
2 is “not to invest” (d2). At the end of the clinical trial, the two states of nature are the
new drug will be concluded to be efficacious (“drug is efficacious”) and the new drug will
be concluded not to be efficacious (“drug is not efficacious”) with probability θ1 and θ2
respectively, where θ1+θ2 = 1. Suppose that if the new drug is concluded to be efficacious
at the end of the clinical trial, the drug company will make £k from marketing the new
drug. Then if the drug company decides to undertake the drug development, and the drug
is concluded to be efficacious, the drug company will improve its capital to £(m− c+ k)
while if the drug is concluded not to be efficacious, then its capital will decrease by £c
to £(m − c). If the drug company chooses not to undertake the drug development, the
drug company will neither lose nor gain anything regardless of whether the drug will have
been concluded effective or not as shown in row corresponding to decision d2. To compare
decision d1 and d2, the expected gain function for decision di (i=1,2) is defined by
E(di) =
2∑
j=1
θjGi(θj), (2.8)
where Gi(θj) is the final capital base if state j (j = 1, 2) occurs for decision i (i=1,2). The
resulting expected gains from decision d1 and d2 are respectively
E(d1) =
2∑
j=1
θjG1(θj) = m+ kθ1 − c and E(d2) =
2∑
j=1
θjG2(θj) = m, (2.9)
where Gi(θj) (i = 1, 2) is as defined above. If the initial capital base (£m) invested is
ignored so that Gi(θj) is the gain if state j occurs for decision i, then the expected gains
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Table 2.1: Simplest decision making problem
State of Nature
Drug efficacious Drug not efficacious
Decision (Prob of this state is θ1) (Prob of this state is θ2)
d1 : Invest m− c+ k m− c
d2 : Do not invest m m
are evaluated as follows
E(d1) =
2∑
j=1
θjG1(θj) = kθ1 − c and E(d2) =
2∑
j=1
θjG2(θj) = 0. (2.10)
The two expressions (2.9 and 2.10) show that the difference in expected fortune between
decisions d1 and d2 only depends on the amount the drug company will make from selling
the new drug if it is concluded to be effective and the amount it will lose if the new drug
will be concluded not to be effective. Hence the gain functions can be compared relative to
any baseline.
In the example of Table 2.1, the decision is whether to invest or not to invest. A more
natural decision in clinical trials is whether to proceed from one phase of a clinical trial to
the next phase. For example, in a phase II study, one may want to choose between a decision
to proceed from phase II to phase III (d1) and decision to abandon drug development after
the phase II study (d2). Another example would be a phase II clinical trial that allows more
than one inspection of data during the trial. Before the final inspection, one may choose to
stop the phase II study and proceed to phase III study (d1), stop phase II study and abandon
drug development (d2) or continue with the phase II study and make another inspection
(d3). Thus the number of decisions to choose from may be more than 2 but often will be
finite.
Further in Table 2.1, the state of nature is that the drug is efficacious, in a clinical trial
the unknown state of nature would be the probability of efficacy for an experimental drug,
denoted by p ∈ [0, 1]. In Bayesian decision theory, the decision maker’s prior knowledge of
p is encoded by a prior distribution pi0(p) (French and Insua, 2000). Then data are observed
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that are drawn from a distribution that depends on the unknown state of nature p. These
data are used to update the distribution of p using the Bayes’ theorem given by equation
(2.2) resulting to a posterior distribution pi(p|x). Then the expected gain Ga, for action
a ∈ D, where D is the set of actions that may be chosen is given by∫ 1
0
Ga(p, n)pi(p|x)dp, (2.11)
where Ga(p, n) is the gain associated with action a and depends on the probability of suc-
cess p and the number of patients in the trial n. To give an example of the form ofGa(p, n),
suppose in a phase II clinical trial one of the actions that may be taken is to proceed to phase
III. Suppose the average amount of money required to treat one patient in the phase II trial
is k and the amount required to test a drug in a phase III trial is m ≥ 0. After the phase III
trial, the company gets a reward denoted by l ≥ 0 which depends on the probability that
the drug is concluded effective by a phase III clinical trial. This probability is given by the
power function of the test denoted by κ(p). Then the gain may be expressed as
−nk −m+ lκ(p),
which is 0 (baseline value) less the expenses in phase II and phase III plus the reward after
phase III. More gain functions are defined in the next chapter.
Chapter 3
Clinical trials
In the introduction, we mentioned that in drug development, clinical trials are categorized
into three phases. In this chapter, we will first in Section 3.1 give the broader definition
of a clinical trial and the definition of clinical trials in the development of a new drug and
then in Sections 3.2, 3.3 and 3.4 respectively, we will give the objective and review some
of the statistical models used to design and analyse clinical trials in phase I, phase II and
phase III. Most of the models reviewed in this chapter will assume that the clinical trials
are carried out in the traditional set-up where each phase of a clinical trial is carried out
separately.
3.1 What is a clinical trial?
In this section, we define a clinical trial, describe the drug development process, and de-
scribe the different phases of a clinical trial. The section was compiled from various lit-
erature. Some of the text books used are Wang and Bakhai (2006) and Cook and DeMets
(2008). The papers reviewed in later sections were also used in developing this section. A
clinical trial is a research study to test how well a new intervention such as a new therapy or
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a different mode of administration of an existing drug works on people. We will consider a
clinical trial in the development of a new drug. The broad aim of a clinical trial in the de-
velopment of a new drug is to find out whether there is a dose (or dose range) and schedule
at which the drug can be shown to be simultaneously safe and effective, to the extent that
the risk-benefit relationship is acceptable. The particular subjects who may benefit from
the drug, and the specific indications for its use, also need to be defined.
The modern drug development process involves a series of experiments that are
carried out with specific objectives. First, tests are carried out in the laboratory in isolation
from living organisms. After obtaining promising results, the next step is to test the new
substance in animals (animal pharmacological studies) before the testing can proceed to
human beings. The testing in human beings is what is referred to as a clinical trial and is
categorized into phase I clinical trials, phase II clinical trials and phase III clinical trials.
Phase I is the stage where the drug is first tested in human beings. The primary ob-
jective is to determine the safety of the new therapy. Several dose levels are made available
for testing. The dose levels are determined from the animal pharmacological studies. If
a safe dose (or dose range) is found, the drug is then tested for biological activity (anti-
disease activity) in a small clinical trial. Such a trial is referred to as a phase II clinical trial.
Before the product is released into the market, a confirmatory trial (phase III trial) has to be
carried out. While phase I and II trials could include only a treatment arm, phase III trials
are almost always randomized studies comparing a control (standard therapy) arm and a
treatment (new drug) arm.
3.2 Phase I clinical trials
The primary objective of phase I clinical trials is to study toxicity of the new drug and
determine a dose that has acceptable toxicity (tolerable dose) for further testing. In this
section we give the basic set-up of phase I clinical trials and give some of the designs used
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to achieve this primary objective. The basic set-up of phase I clinical trials described in
Section 3.2.1 is generally adopted from combining materials in the articles later cited in
this section.
3.2.1 Basic set-up of a phase I clinical trial
Phase I clinical trials are typically small, having as few as 10 participants while rarely
exceeding 30 participants. Except for cancer trials (oncology), where subjects are usually
patients who are at an advanced stage of the disease and/or have failed to respond to the
standard therapies, healthy volunteers are used. In oncology, sick patients are used because
potential cancer drugs are known to be highly toxic and it would be unethical to administer
them to healthy volunteers who have not been diagnosed with cancer. These are normally
patients who have not responded to existing therapies. Since in oncology the subjects are
patients, it may be desired that most of the patients available are allocated to the dose that
will be proposed for testing in the next phases of a clinical trial. This is to enable them
have maximum benefit in case the new cancer therapy has therapeutic effect on this group
of patients.
Most designs, such as those proposed by O’Quigley et al. (1990), Babb et al. (1998)
and Durham et al. (1997) among others, have been developed for cancer trials but can be
modified for other therapies. Suppose k different doses, d1 < d2 < ... < dk, are chosen
for consideration in an oncology trial and we wish to establish the maximum tolerated
dose (MTD). We define MTD as the dose, d∗, for which the probability of a medically
unacceptable dose limiting toxicity (DLT) is equal to some specified value θ. That is MTD
is the dose d∗ such that
Prob{DLT|d∗} = θ.
The value of θ is the maximum accepted probability of a DLT and is chosen depending on
the nature of the DLT and the potential benefit expected from the drug. The reason that it
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is not necessarily the safest dose that is sought is because it is widely assumed that toxicity
is a prerequisite for antidisease activity such as antitumor activity in cancer treatment. The
MTD d∗ is not necessarily one of the experimental doses d′is, i = 1, ..., k. It is hoped that
the lowest dose (d1) is safe and that
d1 ≤ MTD ≤ dk.
Most investigators assume that there is an underlying dose-response relationship but not
all phase I designs explicitly involve fitting the dose-response curve. Each dose level has
a corresponding probability of DLT. The probability of DLT is assumed to be monotonic
increasing in dose. Diagrammatical representation of the set-up is given by Figure 3.1. The
experiment is performed using k dose levels d1, ..., dk whose respective probabilities of
DLT are θ1, ..., θk. With the maximum accepted probability of DLT denoted by θ, the
dose that corresponds to this value is d∗ as is shown in the figure. In Figure 3.1, it has been
assumed that the MTD has been captured by the experimental dose range d1 to dk.
For safety reasons, the available patients (volunteers) are sequentially entered into
the trial in small cohorts. Each cohort usually includes at most three volunteers. The
early designs are intuitive and approach the MTD conservatively from the lowest dose
(d1) while recent designs are based on statistical principles where the cohort of volunteers,
for example in the Bayesian setting, are allocated to the experimental doses based on the
predictive probability of toxicity at the experimental doses.
In addition to allocation based on safety reasons, ethical issues based on other fac-
tors are also considered and hence some patients may be allocated to different doses from
those which the design proposes. Investigators’ opinion may lead to allocation of a trial
subject to a different dose from the one the design proposes. For example, for a therapy
which seems to have therapeutic effect, if a design based on safety only proposes a lower
dose whereas a higher dose may be fairly safe, the investigator(s) may want a very sick
patient to be allocated the higher dose.
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Figure 3.1: Phase I set-up
3.2.2 Early designs
Storer (1989) describes a traditional design (which he calls design A) and also defines three
more designs (B, C and D). In design A, whose flowchart is given by Figure 3.2, cohorts
of 3 patients are treated at a time starting from the lowest dose. The patients’ responses
are observed before allocating the next cohort to one of the experimental doses. If no DLT
is observed in all 3 patients, escalation to the next higher dose occurs. If 2 or 3 DLTs are
observed, the MTD is reached and the trial stops. If only 1 patient experiences a DLT, 3
more patients are allocated to the same dose and if no extra DLT is observed, escalation
again continues; otherwise the MTD is reached and the trial stops.
Designs B, C and D are “up and down” schemes in which both escalation and de-
escalation takes place. In design B, one patient is treated at a time. If a DLT occurs, the
next patient is treated at the next lower dose; otherwise escalation to the next higher dose
takes place. The only difference between designs C and B is the escalation rule. For design
C, escalation takes place after two consecutive patients treated at the same dose do not
experience a DLT. For design D, cohorts of 3 patients are treated at a time. Escalation
occurs if no DLT is observed and de-escalation if more than 1 DLT is observed. If only
1 DLT is observed, then the next cohort is treated at the same dose level. A flowchart of
this procedure is given in Figure 3.3. The difference between designs A and D is that D
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Figure 3.2: Flowcharts of the traditional design (Design A)
allows de-escalation to lower doses and all available patients are entered in the trial. For
this design, there is no outcome that leads to stopping so that all available patients are
tested.
Storer has proposed two two-stage designs, denoted by BC and BD which combine
the single-stage designs (that is B followed by either C and D). The first stage follows
design B until the first toxic response occurs. From the point at which the next patient is
entered at the next lower dose level, the second stage design (C or D) is implemented. He
showed the two stage designs (BC and BD) estimated the MTD with reduced bias relative
to the single stage designs A, C and D.
In all these designs (A, B, C, D, BC and BD), the dose to be recommended for
testing in further clinical trials depends on the results of the highest dose administered to
the participants. If this highest dose administered is deemed nontoxic, it is recommended
for further testing. Otherwise, the immediate lower dose is recommended.
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Figure 3.3: A variation of the traditional design (Design D)
3.2.3 The continual reassessment method
The Continual Reassessment Method (CRM) was developed by O’Quigley et al. (1990) for
a cancer trial. Several authors, for example Babb et al. (1998), Whitehead et al. (2006), Fan
and Wang (2006) and Durham et al. (1997) among others, have compared their methods’
operating characteristics with those of CRM. Let Xj be a binary random variable (that is,
Xj ∈ {0, 1}), where 1 denotes occurrence of a DLT and 0 nonoccurrence of a DLT for the
jth patient (j = 1, ..., n) entered in the trial. Further, as above, let d∗ (not necessarily one
of the experimental dose levels d1 < d2 < ... < dk) be the MTD. The probability of DLT
is modeled by a simple dose-response curve ψ(d, a) that depends on the dose level d and
a single parameter a. The dose-response function is assumed to be monotonic in d and a
and that for some a, say a0, from the set A of possible values of a, we have ψ(d∗, a0) = θ,
where θ is the maximum accepted probability of DLT.
The version of the CRM proposed by O’Quigley et al. (1990) uses the Bayesian
principle where the parameter a is considered to be a random variable. Let (x1, ..., xj−1),
the data before experimentation on the jth patient, be denoted by xj and let pi(a|xj) denote
the prior density of the parameter a before experimentation on the jth patient. The form of
pi(a|xj) is given later. When j = 1, pi0(a) = pi(a|x1) is the prior density for a before the
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experimentation. They take A = (0,∞) so that
∫ ∞
0
pi(a|xj)da = 1, (j = 1, ..., n).
Using the accumulated information on the (j − 1) patients responses, the probability of
DLT at dose level i (denoted by θij) is estimated by
θij =
∫ ∞
0
ψ(di, a)pi(a|xj)da, (i = 1, ..., k). (3.1)
This is the expected value of the probabilities over A. As an approximation to equation
(3.1), O’Quigley et al. (1990) suggest one could obtain the posterior mean of a and substi-
tute this in the dose-response function resulting in a simple to evaluate estimate of θij given
by
θ
′
ij = ψ(di, a¯(j)), (i = 1, ..., k), a¯(j) =
∫ ∞
0
api(a|xj)da.
We continue explanation of the CRM using θ′ij but the same procedure would be followed
if one chose to use θij . In order to determine the best dose to allocate to the jth patient,
the estimates of probabilities of DLT θ′ij , (i = 1, ..., k) are compared with the accepted
proportion of DLT θ by defining some measure of distance ∆ of θ′ij from θ. A commonly
used choice is the absolute difference ∆(θ′ij , θ) = |θ′ij − θ|. The jth entered patient is
assigned to the dose di such that ∆(θ
′
ij , θ) is minimized.
Given the response of the jth patient, which updates the knowledge about a0, the
posterior distribution pi(a|xj+1) is obtained from pi(a|xj) using Bayes’ formula given by
equation (2.2). The likelihood of the outcome for the jth patient is Bernoulli given by
φ(d(j), xj, a) = (ψ(d(j), a))
xj{1− ψ(d(j), a)}1−xj ,
where d(j) is the dose allocated to the jth patient and ψ(d(j), a) is the probability of DLT
given by the dose-response curve ψ(d, a). The prior distribution of a before experimenta-
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tion with jth patient is pi(a|xj) so that the posterior distribution has density equal to
pi(a|xj+1) = φ(d(j), xj, a)pi(a|xj)∫∞
0
φ(d(j), xj, u)pi(u|xj)du
=
pi0(a)
∏j
l=1 φ{d(l), xl, a}∫∞
o
pi0(u)
∏j
l=1 φ{d(l), xl, u)}du
.
Patients are entered in this way until the results of the last patient entered are avail-
able. The recommended dose level for further testing will be the dose di (i = 1, ..., k) such
that ∆(θ′i,n+1, θ) is minimized. As seen in the allocation of the patients to the dose levels,
the design takes into consideration the large potential gain to the patients by aiming to treat
as many patients as possible at the MTD. This makes it superior to the designs that begin
testing at the lowest dose; these designs tend to under-treat more patients particularly if the
MTD is the highest dose considered for experimentation.
O’Quigley and Shen (1996) proposed a likelihood based version of the CRM (CRML).
Suppose (j − 1) subjects have been entered in the trial and a dose-response function is de-
fined as before, then the likelihood is equal to
L(a) =
j−1∏
l=1
(ψ(dl, a))
xl{1− ψ(dl, a)}1−xl,
where dl ∈ {d1, ..., dk} is the dose level allocated to patient l. To obtain an estimate
for a using the maximum likelihood method, the derivative of the logarithm of the above
expression is obtained which results in the score function
U(a) =
j−1∑
l=1
{xlψ
′
ψ
(dl, a)} −
j−1∑
l=1
{(1− xl) ψ
′
1− ψ (dl, a)}. (3.2)
When there is heterogeneity in the outcomes (that is, some patients with DLT and some
without DLT), then the equation U(a) = 0 has a solution. The solution is given by a = aˆj ,
the maximum likelihood estimate of a. The maximum likelihood estimate for probability
of a DLT at dose di for patient j is ψ(di, aˆj), where aˆj is assumed to exist. Patient j is
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allocated to dose di such that ∆(ψ(di, aˆj), θ), i = 1, ..., k, is minimized. The recommended
dose level for further testing will be the dose di such that ∆(ψ(di, aˆn+1), θ) is minimized.
Before heterogeneity, that is, when all patients experience DLTs or all patients do
not experience DLTs, the equation U(a) = 0 has no solution so that it is not possible to
obtain the maximum likelihood estimate of a and consequently the maximum likelihood
estimate ψ(di, aˆj). Before heterogeneity in results is observed, O’Quigley and Shen (1996)
suggest using the Bayesian CRM or one of the early designs described above until a DLT
is observed if the first outcome is a non-DLT or vice versa. This is because the early
designs do not involve estimating a parameter while allocating patients to a dose and in the
Bayesian CRM, a prior distribution for a is defined which is updated by the data so that we
do not have problem of estimating a through maximum likelihood estimate. Comparison
using different starting procedures show that the final results, that is the dose recommended
for testing in the next phases of a clinical trial, are largely robust to the method used before
heterogeneity is achieved. Operational characteristics would be expected to differ when
the lower doses have a very low probability of DLT where starting with the traditional
design, more patients are allocated to the lower dose levels. However, the probabilities
of recommending the experimental doses for further testing are similar to starting with
the Bayesian CRM. Comparison of likelihood CRM and Bayesian CRM using simulation
studies indicated similar results.
O’Quigley and Shen (1996) performed simulation studies and compared the prob-
abilities of recommending the experimental doses for further testing using the following
three methods; (i) the Bayesian CRM, (ii) CRML while starting with traditional design
until heterogeneity is observed and (iii) CRML while starting with Bayesian CRM until
heterogeneity is observed. The probabilities of recommending each of the experimental
doses for testing in the next phases of a clinical were similar for the three methods. Of par-
ticular interest is the scenario for which the lower doses have a very low probability of DLT,
where when the traditional design is used before heterogeneity, many patients are allocated
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to the lower doses. Despite the difference in operating characteristics with this scenario,
the probabilities of recommending experimental doses for testing in the next phases of a
clinical were similar in the three methods. The Bayesian CRM and CRML started with
Bayesian CRM used the same prior distribution for a and the probabilities of recommend-
ing the experimental doses were very close. O’Quigley and Shen (1996) observed that if
less informative prior distributions were used, the results of these two methods would be
closer.
3.2.4 Overdose control
An attractive idea for phase I clinical trials is to impose a safety constraint in order to
minimize the chance of exposing patients to dose(s) with probability of DLT above that of
the MTD. This can be achieved by requiring that a dose d cannot be administered if the
predictive probability of a DLT at that dose is greater than a pre-specified value given the
already collected data. Whitehead et al. (2006) propose an explicit consideration which
they argue is more transparent. For example, using the Bayesian CRM, safety may be
incorporated by allocating the jth patient to dose di such that ∆(θ
′
ij , θ) is minimized and
θ
′
ij ≤ θT , where ∆, θ′ij and θ are as defined above and θT is the probability of DLT which
would be considered too high to allocate patients.
Alternatively, the constraint can be incorporated in the statistical model. Babb et al.
(1998) have proposed a phase I clinical trial design that incorporates safety in the statistical
model. The model selects a dose for each patient so that the predicted probability that the
dose exceeds the MTD is less than or equal to some pre-specified value α. This is accom-
plished by also considering the MTD to be random variable with a prior distribution and
then computing the posterior cumulative distribution function (CDF) of the MTD. We will
only give the rule of how the patients are allocated to the doses and not the details of how
to obtain the distribution of MTD (Babb et al. (1998) give an example of the distribution of
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MTD for binary outcomes). For the jth (j = 1, ..., n) patient, if allocation is to a dose d,
the probability that d exceeds the MTD is related to the posterior CDF of the MTD and is
given by the function pij defined as
pij(d) = Prob{MTD ≤ d|xj},
where xj is the data at the time of jth patient, that is, the responses and the dose levels
administered. Hence, pij is the conditional probability that dose d exceeds the MTD given
the currently available data. Based on this criteria, the jth patient is allocated to the dose
level di such that
pij(di) = α.
That is, each patient is allocated to a dose so that the predicted probability it exceeds the
MTD is equal to α. Babb et al. (1998) assume that any dose is available within the experi-
mental dose range. If only a distinct number of doses are available, the jth patient may be
allocated to the highest dose level di such that
pij(di) ≤ α.
3.3 Phase II clinical trials
The primary objective of phase II clinical trials is to study efficacy of the new drug in
comparison with the standard treatment(s). Hence, although such studies can be carried
out in a single arm setting, the trials are inherently comparative. In addition to efficacy,
consideration of toxicity (safety) and cost of the trial may also be incorporated in a phase II
trial. The trials are used to determine whether to proceed to a phase III trial depending on
the efficacy level, evaluation of toxicity and cost involved in the development of the drug.
Designs utilizing frequentist techniques as well as purely Bayesian and Bayesian decision
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techniques have been proposed. After outlining the set-up of phase II clinical trials, we will
give a review of the popular designs and the emerging new designs.
3.3.1 Set-up of phase II clinical trials
For ethical reasons, it is often important to monitor the outcomes for patients in a phase
II clinical trial. For this reason, phase II trials are sometimes designed such that at least
two inspections are carried out so that there are opportunities to stop early either for futility
or highly promising results before all the patients available for phase II testing are entered
into the trial. Suppose there are k inspections where all remaining patients are entered into
the trial after the (k− 1)th inspection. At the ith inspection (i = 1, ..., k− 1), three actions
(decisions) can be taken
• Action A: Stop the phase II study and abandon development of the drug
• Action P: Stop the phase II study and proceed to phase III study
• Action C: Continue with the phase II study and make the (i+ 1)th inspection.
Focussing on studies in which actions are based only on efficacy, Action A is taken when
evidence of efficacy is below a certain level so that the new drug is not promising. The
motivation for Action A is that patients should not continue to be exposed to a drug that
is clearly not effective. Action P is taken when the evidence for efficacy of the new drug
is high enough to mean that more evidence on efficacy from subsequent inspections in
phase II is not required. The motivation for Action P is that if based on accumulated data
at the ith (i = 1, ..., k − 1) inspection, there is high probability the new drug is more
beneficial compared to the standard drug, the trial should proceed to phase III stage to
reduce the development duration for the new drug. Reducing the development duration
avoids delay of potential benefit to the society if the new drug will be concluded better than
the standard treatment after the phase III stage and saves cost for the drug company because
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fewer patients are recruited and treated. Also, reducing the development duration increases
profit to the drug company because lesser time of the patent life is used to develop the new
drug. On the other hand Action C is taken when the drug shows evidence of efficacy but
not strong enough to suggest stopping the phase II testing after the ith (i = 1, ..., k − 1)
inspection to proceed to phase III testing. At the kth (last) inspection only actions A and P
can be taken.
In some settings, not all three actions are considered. For example some trials allow
for action P only at the kth inspection; that is, they do not allow for early stopping of phase
II due to highly promising results from the new drug and proceeding to phase III before all
trial subjects are treated and observed. Decision (action) boundaries depend on the design
being utilized. For binary data, it makes sense action P will be taken if enough successes
are observed, action A will be taken if too few successes are observed and action C will be
taken if the number of successes is between the number of successes required to take action
A and the number of successes required to take action P. A pictorial representation of the
decision boundaries is shown in Figure 3.4. In the general case, before the last inspection,
if all the three actions can be taken at the ith inspection (i = 1, .., k − 1), two values Ui
and Li (Li < Ui) are predetermined. The two values are used as the decision boundaries
for the action to be taken. Suppose at the ith inspection the total number of treated patients
in the phase II trial is ni and si are treated successfully. If si < Li, drug development is
abandoned (Action A). If si > Ui, phase II trial is stopped and drug development proceeds
to phase III (Action P). On the other hand, if Li ≤ si ≤ Ui, more patients are treated and
(i + 1)th inspection is made (Action C). If the design does not allow Action P, no upper
values U ′is in Figure 3.4 are defined.
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Figure 3.4: A phase II setting allowing for 3 actions at each inspection
3.3.2 Frequentist designs
Frequentist designs focus on determining decision boundaries that control the error rates.
Suppose that the true probabilities of success using the standard treatment and the new drug
are p0 and p1 respectively. Then the new drug may be considered to be sufficiently more
efficacious than the control treatment if p1 ≥ p0 + δ, where δ > 0 is a clinically relevant
improvement of the new drug over the standard treatment. The hypothesis would then be
to test H0 : p1 = p0 Vs H1 : p1 ≥ p0 + δ. The experiment is set up such that the error of
rejecting H0 when actually H0 is true (type I error, usually denoted by α) and the error of
concluding H0 when in reality H1 is the truth (type II error, commonly denoted by β) are
controlled to some specified levels.
Making a type II error in a phase II clinical trial means that treatments that offer
larger benefits compared to the existing treatments are rejected based on a small sample
size clinical trial. Schoenfeld (1980) notes that investigators do not want to reject treatments
with larger benefit on the basis of small sample size trials. Making a type I error means that
a new treatment that is not better than the existing treatment is concluded to be better than
the existing treatment. Schoenfeld (1980) observes that Type I error is minimized in a large
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phase III clinical trial. Hence unlike in phase III clinical trials, Schoenfeld proposes that
in a phase II clinical trial, preference should be given to minimizing type II error (hence
increasing the power; power = 1 − β). He proposes setting type II error to less than 0.10
and type I error to less than 0.25.
Gehan (1961) proposed a design which has had considerable application in the past.
The design has two stages. He stated that two decisions can be made
• Decision I: Drug is unlikely to be effective in a proportion p1 of the patients or more
• Decision II: Drug could be effective in a proportion p1 of patients or more.
When Decision I is made at inspection 1, Action A is taken while if Decision II is made,
Action C is taken. There is no opportunity for Action P. Gehan illustrated how to determine
the decision boundaries by taking p1 = 0.20. With p1 = 0.20, the chance of consecutive
treatment failures is summarized in Table 3.1. The probability of treatment failure is 1 −
p1 = 0.8. Assuming the observations are independent, the probability of i (i = 1, ..., 14)
consecutive failures is (0.8)i. The chance of at least 1 success after i patients will then be
given by 1− (0.8)i. For example as shown in the table, the chance of 3 consecutive failures
is (0.8)3 = 0.8 × 0.8 × 0.8 = 0.512 and the chance of at least 1 success after 3 patients
have been treated will be 1− (0.8)3 = 0.488.
Supposing that 14 patients are inspected at the first inspection, Gehan (1961) pro-
posed decision boundaries summarized in Table 3.2. Action A is taken if they are 14
consecutive failures while Action C is taken if 1 or more treatment successes out of the 14
patients is observed. With p1 = 0.2, the probability of taking Action A is 0.044. That is,
type II error is controlled at less than 5% and hence the chance of concluding the drug may
be working when true probability of success is 0.2 (power) is greater than 95%. On the
other hand, using the same ideas, if one is prepared to accept a type II error rate of 0.1, 11
patients are required at the first inspection where as before Action A is taken if there are 11
consecutive failures and Action C is taken otherwise.
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Table 3.1: Chance of successive treatment failures when probability of success is 0.2
CONSECUTIVE CHANCE OF TREATMENT FAILURE IN GIVEN
PATIENTS CONSECUTIVE NUMBER OF PATIENTS
1 0.8
2 0.8×0.8=0.64
3 0.8×0.8×0.8=0.512
. .
. .
8 0.168
. .
. .
11 0.086
. .
. .
14 0.044
The number of additional subjects for the second stage is determined so that the
true effectiveness of the drug is estimated with a given precision, i.e, standard error. The
standard error of the estimated proportion of the treatment successes after the first sample
of n1 patients is √
p(1− p)
n1
,
where p is the proportion of treatment successes in the first sample and n1 the size of the
first sample. If the proportion of successes is approximately the same for future patients,
the standard error with the total number of patients is about√
p(1− p)
n2
, (3.3)
where n2 is the combined size of the first and the second stage samples and p is the same as
above. The second sample number (n2 − n1) can be determined so that approximately the
required precision will result. It is hoped that p is near the true rate of treatment successes.
A more conservative value of p to substitute in equation (3.3) would be the 75% confidence
limit for the true rate of successes as derived from the first sample.
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Table 3.2: Decision boundaries at inspection 1 using Gehan’s method
TREATMENT SUCCESSES ACTION
0 Drop drug
1 Include more patients in
.
. study to pinpoint
.
14 effectiveness
The sample size for second stage using Gehan’s (1961) method depends on the
success rate in the first stage. Also, Gehan’s design controls the error rates for the first
inspection only. Simon (1989) proposed an optimal two-stage design that like Gehan’s
method allows for Actions A and C but the second stage sample size does not depend on
first stage success rate and his design controls the error rates for the entire phase II trial.
At the first inspection, the number of successes, S1, from n1 patients is observed. A lower
bound L1 is predetermined so that if S1 ≤ L1, action A will be taken. Otherwise action
C is taken, with a further (n2 − n1) treated at the second stage. A lower bound L2 for the
second stage is also set such that if the total number of successes (in both stages) S2 ≤ L2,
development of the drug will be abandoned.
The probability of treatment success depends on the true probability of success,
p, for the new drug. Assuming that the responses from the patients are independent and
identically distributed as Bernoulli with parameter p the probability of i (i = 0, 1, ..., n1)
successes in the first stage is Bin(n1, p). Thus the probability of abandoning the drug at
first stage, that is prob(S1 ≤ L1), is given by
L1∑
i=0
(
n1
i
)
pi(1− p)n1−i = FB(L1; p, n1), (3.4)
where FB denotes the cumulative distribution function of a binomial distribution. Action A
is taken at the end of the second stage if S1 = i (for i ≥ L1 +1) and (S2− S1) ≤ (L2− i).
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Thus the probability of proceeding at stage 1 and abandoning at stage 2 is expressed as
n1∑
i=L1+1
prob(S1 = i and S2 − S1 ≤ L2 − i; p).
Since (S2−S1) is binomial with parameter vector (n2−n1, p), with (S2−S1) independent
of S1, the above probability is
n1∑
i=L1+1
L2−i∑
j=0
(
n1
i
)
pi(1− p)n1−i
(
n2 − n1
j
)
pj(1− p)n2−n1−j
=
n1∑
i=L1+1
fB(i;n1, p)FB(L2 − i;n2 − n1, p), (3.5)
where fB denotes a binomial mass function and as before FB denotes the cumulative dis-
tribution function of a binomial distribution.
The expected sample size is EN = n1 + (1 − PET)(n2 − n1) where PET is the
probability of early termination after the first stage. Parameters p0, p1, α and β are specified
and then the two-stage design that satisfies the error probability constraints and minimizes
the expected sample size when the response probability is p0 is determined. Optimization
is taken over all values of n1 and (n2−n1) as well as L1 and L2. This is found by searching
over the range of L1 ∈ (0, n1) and for each value of L1 determine the maximum L2 that
satisfies the type II error.
3.3.3 A Bayesian design
Thall and Simon (1994) have proposed a Bayesian design for phase II clinical trials. Let E
denote the new (experimental) drug and S the standard (control) drug and that all patients
entered in the trial receive new drug. Further let pE and pS respectively denote the proba-
bilities of success after treatment with the new drug and the standard treatment. The prior
distributions for pE and pS are respectively denoted by pi0(pE) and pi0(pS). Because Thall
and Simon (1994) assume that all patients in the phase II trial will receive the new drug, the
posterior distribution of pS after the phase II trial is equal to its prior distribution pi0(pS).
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Let the response for the jth patient in the phase II clinical trial, Xj (j = 1, 2, ...)
take values 0 and 1 for treatment failure and successful treatment respectively. Assuming
the responses X ′js are independent, the total number of successes after n patients, Sn =
X1 + X2 + ... + Xn, is Bin(n, pE). Suppose in an experiment after n patients, sn are
treated successfully, then the posterior distributions for pE after observing data (sn, n) is
denoted by pi(pE|sn, n). Assuming an improvement of size δ is of medical significance, the
objective is to determine the probability that the effect of the new treatment (pE) is greater
than the effect of the standard treatment plus δ (pS + δ) expressed as
λ(sn, n; piS, piE , δ) = Prob(pS + δ < pE|Sn = sn out of n)
=
∫ 1−δ
pS=0
∫ 1
pE=pS+δ
pi(pE|sn, n)pi0(pS)dpEdpS. (3.6)
Figure 3.5 demonstrates the range of the parameter values used to obtain the probability.
Since we want to determine the probability that the new drug is better than the control by
effective size δ, pS and pE are integrated over values such that (pE − pS) ≥ δ. Hence
parameter ps is allowed to take values from 0 to 1− δ, since beyond 1− δ, (pE − pS) will
be less than δ. The parameter pE is similarly integrated from pS + δ to 1 to make sure that
(pE − pS) ≥ δ.
Thall and Simon (1994) proposed beta prior distributions for both pE and pS . Sup-
pose that pi0(pE) is Beta(aE , bE) and pi0(ps) is Beta(aS, bS). Since there is no experimenta-
tion with the control treatment, the posterior distribution of pS is also Beta(aS, bS). For the
new drug the likelihood is Binomial so that following the discussion of Section 2.2.1, the
posterior distribution pi(pE|sn, n) is Beta(aE + sn, bE + n− sn) and since∫ 1
ps+δ
fβ(pE ; aE + sn, bE + n− sn)dpE = 1− Fβ(pS + δ; aE + sn, bE + n− sn),
where fβ and Fβ are respectively the probability density function and the cumulative dis-
tribution function of a beta distribution, then equation (3.6) simplifies to∫ 1−δ
0
{1− Fβ(pS + δ; aE + sn, bE + n− sn)}fβ(p; as, bs)dpS, (3.7)
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Figure 3.5: Range of the parameter values
where fβ and Fβ are as defined above.
Thall and Simon assume the parameters aS, bS , aE and bE can be elicited from
the investigators and the parameters represent pseudo-patients. For example aS and bS are
elicited such that if (aS+bS) patients are treated with the standard drug, then aS would have
successful responses to the treatment while bS will not respond positively to the standard
drug. Similarly, aE patients would be treated successfully after aE + bE are treated with
the new drug. Thall and Simon assume an informative prior distribution pi0(pS) and an at
most slightly informative prior distribution pi0(pE). They suggest eliciting and quantifying
the prior distributions by setting width of the 90% interval (W90) and examining the Beta
curves as described in Section 2.2.1.
The design allows for the three actions (A, P and C) stated in Section 3.3.1. To
determine the decision boundaries, a small value pL such as (0.01-0.05) and a large value
pU such as (0.95-0.99) for equation (3.7) are predetermined. Let λ denote the expression
(3.7) after the prior distributions (pi0(pE), pi0(pS)) and parameter values sn, n and δ are
given. The lower and upper cut-offs are then given by
Un = smallest integer sn such that λ(sn, n, piS, piE , 0) ≥ pU
Ln = Largest integer sn < Un such that λ(sn, n, piS, piE , δ) ≤ pL.
The decision rule after n patients are treated is:
if Sn ≤ Ln, take action A,
if Sn ≥ Un, take action P, and
if Ln < Sn < Un and n < nmax, take action C,
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where nmax is the maximum number of patients that can be entered into the phase II clinical
trial.
3.3.4 A Bayesian decision design
The decision boundaries (rules) for the frequentist and Bayesian designs described in Sec-
tions 3.3.2 and 3.3.3 respectively depend only on the number of successfully treated pa-
tients. Fully Bayesian decision theory techniques can be used to define gain function which
incorporate other measures such as the monetary gain for the pharmaceutical company.
Stallard (1998) has proposed a method for sample size determination for phase II clinical
trials using Bayesian decision theory. Here we will dwell more on Stallard’s proposal for
defining decision boundaries after evaluating data rather than on sample size determina-
tion. He defines a gain function that depends on the true efficacy and stage of the trial at
which the decision is made. Suppose a maximum of K inspections are planned at phase
II and that the ith inspection (i = 1, ..., K) is carried out after a total of ni patients have
been entered into the trial. Further let the true probability of efficacy be denoted by p.
Then the gain is a function of p and ni and for action a(a ∈ {A, P, C}), it is denoted by
Ga(p, ni). Actions A, P and C are as defined in Section 3.3.1. Let Xj be the indicator
variable for successful treatment of patient j, j = 1, ..., ni and Sni =
∑ni
j=1Xj be the
number of successfully treated patients after ni patients have been treated. After observing
data X1 = x1, X2 = x2, ..., Xni = xni with Sni = sni , using the Bayesian decision theory
principles of Section 2.3, the expected utility from action a is
Ga(sni) = E{Ga(p, ni)|sni, ni} =
∫ 1
0
Ga(p, ni)pi(p|sni, ni)dp,
where pi(p|sni, ni) is the posterior distribution of p given the data (sni, ni). The optimal
action is the one with largest expected utility.
The baseline for the utility function defined here is 0 so that if the phase II study
is assumed to have a cost k(≥ 0) per patient, the utility function for abandoning the trial
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(action A) at the ith inspection is given by
GA(p, ni) = −nik
which is 0 (baseline value) less the number of patients entered multiplied by the cost per
patient.
To proceed to phase III (action P), in addition to the cost of the phase II trial, the
gain function needs to incorporate the cost of the phase III trial and the expected reward
if the phase III trial shows that the new drug is efficacious. Stallard assumed that the total
cost of the phase III trial is fixed and equal to some amount m(≥ 0). The reward l(≥ 0) is
taken to depend on the speed with which the drug can be developed. Assuming the length
of phase III is fixed, the variability of speed of the drug development will depend on the
length of the phase II trial and hence l will be taken to be a function of ni. Further, the
reward will depend on the probability that the drug will be indicated efficacious by the
phase III trial. This probability depend on p and is given by the power function of the test
denoted by κ(p). The utility function for action P at the ith inspection will thus be of the
form
GP (p, ni) = −nik −m+ l(ni)κ(p).
Expectations for the two gain functions corresponding to actions A and P are given by
GA(p, ni) = E[GA(p, ni)] = −nik (3.8)
and
GP (p, ni) = E[GP (p, ni)] = −nik −m+ l(ni)E(κ(p)|sni, ni) (3.9)
respectively, where E(κ(p)|sni, ni) which we define as the predictive power in Chapter 5,
is the expected value of κ(p) obtained using the posterior distribution of p given (sni , ni).
At i = K, further continuation (that is action C) is not possible. At this inspection,
GC will be taken to be −∞ so that it will have the least gain among actions A, P and
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C. When i 6= K, the utility from action C, depends on the action that will be taken at the
(i+1)th inspection and subsequent inspections. At the (i+1)th inspection, if Sni+1 = sni+1
and the optimal action is taken, the expected utility will be
maxa∈{A,P,C}Ga(sni+1, ni+1)
The expected utility from action C at the ith inspection can thus be given recursively by
GC(sni, ni) =
sni+ni+1−ni∑
Sni+1=sni
maxa∈{A,P,C}{Ga(sni+1, ni+1)}fni+1(sni+1 |sni, ni), (3.10)
where fni+1(sni+1|sni, ni) is the density of Sni+1 given Sni = sni given by
fni+1(sni+1|sni, ni) =
∫ 1
0
gni+1(sni+1|sni, p)pi(p|sni, ni)dp
with gni+1(sni+1|sni, p) the density of Sni+1 given Sni = sni and the value of p.
Figure 3.6 gives all possible outcomes at stage (i + 1) and the probability of each
possible outcome given the outcome at stage i. Suppose at inspection i, sni successes are
observed. With the (i + 1)th inspection carried out after ni+1 patients have been treated,
at inspection (i + 1) an extra (ni+1 − ni) patients are entered so that the extra number
of successes takes values 0, 1, ..., (ni+1 − ni) and consequently Sni+1 can take values
sni + 0, sni + 1, ..., (sni + ni+1 − ni). Thus
Prob(Sni+1 = sni + s(ni+1−ni)|p) = Prob(S(ni+1−ni) = s(ni+1−ni)|p)
which is Bin((ni+1 − ni), p) where S(ni+1−ni) is the random variable denoting the extra
number of successes at inspection (i+ 1). This is the distribution of gni+1(sni+1 |sni, p).
If K is finite, that is for a truncated test, equation (3.10) can be solved using equa-
tions (3.8) and (3.9) using backward induction starting at i = K. It is thus possible to
compare the utilities for the three actions A, P and C given respectively by equations (3.8),
(3.9) and (3.10) and choose the optimal action. For a truncated test, it can be shown that
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Figure 3.6: Possible outcomes at stage (i+ 1)
functions c and d exist that determine decision boundaries so that
maxa∈{A,P,C}Ga(sni , ni) =


GA(sn1, ni), sni < c(i)
GC(sni, ni), c(i) ≤ sni < d(i)
GP (sni , ni), d(i) ≤ sni.
3.3.5 Phase II studies based on therapeutic benefit and toxicity
The phase II designs described above focussed only on efficacy data. However, it may be
desirable to make the decision on which doses to consider for further testing based on both
efficacy and safety data. Both frequestists and Bayesian methods that use both efficacy and
safety are available. We will mention several methods but we will describe in detail one
frequentist method and two Bayesian methods.
A frequentist method
In the frequentist setting, if both efficacy and safety are considered, the type I error needs
to be controlled at some level α. Let X1 and X2 denote the outcome variables for efficacy
and toxicity (DLT) respectively. Following Pocock et al. (1987), one possible solution is to
consider X1 as the primary endpoint whose p-value for treatment difference is used for the
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formal test of hypothesis and toxicity as a subsidiary endpoint requiring exploratory rather
than formal interpretation. However, this may sometimes not be desirable so that X2 may
also be used in the hypothesis testing. Because a family of hypotheses (hypothesis testing
X1 and hypothesis testing X2) are tested, procedures that control the type I familywise
error rate (FWER), the probability of rejecting at least one true null hypothesis in the family
under any configuration, need to be employed. By under any configuration, we mean when
only one null hypothesis is true or both the null hypotheses are true. One possible method as
pointed by Geller and Pocock (1987) and Pocock et al. (1987) is the Bonferroni correction,
where to control the type I FWER, each variableXi, (i = 1, 2) is tested at level α/2. Other
methods that may be used to control the type I FWER by adjusting the level of the tests
are ˇSida´k’s method and Holm’s procedure among others. These methods are described in
detail in Section 4.3. In this section we will describe the method proposed by Jennison and
Turnbull (1993, 2000).
Jennison and Turnbull (1993, 2000) consider pairsX = (X1, X2) that have bivariate
normal distributions with mean µ = (µ1, µ2), correlation ρ and known variances which by
appropriate re-scaling are such that var(X1) = var(X2) = 1. They also assume that X1 and
X2 are defined such that higher values of µ1 and µ2 are desirable. Jennison and Turnbull
(1993) further assume that with regard to Xi (i = 1, 2), there are constants εi < ∆i such
that the new drug is preferred if µi > ∆i and is unacceptable if µi ≤ εi, but the region
with εi < µi ≤ ∆i is a region of indifference so that the parameter space for µ is divided
into nine preference regions as shown in Figure 3.7 (a). In the pairs, the first position
corresponds to X1 and the second position to X2. The symbols −, 0 and + respectively
indicate that the new drug is unacceptable, new drug is indifferent to the standard treatment
and the new drug is preferred. After a trial, the objective is to decide whether to accept (A)
or reject (R) the new drug so that for each of the nine regions, the investigators will either
accept the new drug or drop (reject) it. We have given one example of collapsing the nine
regions in Figure 3.7 (b). In this case, the investigators would be interested in a new drug
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Figure 3.7: (a) The preference regions for µ = (µ1, µ2). The first position in the pair
correspond to X1 (efficacy) and the second position to X2 (toxicity). The symbols +, 0 and
- respectively indicates new drug is preferred, considered equivalent and unacceptable. (b)
An example of appropriate actions for specified values of µ; R (reject new drug) and A
(accept new drug)
that is more efficacious than the standard drug while it is at least as safe as the standard
drug. Hence the new drug is preferred if µ1 and µ2 are either in the region (+, +) or (+, 0).
More examples of categorization are presented in Jennison and Turnbull (1993).
Jennison and Turnbull (1993, 2000) propose a unified method for different catego-
rization based on preferences for the new drug which is achieved by shifting X . For the
example presented in Figure 3.7 (b), the shifted random vector is X − (∆1, ε2). With the
transformation, there is a single region over which to control type I FWER. The type I
FWER is controlled at level α if
max{PA(µ1, µ2);µ1 ≤ 0 or µ2 ≤ 0} ≤ α,
where PA(µ1, µ2) is the probability of concluding that the new drug is preferred when
µ = (µ1, µ2). Suppose after n patients data Xij ; i = 1, 2; j = 1, ..., n are taken. Let
X¯i = n
−1(Xi1 + ... +Xin), i = 1, 2 to be the sample means with the standardized values
Zi = X¯i
√
n, i = 1, 2. The decision rule is:
• If min(Z1, Z2) > Φ−1(1− α), accept new drug;
• Otherwise, reject new drug.
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Jennison and Turnbull (1993, 2000) show that with this decision rule, the type I FWER
is controlled at level α. To show this result, they first show that PA(·, ·) is monotone
in both directions for this decision rule. This is accomplished by comparing the proba-
bility of concluding that a new drug is preferred based on two sets of bivariate random
vectors Z and Z ′ . Let the first random vector Z = (Z1, Z2) be bivariate normal with
mean (µ1
√
n, µ2
√
n), var(Z1) = var(Z2) = 1 and corr(Z1, Z2) = ρ. Let the second
random vector Z ′ = (Z ′1, Z
′
2) = Z + (v1
√
n, v2
√
n), where v1 > 0 and v2 > 0 so that
Z ′ is distributed as Z except that its mean is greater than the mean of Z and is equal to
([µ1 + v1]
√
n, [µ2 + v2]
√
n). Since Z ′1 > Z1 and Z
′
2 > Z2 for all values of Z1 and Z2,
PA(µ1 + v1, µ2 + v2) = Prob{min(Z ′1, Z
′
2) > Φ
−1(1− α)} (3.11)
≥ Prob{min(Z1, Z2) > Φ−1(1− α) = PA(µ1, µ2)}.
The equality (3.11) holds from the definition of PA(·, ·) and the decision rule. The above
inequality indicates that PA(µ1, µ2) is monotone increasing in both arguments. Hence, for
any value of ρ,
max{PA(µ1, µ2);µ1 ≤ 0 or µ2 ≤ 0} ≤ max{PA(0,∞),PA(∞, 0)} (3.12)
= max{Prob[Z1 > Φ−1(1− α)|µ1 = 0],
Prob[Z2 > Φ−1(1− α)|µ2 = 0]}
= α,
since Prob[Z1 > Φ−1(1 − α)|µ1 = 0] = Prob[Z2 > Φ−1(1 − α)|µ2 = 0] = α. The right
hand side of inequality (3.12), by monotonicity of PA(µ1, µ2), represents scenarios where
the probability of making type I error is highest. Although Jennison and Turnbull (1993,
2000) consider normally distributed random variables, using the central limit theorem, the
method can be used for binary outcomes if the number of patients is large enough. Fur-
ther, Jennison and Turnbull (1993) have extended the method to allow for more than one
inspection.
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Bayesian methods
In Bayesian setting the possible outcomes (based on efficacy and toxicity) are assigned
some utility values. While focussing on efficacy only, for a binary outcome, binomial
models are reasonable. The same is true for toxicity (DLT). When interest is in both efficacy
and toxicity, two categories are no longer adequate. Combinations of efficacy and toxicity
outcomes will result in more than two categories. Suppose we consider the simplest case
where both efficacy and toxicity are binary outcomes. The possible outcomes are shown
in Table 3.3. Administration of a drug to a patient will either result in efficacy and DLT
(Y Y ), DLT without efficacy (NY ), efficacy without toxicity (Y N) or neither efficacy nor
toxicity (NN). Let l denote the possible categories based on efficacy and toxicity. Loke
et al. (2006) propose a method that models the probability of the four outcomes so that
l = 4. Whitehead et al. (2006) give priority to avoiding a DLT such that the four outcomes
Y Y , NY , Y N and NN reduce to ∗Y , Y N and NN where ∗Y means eitherNY or Y Y so
that l = 3. Stallard et al. (1999) noted that these two cases of l = 3 and l = 4 encompass a
very large proportion of phase II clinical trials.
The method by Loke et al. (2006) was intended for phase I trials but like the method
proposed by Whitehead et al. (2006), it could be used in early phase II clinical trials where
another separate phase II trial is expected to be carried out. In the two methods, all patients
are allocated to the experimental treatment. The method by Stallard et al. (1999) includes
a control arm and is applicable to the late phase II clinical trials. Loke et al. (2006) and
Stallard et al. (1999) assume the outcomes in Table 3.3 have a multinomial density and
Dirichlet prior distribution can be elicited. To compare the outcomes, utilities are assigned
to the different possible outcomes. Whitehead et al. (2006) model two dose-response curves
to estimate the probabilities of the three outcomes ∗Y , Y N and NN . In this subsection,
we will describe the method by Stallard et al. (1999) because it is different from the other
two methods in that it has a control arm. We will also describe the work of Whitehead et al.
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Table 3.3: Cross tabulation of toxicity and efficacy
Toxicity (X2)
Efficacy (X1) Y es (Y ) No (N)
Y es (N) Y Y Y N
No (N) NY NN
(2006) because later in this thesis we borrow ideas from this method.
Stallard’s method
The phase II design proposed by Stallard et al. (1999) is a decision theoretic method which
allows for more than one data inspection and at any data inspection, the decision theoretic
design they propose is flexible enough to allow the three actions (A, P and C) described in
Section 3.3.1 or only actions A and C. In their design, they assume a maximum sample size
of M patients is available for testing in phase II. In order to determine whether to accept
or not to accept early stopping in phase II in favour of the new drug, some M1 ≤ M is
pre-determined such that at least M1 patients are treated before action P can be allowed.
M1 = 0 allows proceeding to phase III at any data inspection while M1 = M only allows
proceeding to phase III when all the available patients have been treated.
The possible actions (A, P and C) may be compared using gain functions. The gain
functions Stallard et al. (1999) proposed are similar to the gain functions given in Section
3.3.4. As before, letE denote the new drug and S the standard drug and that the probability
of outcome i, i = 1, ..., l (l ≤ 4) for treatment t, t ∈ {E, S} be denoted by θti such that
θt1 + ... + θtl = 1. Further let the probability vectors (θE1, ..., θEl)
′ for the new drug and
(θS1, ..., θSl)
′ for the standard drug be denoted by θE and θS respectively. The addition in
the gain functions of Section 3.3.4 is the patient gain which we denote by some function
g(θE, θS) for patient treated with E under the pair (θE , θS). To specify the form of this
function utilities are assigned to the l possible outcomes such that the expected utility when
a patient is treated with the new drug E is u′θE = u1θE1 + ... + ulθEl. The corresponding
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expected utility for a patient treated with the standard drug is u′θS = u1θS1 + ... + ulθSl
and the patient gain could be defined as
g(θE, θS) = u
′
(θE − θS). (3.13)
The utilities u1, ..., ul may be elicited from the investigators. One way is to assign the
best outcome utility value +1 and the worst outcome utility value −1. Other outcomes are
elicited such that they take values in the interval [−1,+1].
In Section 3.3.4, the gain function for action A at the ith inspection was defined as
GA(p, ni) = −nik where p was the parameter of interest, ni the number of patients treated
at the ith inspection and k the cost of treating 1 patient. Now when the patient gain is
included and p replaced with the new parameter vector (θE , θS) the gain function becomes
GA(θE , θS, ni) = nig(θE, θS)− nik
= ni{u′(θE − θS)− k}. (3.14)
The gain function for action P in Section 3.3.4 was given asGP (p, ni) = −nik+l(ni)κ(p)−
m, where m is the total cost of the phase III clinical trial. By including the patient gain
for patients treated at the end of ith inspection, the term −nik, as in equation (3.14), is
replaced by ni{u′(θE − θS)− k}. Stallard et al. (1999) take the benefit to future patients to
be Πg(θE , θS) for some Π > 0. Because Πg(θE , θS) is in the same scale as the patient gain,
Π may be interpreted as the number of future patients to benefit from treatment with E.
The values of Π might also reflect the gains to the clinicians or pharmaceutical companies
and thus need not to be equated to a number of potential patients. Thus the term l(ni)κ(p)
is replaced by Πg(θE , θS) so that
GP (θE , θS, ni) = ni{u′(θE − θS)− k}+Πg(θE, θS)−m
= ni{u′(θE − θS)− k}+Πu′(θE − θS)−m. (3.15)
To compare the actions, expectations of equations (3.14) and (3.15) are evaluated. The
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expected gain function for action C at ith inspection depends on the action that will taken
at (i+ 1)th inspection and is obtained as was explained in Section 3.3.4.
Whitehead’s method
As mentioned before, Whitehead et al. (2006) give priority to avoiding a DLT so that the
four outcomes in Table 3.3, Y Y , NY , Y N and NN reduce to ∗Y , Y N and NN where ∗Y
means either NY or Y Y . The probabilities for the three outcomes are respectively denoted
by p∗Y (d), pY N(d) and pNN (d) and the conditional probability of DO, given no DLT is
denoted by pY |N(d). Two logistic models are used to describe the probabilities;
p∗Y (d) =
exp(α∗Y + β∗Y log d)
1 + exp(α∗Y + β∗Y log d)
(3.16)
pY |N(d) =
exp(αY |N + βY |N log d)
1 + exp(αY |N + βY |N log d)
. (3.17)
The advantage of modeling the conditional probability (pY |N(d)) is that this does not re-
quire modeling the association between DO and DLT. Using the multiplicity probability
law p(A ∩ B) = p(B|A)× p(A), we have
pY N (d) = pY |N(d)× (p∗Y )c = pY |N(d)× (1− p∗Y )
=
exp(αY |N + βY |N log d)
{1 + exp(α∗Y + β∗Y log d)}{1 + exp(αY |N + βY |N log d)} .
Using the law of probability p∗Y (d) + pY N(d) + pNN(d) = 1, then
pNN(d) = 1− p∗Y (d)− pY N(d)
=
1
{1 + exp(α∗Y + β∗Y log d)}{1 + exp(αY |N + βY |N log d)} .
The Whitehead et al. (2006) method for recommending the doses to which the next
cohort of patients should be allocated uses the Bayesian principle. The joint distribution
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for (α∗Y , β∗Y ) in model (3.16) and the joint distribution for (αY |N , βY |N) in model (3.17)
are elicited separately. Figure 3.8 shows the curves of the prior means for different dose
response relationships using the prior distributions that Whitehead et al. (2006) use in their
illustrating example. Using the elicited prior distributions, the dose-response curves based
on prior means indicate the probability of a DLT (p∗Y ) and the probability of DO given
no DLT (pY |N ) increase with dose level. The other curves are derived from these two
models. The probability that the administration of a drug to a patient results in neither a
therapeutic effect nor a toxic effect (pNN ) decreases with the dose level. The highest dose is
not necessarily the best choice as the curve of pY N(d) shows. The posterior probability of
a therapeutic effect and no toxic outcome increases to some dose level and then decreases.
Thus if the investigators’ objective is to identify a dose that has the highest chance of
therapeutic effect but no DLT, this dose is not necessarily the highest experimental dose
level although the probability of DO given no DLT (pY |N ) increases with dose level. This
is similar to the objective of the dose selection procedure we propose in Chapter 5. We will
aim to select the dose that is more efficacious compared to the control treatment and has
the probability of DLT less than a specified value.
The joint prior distributions for the parameter vectors (α∗Y , β∗Y ) and (αY |N , βY |N)
are obtained as described in Section 2.2.2. For model (3.16), pseudo-data are used to define
the prior distributions at two dose levels di1 (i = −1, 0). These consist of ni1 = ai + bi
pseudo-subjects treated at dose di1, of whom ai suffer DLTs. The second subscript on dose
di1, that is 1, is an indicator for model (3.16). Thus assuming the prior distribution of the
form (2.6), the prior distribution for (α∗Y , β∗Y ),
pi01(α∗Y , β∗Y ) =
0∏
i=−1
paii1(1− pi1)bi
B(ai, bi)
∣∣∣∣log
(
d−11
d01
)∣∣∣∣ , (3.18)
where
pi1 =
exp(α∗Y + β∗Y log di1)
1 + exp(α∗Y + β∗Y log di1)
, i = −1, 0.
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Figure 3.8: Dose response curves using the prior means
After the trial starts, suppose that ni1 subjects have been treated with the experimental dose
di1 of whom mi have shown no response, ti have exhibited a DO without a DLT, and ai
have suffered a DLT so that mi + ti + ai = ni1 for i = 1, ..., k. Denoting these observed
data by x, the posterior distribution will be of the form given by (2.7) so that
pi(α∗Y , β∗Y |x) ∝
k∏
i=−1
paii1(1− pi1)bi, (3.19)
where
pi1 =
exp(α∗Y + β∗Y log di1)
1 + exp(α∗Y + β∗Y log di1)
, i = −1, 0, 1, ..., k.
Similarly, for model (3.17), to define the prior distribution for αY |N and βY |N , let ni2 =
ti + ui pseudo-subjects treated at dose di2, all of whom have no DLT, and ti of whom have
a DO. The second subscript on dose di2, that is 2, is an indicator for model (3.17). Thus
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assuming the prior distribution of the form (2.6), the prior distribution for (αY |N , βY |N),
pi02(αY |N , βY |N) =
0∏
i=−1
ptii2(1− pi2)ui
B(ti, ui)
∣∣∣∣log
(
d−12
d02
)∣∣∣∣ ,
and the joint posterior density for αY |N and βY |N is
pi(αY |N , βY |N |x) ∝
k∏
i=−1
ptii2(1− pi2)ui, (3.20)
where
pi2 =
exp(αY |N + βY |N log di2)
1 + exp(αY |N + βY |N log di2)
, i = −1, 0, 1, ..., k,
and ui = mi, ni2 = ui + ti with di1 = di2 for i = 1, ..., k.
Let us define the therapeutic window as the interval (dL, dU) for which pNN(dL) =
cL and p∗Y (dU) = cU (cL and cU small values such as 0.2). Whitehead et al. (2006) propose
dose allocation so as to maximize the inverse of the sum of the variances of the boundaries
of the therapeutic window defined as
G(θ) = {wLV ar(dL|xa) + wUV ar(dU |xa)}−1,
where θ is a vector of parameters α∗Y , β∗Y , αY |N and βY |N , xa denotes the current data x
augmented with the data that will be observed on the next cohort of subjects, and wL and
wU are appropriate weights. The number of inspections with this method depend on the
total sample size for the whole trial and the cohort sizes.
3.3.6 Phase II studies with several doses
In the late phase II studies, the investigators while doing tests to decide whether it is worth
continuing to phase III studies, may still be uncertain as to which is the best potential dose
of the new drug to test in the phase II clinical trial. To overcome this difficulty, several
doses of the new drug may be compared to the standard treatment. This results to testing
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multiple hypotheses comparing the standard treatment to many doses of the new drug. In
frequentist testing, if it is desired to control the type I FWER associated with comparing
several doses to a control treatment at some level α, then the pairwise p-value comparing
each dose to the control needs to be adjusted. These methods are discussed extensively in
Section 4.3. Bayesian methods are also available. For example, the ideas in the works by
Stallard et al. (1999) and Loke et al. (2006) could be combined to develop a method that
allows for several doses. The method by Loke et al. (2006) uses several doses and Stallard
et al. (1999) define gain functions which incorporate whether it is worth continuing to the
phase III stage.
3.4 Phase III clinical trials
Phase III trials are typically large confirmatory trials for efficacy. The main focus is placed
on efficacy but safety is also monitored. The new drug is compared with a commonly used
drug (the control or the standard drug) usually in a randomized trial. The trial subjects are
allocated randomly to the new drug treatment arm and the standard drug treatment arm and
the measure of efficacy, side effects and all information that will allow the new treatment to
be used safely are examined. Evidence of efficacy is usually assessed by testing hypotheses
usually using frequentist methods.
3.4.1 Sample size calculation in fixed sample trials
The statistical aspects involved in designing a phase III clinical trial include determining
whether there will be interim analyses or not and calculating the sample size. Adopting
the definition of Whitehead (1997), we refer to clinical trials where analysis is carried out
after all patients have been entered in the trial and the outcomes observed as fixed sample
clinical trials. In this subsection, we briefly describe the rationale for sample size formulae
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for a fixed sample clinical trial. More detail of the rationale for sample size formulae are
given by Friedman et al. (1998), Machin et al. (2009) and Cleophas et al. (2009) among
others.
For simplicity, suppose a new drug is being tested for superiority. Before a new
drug is accepted for use by the regulatory authorities, the investigators must demonstrate
clearly that the new drug is better than the standard drug. For this reason, the probability
of concluding that the new drug is better than the standard drug while the truth is that the
new drug is not better than the standard drug, is often set to a maximum of 2.5% (0.025).
This probability is referred to as the type I error and is usually denoted by α. On the
other hand it is essential to have a clinical trial with sufficient statistical power to detect a
difference between the new drug and the standard drug when it truly exists. The probability
of concluding that the new drug is better than the standard drug when the new drug is truly
better than the standard drug by some specified amount is called the power and is usually
denoted by (1 − β), where β denotes the type II error. Type II error is the probability of
failing to reject the null hypothesis that the new drug is not better than the standard drug
when the truth is that the new drug is better than the standard drug by the specified amount.
The danger of conducting a clinical trial with low power is that new treatments that are
beneficial are discarded without adequate testing and may never be considered in future
(Friedman et al., 1998). In addition to the monetary loss the drug company will incur, this
leads to loss to society associated with the lack of effective therapies. In practice trials are
normally designed to have power of between 0.8 and 0.95 so that the probability of a type
II error is controlled at between 0.05 and 0.2.
To plan a trial with the desired statistical power and control type I error, sample
size calculation is based on α and β. To determine the power of a test the effectiveness
of the new and standard drug are required. In sample size calculation, the hypothetical
effectiveness of the standard is determined and the effectiveness of the new drug is taken
as the sum of the effectiveness of the standard drug and a difference of medical relevance.
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For example for binary outcomes, suppose the probability of successful treatment with the
standard drug is p0 and with the new drug is p1 = p0+ δ, where δ is a difference of medical
relevance, then one of the sample size approximation for a one-sided test at level α is given
by
2N =
2
{
Zα
√
2p¯(1− p¯) + Zβ
√
p0(1− p0) + p1(1− p1)
}2
(p0 − p1)2 ,
where p¯ = (p0 + p1)/2 and N is the number of patients in each treatment arm, and Zα and
Zβ are standard normal values such that Φ(Zα) = 1− α and Φ(Zβ) = 1− β, where Φ as
before is the standard normal distribution function. Alternative sample size formulae are
given for example by Friedman et al. (1998) and Machin et al. (2009) but they point out that
these formulae give similar results to the above sample size formula. Sample size formulae
for other outcome variables such as survival outcomes, continuous outcomes are available
in most clinical trials books such as the ones cited at the beginning of this subsection. Due
to loss in follow-up visits, some investigators increase the calculated sample size by some
factor.
3.4.2 Sequential investigations
Recruitment of patients in a clinical trial occurs gradually during the course of the trial
which can extend to years depending on the prevalence of the targeted disease and the size
of targeted population. This feature opens the possibility of stopping the trial earlier based
on the emerging evidence (Armitage, 1975; Whitehead, 1997). In clinical trials based on
efficacy, on ethical grounds, it may be desirable to stop the trial if there is a clear advantage
of either drug (new or standard) over the other thereby avoiding the allocation of more pa-
tients to the less efficacious drug. The pharmaceutical company may also wish to save costs
by stopping a trial early for a drug which appears to have little chance of demonstrating im-
proved efficacy. In principle sequential investigation may be carried out after the outcome
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of each patient has been observed but for practical reasons, sequential investigations are
performed either at some pre-specified times or after a pre-specified number of patients (or
pre-specified number of events such as number of deaths for survival outcomes) have been
observed.
In sequential trials, some method for combining evidence from the interim analyses
is required. In this thesis, we will describe two methods. In the first method, raw data or
sufficient statistics are merged to make the final analysis. We will refer to this method of
combining evidence as the group sequential technique. In the second method, data from
each interim analysis are analysed separately and some combination function is used to
combine the p-values. We will refer to this method of combining evidence using the p-
values as the method of combination tests. In Chapter 4, we will introduce seamless phase
II/III clinical trials which are trials that combine phase II and phase III into single trial.
Analysing these trials require combining evidence from phase II stage and the phase III
stage which can be done using the group sequential technique or by combination tests so
that these methods of combining evidence will be described in detail in Chapter 4.
In the next chapter, while demonstrating how evidence from the phase II and phase
III stages may be combined using the group sequential technique and by use of combination
tests, we will assume that there will be no opportunity to stop the trial after the phase II
stage for futility or for strong evidence against the null hypothesis that the new drug is
not better than the control treatment. Phase III clinical trials with sequential investigation
(testing) would allow for early stopping either for futility or overwhelming evidence that
the new drug is better than the control treatment. Suppose in the entire trial we aim to
control the type I error at level α. Armitage (1975), by use of examples based on binary
and continuous data, has shown that if at each stage of the investigation hypothesis testing
is carried out at level α, the overall type I error is inflated above α. Accordingly, methods
for analysing data sequentially without inflating overall type I error have been developed.
Pocock (1977), O’Brien and Fleming (1979), and Lan and DeMets (1983) have developed
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methods based on group sequential testing that allow for early stopping while controlling
overall type I error rate α and Brannath et al. (2002) have developed methods for adjusting
for early stopping without inflating overall rate α based on combination tests.
Chapter 4
Seamless phase II/III clinical trials
In the last chapter, we have stated the objective of each phase of a clinical trial, reviewed
some methods used to design trials in each phase, and discussed how conclusions are made
from these trials. In the methods described, the conclusion from a trial did not include
evidence from the previous trials. In this chapter, we introduce seamless phase II/III clinical
trials, which are trials that combine phase II and phase III clinical trials into a single trial.
These trials are attractive because data from both phase II and phase III are used in the
final confirmatory analysis. The combination of phases II and III does, however, introduce
complexity in analysis. The analysis poses a challenge of how to combine evidence from
the phase II stage and phase III stage without inflating the type I error rate. Further, if
multiple hypotheses are tested, the analysis poses a second challenge of how to adjust for
multiple testing associated with testing several hypotheses. In the next section, we describe
the testing process in phase II/III clinical trials and explicitly describe the challenges posed
by these trials. In Section 4.2, we review some methods that can be used to combine
evidence from the phase II stage and phase III stage. In Section 4.3, we review some
methods that can be used to adjust for multiple testing. In Section 4.4, we describe the
proposal by Bauer and Kieser (1999), Hommel (2001) and Bretz et al. (2006) to analyse
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phase II/III clinical trials data that address both the challenge of combining evidence and
testing multiple hypotheses without inflating the type I error rate. The notation given in
Bretz et al. (2006) is used. In Section 4.5, we review some of the existing methods for
treatment selection in phase II/III clinical trials.
4.1 The testing process and challenges in phase II/III clin-
ical trials
In most of the designs that we reviewed in Chapter 3, it was assumed that the testing of
the new drug takes place in the traditional way: each phase is carried out as a separate
trial. Furthermore, it may appear as if in each phase, only one trial is required. However,
for example in phase II, two or more trials may be carried out. If two trials are carried
out in phase II, the first trial may be a proof of concept trial, where some dose-response
modelling is done with the intention of identifying the minimum effective dose (MED).
The second trial would then be a phase IIb trial, which may involve testing of hypotheses,
where for example, several doses of a new drug (of higher efficacy level than MED) are
compared to the standard treatment. Each clinical trial requires careful planning which
means considerable time may be required to plan a trial. Thus the traditional procedure for
testing a new drug, with many trials to be carried out, is very time consuming. Secondly,
in the traditional procedure, data from the previous trials are not used in the analysis of the
current trial data. This means to achieve adequate power, more patients are required, hence
prolonging the recruitment time.
When a drug company starts testing a new product, the product is registered and
the company is given a patent period during which no other company is allowed to test
or produce that product. The patent period includes the development process time; hence
there is a financial benefit to a drug company if the development time is reduced, increasing
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the period the drug company will have a monopoly to produce and market the new drug. In
addition to the financial benefit to the drug company, accelerated drug development avoids
delay in potential benefits to the society. Hence any procedure or technique that will reduce
the duration of drug development while maintaining the trial integrity is welcome.
In order to reduce the time before approval of a new drug, there has been interest in
combining different phases of a clinical trial. Trials which combine phase II and phase III
into a single trial with a phase II stage and phase III stage are referred to as (seamless) phase
II/III clinical trials. Such trials are conducted in two stages. In stage 1 (phase II stage) of
phase II/III clinical trials, usually several hypotheses are of interest. For example, a new
drug may be tested in different sub-populations such as different age-groups or groups
based on a set of biomarkers which could affect sensitivity to the new drug, with the aim of
identifying the sub-populations that respond favorably to the new drug. Another example
is that in stage 1, a control treatment is compared to different experimental treatments,
which could be different doses of a new drug, with the aim of identifying promising new
treatments. In the case of sub-population selection, sub-populations that show promising
results continue to stage 2 (phase III stage). Similarly, in the case of treatment selection,
sufficiently promising treatments continue to stage 2 along with the control treatment. After
stage 2 results, at the end of the phase II/III clinical trial, data from both stages are used to
test the hypotheses of interest. In both the examples that we have given above, two issues
arise while analysing data generated from such a phase II/III clinical trials, namely: (i) how
to combine the evidence from the two stages without inflating the type I error rate, and (ii)
how to control the type I familywise error rate (FWER) associated with testing multiple
hypotheses.
The work in this thesis is based on the second example above, where in the phase
II stage, the objective is to identify promising treatments that will continue for testing in
the phase III stage. Specifically, in the phase II stage, we will assume that several dose
levels of a new drug are compared to the control treatment, and a subset of the dose levels
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tested in phase II stage continue with the control treatment to the phase III stage. Planning
such a phase II/III clinical trial presents two challenges: (i) how to perform analysis that
controls the error rates, and (ii) how to choose which doses should continue to the phase
III stage after the phase II stage. Methods that control error rates in the analysis of phase
II/III clinical trials with flexible choice of doses exist but there is very little work to guide
the choice of doses. An example of an analysis that allows flexible choice of doses to test
in stage 2 is given in Section 4.4. The objective of this thesis is to provide a solution for
the second challenge by developing a new dose selection procedure. This procedure is
described in the next chapter. In order to point out the differences between this procedure
and the existing methods that can be used to make a choice of the doses to test in stage 2,
in Section 4.5 we review some methods available in literature that may be used to select
the doses that proceed to stage 2.
4.2 Combining evidence from two stages
In Section 3.4.2, we explained that a phase III trial could include one or more interim
analyses. We mentioned two techniques of including evidence from interim analyses in the
final analysis: the group sequential method, and the use of combination tests. The same
techniques would apply in a phase II/III clinical trial, where the phase II stage could be
viewed as being equivalent to an interim analysis. In this Section, we describe how the two
methods may be used to test data from a phase II/III clinical trial when we assume there is
no stopping after stage 1 (phase II stage).
4.2.1 Combining evidence using group sequential technique
Using the group sequential techniques, data from stage 1 and stage 2 are merged and an
analysis is carried on the merged data set. Alternatively, as has been the case while design-
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ing group sequential clinical trials, some sufficient statistics could be used to combine the
evidence from the two stages. We demonstrate combining evidence in a two-stage group
sequential using the efficient score statistics described by Whitehead (1997). Suppose that
the new drug and the control are compared using some parameter θ, which is a measure of
the treatment difference between the new and the control drug. For example if the outcome
of interest is continuous and normally distributed, the parameter θ could be given by the
standardized mean difference
θ =
µE − µC
σ
,
where µE and µC are treatment means for the new drug and the control drug respectively
and σ is the population standard deviation for patients treated using the new drug and the
control drug. The inference on θ using the data from stage s alone (s = 1, 2), is based
on a statistic Zs. The statistic Zs is the efficient score and is asymptotically normally
distributed with mean θVs and variance Vs, where Vs is the Fisher’s information about θ
contained in Zs, that is, Zs will be taken to be normally distributed N(θVs, Vs). As Z1 and
Z2 are calculated from data from separate stages, they are independent. This notation is
used to facilitate comparison with the method described in Section 4.2.2. Notation used by
Whitehead (1997) is different with Z2 being the efficient score based on both stage 1 and
stage 2 data and V2 the accumulated Fisher’s information so that Z2 − Z1 ∼ N(θ(V2 −
V1), V2 − V1) and is independent of Z1.
To describe how the statistics Zs and Vs are derived, we for the moment ignore the
subscript denoting the stage for which the statistics are based so that we describe using
notation Z and V . The statistics Z and V can be derived from appropriate likelihood
functions. If there are unknown nuisance parameters, the profile likelihood is used and this
guarantees
l{θ, φˆ(θ)} = const + θZ − 1
2
θ2V +O(θ3),
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where φˆ(θ) is the maximum likelihood estimate of the nuisance parameter vector φˆ given
the value of θ. In the absence of nuisance parameters,
Z = lθ(0)
and
V = −lθθ(0),
where lθ(0) and lθθ(0) denote respectively the first and second derivatives of l(θ) evaluated
with respect to θ, evaluated at θ = 0. To illustrate with inference for mean of normal
data with known variance, let a sample x1, ..., xn be observations from a normal population
distributed as N(µ, 1) so that the likelihood of these data is given by
L(µ) =
n∏
i=1
(2pi)−1/2exp
(−(xi − µ)2
2
)
= (2pi)−n/2exp
(−(∑ni x2i − 2µ∑ni xi + nµ2)
2
)
.
The corresponding log-likelihood has the form
l(µ) = const + µSn − 1
2
µ2n,
where Sn =
∑n
i=1 xi so that Z = Sn and V = n and inference on µ is made from the
statistic Sn which is such that Sn ∼ N(µn, n). Whitehead (1997) also gives forms for Z
and V for comparative studies.
Reverting to Zs and Vs to denote the statistics at stage s (s = 1, 2), the statistic
Z = (Z1 + Z2) ∼ N(θ(V1 + V2), (V1 + V2))
is the efficient score statistic based on data from both stage 1 and stage 2. Suppose that
after collecting data in stage 1 and stage 2, the realizations for the efficient scores Z1 and
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Z2 are z1 and z2 respectively. Then, using the group sequential approach, the p-value from
the two stages is given by
Prob(Z ≥ z1 + z2|θ0) = 1− Prob(Z ≤ z1 + z2|θ0)
= 1− Prob
(
Z − θ0(V1 + V2)√
V1 + V2
≤ z1 + z2 − θ0(V1 + V2)√
V1 + V2
)
= 1− Prob
(
Z∗ ≤ z1 − θ0V1√
V1 + V2
+
z2 − θ0V2√
V1 + V2
)
= 1− Φ
{
z1 − θ0V1√
V1 + V2
+
z2 − θ0V2√
V1 + V2
}
, (4.1)
where Z∗ ∼ N(0, 1) and θ0 is the value of the parameter θ under the null hypothesis.
4.2.2 Combining evidence using combination tests
Bretz et al. (2006) use the combination test as described by Bauer and Ko¨hne (1994).
Using the combination test, data from each stage are analysed separately. In order to make
a single conclusion from the two stages, p-values obtained at the end of each stage are
combined using some functionC into a single p-value. Bauer and Ko¨hne (1994) implement
combination tests in adaptive clinical trials but the technique of combining evidence using
combinations tests had been proposed by Fisher (1932) to address the need to combine
results from a number of independent tests used to test a common hypothesis. Suppose
a null hypothesis H (notice here we do not use the conventional notation H0) is tested at
stage 1 and stage 2 obtaining the p-value ps at stage s (s = 1, 2). Further, let the combined
p-value be denoted by C(p1, p2). Zaykin et al. (2002) have reviewed some methods of
combining the p-values. Two of the commonly used methods are the Fisher’s combination
method and the weighted inverse normal method.
For uniformly distributed p1 and p2, the functions −2 log ps (s = 1, 2), where log
is to base e, have a chi-square distribution with two degrees of freedom. Using the fact
that the sum of random variables that are χ2-distributed has a χ2-distribution with degrees
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of freedom equal to the sum of the degrees of freedom of the summed random variables,
Fisher (1970) noted that
T = −2
2∑
s=1
log ps = −2 log
2∏
s=1
ps
has a χ2-distribution with 4 degrees of freedom when the null hypothesis H is true and the
p-values p1 and p2 are independent. Therefore, the p-value for testing the null hypothesis
H using the evidence from the 2 stages is the probability of a χ24 variable being greater or
equal to the observed value T ∗ of T so that, using the Fisher’s combination method, the
combined p-value
C(p1, p2) = 1− Fχ2
4
(−2 log
2∏
s=1
ps), (4.2)
where Fχ2
4
is the distribution function of a chi-square distribution with 4 degrees of free-
dom.
The inverse normal procedure uses the normal-transformed p-values. Let X be a
normally distributed random variable with mean 0 and variance 1, that is, X ∼ N(0, 1).
Further, let the distribution function of X be denoted by Φ(x) and suppose that Pr(X ≤
x) = Φ(x) = c. Because X ≤ x is equivalent to Φ(X) ≤ Φ(x), then
Prob(Φ(X) ≤ c) = Prob (Φ(X) ≤ Φ(x))
= Prob(X ≤ x) = Φ(x) = c.
Hence Prob(Φ(X) ≤ c) = c, which implies the distribution function of a standard normal
random variable is Uniform[0,1] so that the p-value ps for hypothesisH at stage s (s = 1, 2)
can be transformed into standard normal score when the hypothesis H is true by taking
zs = Φ
−1(1− ps), s = 1, 2.
LetXj , j = 1, 2, ..., n be distributedN(0, 1) and α1, ..., αn be constants such that
∑
j α
2
j =
1, then the linear combination Y =
∑
j αjXj is distributed N(0, 1). Using this standard
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result, then
z =
2∑
s=1
zs√
2
is standard normal and the combined p-value may be given by
C(p1, p2) = 1− Φ
(
1√
2
2∑
s=1
Φ−1(1− ps)
)
.
Other weights w1 and w2 which satisfy w21 + w22 = 1 can be used in place of the 2 equal
weights 1/
√
2 so that using the weighted inverse normal method for combining evidence
in a phase II/III clinical trial, the combined p-value is given by
C(p1, p2) = 1− Φ[w1Φ−1(1− p1) + w2Φ−1(1− p2)], (4.3)
where 0 < ws < 1, s = 1, 2, are arbitrary weights subject to w21 + w22 = 1. Suppose the
efficient scores given in Section 4.2.1 are used to obtain the p-values at each stage, then
1− p1 = 1− Prob(Z1 ≥ z1|θ0) = Prob(Z1 ≤ z1|θ0)
= Prob
(
Z1 − θ0V1√
V1
≤ z1 − θ0V1√
V1
)
= Φ
(
z1 − θ0V1√
V1
)
. (4.4)
Equivalently,
1− p2 = Φ
(
z2 − θ0V2√
V2
)
. (4.5)
Substituting the expressions (4.4) and (4.5) in the expression (4.3) for inverse normal
method combined p-value and letting ws =
√
Vs/(V1 + V2) (s = 1, 2), then
C(p1, p2) = 1− Φ
{
2∑
s=1
√
Vs
V1 + V2
Φ−1
{
Φ
(
zs − θ0Vs√
Vs
)}}
= 1− Φ
{
2∑
s=1
(
zs − θ0Vs√
V1 + V2
)}
= 1− Φ
{
z1 − θ0V1√
V1 + V2
+
z2 − θ0V2√
V1 + V2
}
. (4.6)
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The combined p-value obtained from expression (4.6) and the p-value obtained using the
group sequential in expression (4.1) are equal. Hence, if the weights ws (s = 1, 2) for
the inverse combination method are appropriately chosen, this combination function cor-
responds to the two-stage group sequential test. Choosing the weights proportional to the
sample size, that is taking ws =
√
ns/(n1 + n2) (s = 1, 2), where n1 and n2 are the stage
1 and stage 2 sample sizes, achieves this since V1 and V2 are approximately proportional to
the respective sample sizes.
Next we give the expressions for the type I error and the critical p-value for testing
hypothesis H such that the type I error is not inflated. Suppose there is opportunity to stop
the trial early after stage 1 for overwhelming evidence against the null hypothesis, that is
when p1 ≤ α1 (α1 ≤ α) or for futility, that is when p1 > α0 (α0 > α). Then, the type I
error is the probability that, under the null hypothesis H , either p1 ≤ α1 or α1 < p1 ≤ α0
and the combined p-value C(p1, p2) ≤ c, that is
ProbH [p1 ≤ α1] + ProbH [C(p1, p2) ≤ c, α1 < p1 ≤ α0],
where c is the combined critical p-value and is obtained by equating the above equation
to overall type I error α and solving for c. Assuming that the p-values p1 and p2 have
independent Uniform[0, 1] distributions under the null hypothesis, then the overall type I
error is given by
α1 +
∫ α0
α1
∫ 1
0
1[C(p1,p2)≤c]dp2dp1, (4.7)
where 1[C(p1,p2)≤c] equals 1 if C(p1, p2) ≤ c and 0 otherwise. For the first part of our
work, we assume we do not stop for overwhelming evidence and stopping for unpromising
results in stage 1 does not depend on the observed stage 1 p-value p1. Note in this case we
do not make any type I error at stage 1 so that equation (4.7), if the trial proceeds to stage
2, simplifies to ∫ 1
0
∫ 1
0
1[C(p1,p2)≤c]dp2dp1. (4.8)
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In expression (4.8), if the overall type I error is controlled at level α, we have c = α, so that
the combined p-values defined by equations (4.2) and (4.3) control error rate at level α.
The p-values defined by (4.2) and (4.3) clearly control the type I error rate because
the p-values p1 and p2 are assumed independent under H . Brannath et al. (2002) explain
this is a strong requirement. The only requirement needed in order for the p-values defined
by equations (4.2) and (4.3) to control the type I error rate is that the distribution of the
p-values p1 and p2 under H to satisfy
PrH(p1 ≤ α) ≤ α and PrH(p2 ≤ α|p1) ≤ α for all 0 ≤ α ≤ 1. (4.9)
Brannath et al. (2002) refer to this property of the distribution of p-values p1 and p2 as “p
clud”.
4.3 Controlling familywise error rate in multiple hypothe-
ses testing
Suppose in an experiment k(> 1) experimental treatments are to be compared with a con-
trol treatment such that k null hypotheses Hj : θj = θ0, j = 1, ..., k comparing each
experimental dose with the control treatment are of interest, where θj and θ0 respectively
denote the measure of effectiveness for experimental treatment j and the control treatment.
Without loss of generality, suppose the first k1 (k1 ≤ k) null hypotheses are true. Let Ej
be the event that the null hypothesisHj (j = 1, ..., k) is rejected, then if no multiple testing
adjustment is made, the overall (type I) FWER associated with testing the k null hypotheses
is
1− Prob(∩k1j=1Ecj | H0k1),
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where the notation “| H0k1” means that given the null hypothesesHj, j = 1, ..., k1 are true.
If the events E ′js, j = 1, ..., k1 are independent the above expression reduces to
1−
k1∏
j
[1− Prob(Ej | H0k1)].
For example, if k1 = 2 and each hypothesis is tested at level α = 0.05 and the hypothesis
H1 and H2 are independent, then the unadjusted type I error is
1− (1− 0.95)2 = 0.0975
so that the FWER is almost double the individual type I errors associated with testing H1
and H2. Indeed, one is almost certain to make a type I error when the number of true null
hypotheses to be tested becomes large (Hochberg and Tamhane, 1987). Thus, for a credible
analysis, methods are required to control the FWER associated with testing the k pairwise
null hypotheses at the pre-specified level α.
There are several testing procedures that can be used to test the multiple hypotheses
so that the FWER is controlled at the desired level α. Hochberg and Tamhane (1987)
explain that the FWER may be strongly or weakly controlled. The FWER is strongly
controlled if
[
1− Prob(∩k1j=1Ecj | H0k1)
] ≤ α, for all k1 ≤ k,
and the FWER is controlled weakly if
[
1− Prob(∩k1j=1Ecj | H0k1)
] ≤ α, only when k1 = k,
that is, when all the tested null hypotheses are true. An example of a test that controls
FWER weakly is due to Fisher (1935). In this test, individual pairwise hypotheses are
tested only when the global null hypothesis of no difference among all the k+1 treatments
(that is the k experimental and the control treatment are all equal) is tested and rejected.
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This test controls the FWER strongly only if k = 2. For k ≥ 3, the test controls the
FWER weakly. All the other procedures we describe later in this section strongly control
the FWER.
Westfall and Young (1993) have reviewed some methods that control the FWER.
The simplest is the Bonferroni method in which each of the k null hypothesis is rejected
when the observed p-value is less or equal to α/k, which leads to the Bonferroni adjusted
p-value p˜j = min(kpj, 1), where pj is the unadjusted p-value obtained from testing the null
hypothesis Hj, j = 1, ..., k. The FWER is protected since
Prob(Reject at least one Hj | H0) = Prob
(
min
1≤j≤k
pj ≤ α/k | H0
)
≤
k∑
j=1
Prob(pj ≤ α/k | H0) = α.
A similar adjustment is by use of the ˇSida´k method, which rejects each of the k null hy-
pothesis when the observed p-value is less than 1 − (1 − α)1/k. This leads to the ˇSida´k
adjusted p-value p˜j = 1− (1− pj)k. This method is less conservative than the Bonferroni
correction and is exact for protecting FWER if all p-values are independent since
Prob(Reject at least one Hj | H0)
= Prob
(
min
1≤j≤k
{1− (1− pj)k} ≤ α | H0
)
= 1− Prob
(
min
1≤j≤k
{1− (1− pj)k} > α | H0
)
= 1− Prob (pj > {1− (1− α)1/k} for all j | H0)
= 1−
k∏
j=1
Prob
(
pj > {1− (1− α)1/k} | H0
) (4.10)
= 1− {(1− α)1/k}k = α.
The equality in step 4.10 holds assuming independence and the final results holds assuming
pj, j = 1, ..., k are Uniform[0,1].
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The Bonferroni and the ˇSida´k methods described above are single step procedures.
Holm (1979) introduced a sequentially rejective algorithm to test multiple hypotheses. The
algorithm is based on the ordered p-values, p(1) ≤ ... ≤ p(k), corresponding to hypotheses
H(1), ..., H(k). The reasoning is that once H(1) has been rejected using for example the
Bonferroni critical value α/k, we should believe that H(1) is false. Thus, there are only
k− 1 hypotheses which might still be true, implying the critical value α/(k− 1) should be
used for H(2) and so on. Holm’s Sequentially rejective algorithm is given below.
• Step 1: If p(1) > α/k, then accept all hypotheses H(1), ..., H(k) and stop; otherwise,
reject H(1) and continue.
.
• Step j: If p(j) > α/(k − j + 1), then accept all hypotheses H(j), ..., H(k) and stop;
otherwise, reject H(j) and continue.
.
• Step k: If p(k) > α, then accept hypothesis H(k); otherwise, reject H(k).
The adjusted p-values of this algorithm are p˜(1) = max{kp(1), 1}, p˜(2) = max{(k −
1)p(2), 1}, ...., p˜(k) = p(k).
Westfall and Young (1993) introduce the Bootstrap adjustments which have the
advantage of capturing the correlation structure. There are also other adjustments meth-
ods in literature. In order to control the FWER associated with testing the k pairwise
null hypotheses at pre-specified level α, Bretz et al. (2006) use the closure principle (CP)
of Marcus et al. (1976). The CP considers the set of all intersection hypotheses HJ =
∩j∈JHj, J ⊆ {1, ..., k} constructed from the initial hypotheses of interest. Marcus et al.
(1976) refer to this set, denoted by H, as the closure set. Using the CP, a null hypoth-
esis Hj, j = 1, ..., k is rejected at FWER α if all hypotheses HJ , J ⊆ {1, ..., k} with
j ∈ J are rejected at level α. Consider Figure 4.1 when k = 3. The closure set H equals
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Figure 4.1: Closure set with 3 treatments. The hypotheses contained in H1 are circled.
{H1, H2, H3, H12, H13, H23, H123}. Hypothesis H1 is rejected if the circled hypotheses
H123, H12, H13, and H1 are all rejected each at level α.
Marcus et al. (1976) have explained how the type I error for this procedure is at most
α. Let X be a random variable with distribution depending on a parameter θ ∈ Ω such that
H, the set of null hypotheses defined above, is a set of subsets of Ω. For each HJ ∈ H, let
φJ(X) be a level α test, that is, Probθ{φJ(X) = 1} ≤ α for all θ ∈ HJ where φJ(X) is an
indicator variable for rejecting HJ . As detailed in the steps for the closure principle above,
any null hypothesis HJ is rejected by means of φJ(X) if and only if all hypotheses H that
are included in HJ (H ⊂ HJ ) and belonging to H (H ∈ H) have been tested and rejected.
A type I error is committed if and only if the intersection of all true hypotheses, Hτ say, is
tested and rejected by means of φτ (X); in other words, if we denote by A the event that
any true HJ is rejected, and by B the event that φτ (X) = 1, then
Prob(A ∩ B) = Prob(B)Prob(A|B) ≤ α,
since φτ is a level α test hence Prob(B) ≤ α and Prob(A|B) ≤ 1. However, sinceA∩B =
A, Prob(A ∩ B) = Prob(A) and hence Prob(A) ≤ α. The probability of making no type I
error with this procedure is thus at least 1− α.
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4.4 Analysing data from a phase II/III clinical trial
Bauer and Kieser (1999), Hommel (2001) and Bretz et al. (2006) propose using the combi-
nation tests and the CP for the analysis of phase II/III clinical trials data. In their proposal,
a null hypothesis Hj (j = 1, ..., k) is rejected at the end of stage 2 if all the combined p-
values for all the hypotheses HJ , J ⊆ {1, ..., k} with j ∈ J are less than the pre-specified
level of testing. For example, suppose there are three experimental treatments at stage 1 and
let ps,J denote the p-value for testing hypothesis HJ , J ⊆ {1, 2, 3} at stage s (s = 1, 2).
Then hypothesis H1 is rejected at the end of stage 2 at level α if
max{C(p1,1, p2,1), C(p1,12, p2,12), C(p1,13, p2,13), C(p1,123, p2,123)} ≤ α.
Figure 4.2 gives the flow chart of this example. Panel (a) gives the stage 1 p-values cor-
responding to the hypotheses given in Figure 4.1. The p-values for hypotheses contained
in H1 are circled. On the other hand, panel (b) gives stage 2 p-values corresponding to the
hypotheses given in Figure 4.1 and once again, p-values for hypotheses contained in H1
are circled. Panel (c) gives the combined p-values. The combined p-values for hypotheses
contained in H1 are circled and they must all be rejected for hypothesis H1 to be rejected
after stage 2.
To illustrate what happens if some treatments are dropped after stage 1, suppose for
example that treatment 3 is dropped after stage 1, so that no data are available for treatment
3 at stage 2. The stage 2 p-values for this scenario are given in Figure 4.3. The tests for
intersection hypotheses H13, H23 and H123 respectively reduce to the tests for hypotheses
H1, H2 and H12 so that p2,13 = p2,1, p2,23 = p2,2 and p2,123 = p2,12. If treatment 3 is tested
for efficacy after stage 2, p2,3 may be fixed to 1. This follows the proposal by Posch et al.
(2005) where stage 2 p-values for hypotheses that do not have stage 2 data are fixed to 1,
which lead to conservative final tests for the hypotheses in the closure set.
To show tests for H13, H23 and H123 respectively using p2,1, p2,2 and p2,12 at stage
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Figure 4.2: P-values required to test 3 elementary hypotheses. Panels (a) and (b) respec-
tively give stage 1 and stage 2 p-values corresponding to hypotheses given in Figure 4.1.
Panel (c) gives the combined p-values for these hypotheses.
2 are level α tests when dose 3 is not tested in stage 2, we use a general case. Suppose
we wish to test a hypothesis HJ using the p-value p2,J ′ for hypothesis HJ ′ with HJ ⊆ HJ ′
(that is J ′ ⊆ J). Since HJ ⊆ HJ ′ , under HJ , HJ ′ is also true so that p2,J ′ ∼ U [0, 1]. Hence
testing HJ using p2,J ′ provides a level α test.
For the test described above to control the type I error rates strongly, the p-values
p1,J and p2,J should satisfy the “p clud” condition given by expression (4.9). In this thesis,
we will consider p-values p1,J and p2,J obtained using separate data, that is, p-value ps,J
(s = 1, 2) will be obtained using stage s data only. For now, we also assume appropriate
level α tests are used so that for all hypotheses HJ , ProbHJ (ps,J ≤ α) ≤ α (s = 1, 2).
Hence, when no treatments are dropped, the p-values p1,J and p2,J are independent so that
under HJ , the distribution of p1,J and p2,J satisfy the “p clud” condition. If some fixed
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Figure 4.3: Stage 2 p-values when treatment 3 is dropped
treatments are dropped after stage 1, as demonstrated above HJ is tested at stage 2 using
the p-value p2,J ′ for hypothesis HJ ′ with HJ ⊆ HJ ′ (that is J ′ ⊆ J). We need to show
that ProbHJ (p2,J ′ ≤ α|p1,J) ≤ α. From above a test for HJ using p2,J ′ is an α test, and
since p1,J and p2,J ′ are independent for a fixed HJ ′ , then ProbHJ (p2,J ′ ≤ α|p1,J) ≤ α so
that the p-values p1,J and p2,J ′ satisfy the “p clud” condition. If the dropped treatments
are tested for efficacy after stage 2, for some hypotheses HJ , J ′ = ∅. If following Posch
et al. (2005), the p-values p2,J ′ for these hypotheses are set to 1, that is p2,J ′ = 1 for
all J ′ = ∅, the p-values for hypotheses with J ′ = ∅ satisfy the “p clud” condition since
ProbHJ (p2,J ′ ≤ α | p1,J) = 0 ≤ α, so that the type I error rate is maintained.
In the next chapter, we develop a new procedure to select the treatments to test in
stage 2 and the selection procedure depends on stage 1 p-values p1,J (J ⊆ {1, ..., k}). We
will set a rule that the intersection hypothesisHJ will be tested using a test for the smallest
intersection hypothesis HJ ′ (HJ ⊆ HJ ′) that can be constructed from all the experimental
treatments that are selected for testing in stage 2. For example, if only experimental treat-
ment j (j = 1, 2, 3) is tested in stage 2, hypothesis H123 is tested using p2,j and if we test
treatments i and j (i, j ∈ {1, 2, 3}) at stage 2, H123 will be tested using p2,ij so that HJ ′
used in test forHJ at stage 2 is random. We need to show that ProbHJ (p2,J ′ ≤ α|p1,J) ≤ α,
where J ′ is random. Under HJ , all hypotheses HJ ′ with HJ ⊆ HJ ′ (that is J ′ ⊆ J) are
also true. Hence a test for HJ using p2,J ′ using hypothesisHJ ′ defined using the above rule
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is a level α test so that ProbHJ (p2,J ′ ≤ α|p1,J) ≤ α. Hence p1,J and p2,J ′ are “p clud”.
In the above discussion, while showing the p-values satisfy the “p clud” condi-
tion, we have assumed appropriate level α tests are used for all the hypotheses HJ (J ⊆
{1, ..., k}). We will illustrate the dose selection procedure developed in the next chapter
using chi-squared tests for the pairwise hypotheses Hj (j = 1, ..., k). Asymptotically, the
chi-square test provides a test with the type I error rate close to the desired nominal level
α. We will assume that sufficiently large samples will be available at stage 1 for each treat-
ment arm so that the type I error rate will be close to the nominal value for hypotheses
Hj (j = 1, ..., k). At stage 2, generally large samples are available so that chi-square tests
for hypotheses Hj (j = 1, ..., k) control type I error rates close to nominal value α. With
treatment selection, at stage 2, the number of experimental treatments to be tested will vary
so that the sample available to test hypotheses Hj (j = 1, ..., k) will vary with more data
available if few treatments are tested in stage 2. However, since large samples are available
at stage 2, the chi-square test will still be adequate to control the type I error rates when
number of treatments to test in stage 2 vary. In the next paragraph, we describe how the
p-values for the hypotheses HJ with |J | ≥ 2 may be obtained. The tests described are
conservative. Hence, all the p-values used to analyse the seamless phase II/III clinical trial
incorporating the treatment selection will be asymptotically “p clud” (Zuber et al., 2006).
Bauer and Kieser (1999), Hommel (2001) and Bretz et al. (2006) do not give de-
tails of how the p-values testing the hypotheses in H should be calculated but Westfall
and Wolfinger (2000) provide a simplified discussion of some methods. The pairwise
hypotheses may be tested using basic tests such as the chi-squared test for binary data
or the t-test for continuous data. There are several tests for the intersection hypotheses
HJ , J ⊆ {1, ..., k} with |J | ≥ 2 but some are specific to certain forms. For example,
Hotelling’s T 2 test described by Johnson and Wichern (2002) is valid for continuous data.
Flexible tests that can be used for many forms of responses (normal, Poisson, etc) are Bon-
ferroni, ˇSidak and Simes tests. Suppose we wish to test a hypothesis of equality of the
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control treatment with m (1 < m ≤ k) experimental treatments. The Bonferroni ad-
justed p-value is given by min{1, (m × minp)}, while ˇSidak adjusted p-value is given by
(1− [1−minp]m), where minp is the minimum p-value of the individual component tests.
The Simes adjusted p-value is given by min{m
i
p(i)}, i = 1, ..., m where p(i) denote the
ordered p-values.
When several treatments are compared to a control treatment using the same control
group, it would be desired rather than assume the pairwise tests are independent, to utilize
correlation in the comparisons because of the pairwise comparisons versus the same control
group. Dunnett (1955) proposed a multiple comparison procedure that makes use of the
correlation associated with comparing several treatments to the same control group for
continuous normal data. This test can be used for all the intersection hypotheses in the
closure set. Let Zj (j = 0, 1, ..., k) be the standardized response from treatment j with
j = 0 corresponding to the control treatment. For hypothesis HJ (J ⊆ {1, ..., k}), let
ZmaxJ = maxj∈J Zj and define
FZmax
J
(z) =
∫ ∞
−∞
[Φ(
√
2z + z0]
|J |φ(z0)dz0,
where as before φ(.) and Φ(.) respectively denote the density and the distribution function
of a standard normal distribution. For observed ZmaxJ = z, the p-value for hypothesis HJ
is given by 1 − FZmax
J
(z). The test can be used for other outcomes such as binary data by
applying the central limit theorem.
To illustrate hypotheses testing in a phase II/III clinical trial with an example, we
assume a new drug is tested at three doses; dose 1, dose 2 and dose 3. The primary hypothe-
ses of interest are Hj, j = 1, 2, 3, where Hj is the null hypothesis comparing dose j to the
control treatment. Suppose that using the stage 1 data, as in the data used to demonstrate CP
in Westfall and Wolfinger (2000), p1,1 = 0.0982, p1,2 = 0.0262 and p1,3 = 0.0067. Using
the Bonferroni adjusted p-values for the intersection hypotheses gives p1,123 = min{1, 3×
min{p1,1, p1,2, p1,3}} = 0.0201, p1,12 = min{1, 2 × min{p1,1, p1,2}} = 0.0524, p1,13 =
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min{1, 2×min{p1,1, p1,3}} = 0.0134 and p1,23 = min{1, 2×min{p1,2, p1,3}} = 0.0134.
Quite naively, suppose the stage 2 data result in similar p-values, that is, p2,1 = p1,1 =
0.0982, p2,2 = p1,2 = 0.0262 and p2,3 = p1,3 = 0.0067 so that p2,123 = p1,123 = 0.0201,
p2,12 = p1,12 = 0.0524, p2,13 = p1,13 = 0.0134 and p2,23 = p1,23 = 0.0134.
Let us assume that the total sample sizes at stage 1 and stage 2 are respectively 120
and 400. Then we could choose the weights proportional to the sample sizes in each treat-
ment arm so that the stage 1 weight w1 =
√
30/130 and stage 2 weight w2 =
√
100/130.
Using the inverse normal method,
C(p1,123, p2,123) = 1− Φ{w1Φ−1(1− p1,123) + w2Φ−1(1− p2,123)}
= 1− Φ
{√
30
130
Φ−1(1− 0.0201) +
√
100
130
Φ−1(1− 0.0201)
}
= 0.0027.
Similarly, C(p1,12, p2,12) = 0.0138, C(p1,13, p2,13) = 0.0013, C(p1,23, p2,23) = 0.0013,
C(p1,1, p2,1) = 0.0397, C(p1,2, p2,2) = 0.0042 and C(p1,3, p2,3) = 0.0004 so that for each
dose j (j = 1, 2, 3),
max{C(p1,J , p2,J)} ≤ 0.05 for J ⊆ {1, 2, 3} with j ∈ J.
Hence at the end of phase II/III clinical trial, all doses are concluded to be more effective
than the control treatment.
4.5 Treatment selection in phase II/III clinical trials
Methods that can be used (or adapted) to select the most promising treatment(s) after stage
1 for testing in stage 2 have been developed by Thall et al. (1988), Schaid et al. (1990),
Stallard and Todd (2003), Schmidli et al. (2007), and Zuber et al. (2006). Thall et al.
(1988) consider binary outcomes and select the most promising treatment if the global null
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hypothesis is not accepted at stage 1. Evidence from stage 1 and stage 2 is combined in
a test similar to the combination test given by equation (4.3). Schaid et al. (1990) con-
sider survival outcomes and their method allows for stopping after stage 1 results either
for futility or overwhelming evidence. The method allows to continue with more than one
experimental treatment and multiple testing is adjusted for using the Bonferroni correc-
tion. The methods by Thall et al. (1988) and Schaid et al. (1990) are respectively specific
to binary and survival outcomes because of the statistics used. Stallard and Todd (2003)
method generalizes these two methods because it assumes using Statistics introduced in
Section 4.2.1 which can be derived for many outcomes. The most promising treatment is
selected for further testing. These authors consider distinct treatments that may be different
doses of the same drug but have not considered the dose-response relationship. The method
we develop in the next chapter is for binary outcomes and we consider a phase II/III trial
where in stage 1 several doses of the same drug are compared to a control treatment so that
we model the dose-response relationship while making the choice of the dose(s) to test in
stage 2.
Like Schmidli et al. (2007) and Zuber et al. (2006), we will assume the analysis will
be conducted as described in Section 4.4. Given the stage 1 data, for each candidate set
of the treatments (or subgroups) to be tested in stage 2, Schmidli et al. (2007) and Zuber
et al. (2006) obtain the expression for the probability of all stage 2 data for which the null
hypothesis will be rejected after stage 2. They use the Bayesian tools so that the expected
value of this expression, which is referred to as the predictive power, is obtained. The
treatment (or subgroup) that results in highest predictive is proposed for testing in stage 2.
Schmidli et al. (2007) and Zuber et al. (2006) consider survival outcomes. In our proposed
method, we use the same ideas but for binary outcomes. In addition, because we consider
experimental treatments that are different dose levels of the same drug, we incorporate
dose-response relationship. Also, we explicitly include safety data in the dose selection
procedure.
Chapter 5
Dose selection in phase II/III trials
In Chapter 4, we reviewed methods of how phase II/III clinical data may be analysed. We
also briefly described procedures that may be used to select experimental dose(s) to test
at stage 2 after the stage 1 results. In this chapter, we expound a new procedure we have
proposed (Kimani et al., 2009) for selecting the doses to test in stage 2 based on stage 1
data and prior knowledge. The selection procedure is different from the methods described
in Section 4.5 in at least one of the following characteristics of our new procedure; the out-
comes of interest are binary, more than one experimental dose may be selected to continue
to stage 2, dose-response relationships are incorporated in the dose selection procedure and
safety data is considered explicitly to make the choice of the doses to test in stage 2. This
selection procedure assumes the efficacy data will be analysed as described in Section 4.4,
where the closure principle is used to control the type I FWER associated with comparing
the control treatment to several experimental doses and the combination tests are used to
combine evidence from stage 1 and stage 2.
In the next section, we explicitly describe the setting of interest while introducing
the notation that we will use to develop the dose selection procedure. In Section 5.2, we
develop expressions for the probability that at least one of the candidate set of doses that
79
80 CHAPTER 5. DOSE SELECTION IN PHASE II/III TRIALS
may continue to stage 2 is concluded to be effective and safe. We refer to this expression
as the (penalized) conditional power. In Section 5.3, we propose a prior distribution for
the parameters in the penalized conditional power which is updated by the stage 2 data to
obtain the posterior distribution. We define the expected value of the penalized conditional
power using the posterior distribution as the (penalized) predictive power. We propose to
test at stage 2 the set of doses that has the highest predictive power. We summarise the dose
selection procedure developed in this chapter in Section 5.4. In Section 5.5, we compare
the new dose selection procedure to the some of the selection procedures in literature. The
chapter ends by remarks describing how various associations are modeled in Section 5.6.
5.1 Setting of interest
Consider an experiment with k1(> 1) experimental doses in stage 1 of which a subset
remains for testing in stage 2. Suppose the sample size for stage 1 is fixed to be n1(k1+1),
so that n1 patients are randomized to receive each experimental dose and n1 are randomized
to receive the control. The data from stage 1 can be summarized by the number of observed
successes, x1j , and the number of observed toxicities, t1j , at dose j for j = 0, ..., k1,
with j = 0 corresponding to the control treatment. At the onset of the phase II/III trial,
the interest is to determine whether there is a safe dose among the k1 experimental doses
which is more effective than the control treatment. Thus the null hypotheses of interest
are H1 : θ0 = θ1, ..., Hk1 : θ0 = θk1 where θj , j ∈ {0, 1, ..., k1} is a measure of the
effectiveness of treatment j. Based on the efficacy data x1 = {x10, x11, ..., x1k1} and with
the intention of using the closure principle to control the FWER, a set of p-values p1,J for
HJ , J ⊆ {1, ..., k1} can be constructed.
Suppose that the total sample size for stage 2 is fixed. The number of patients
randomized to each dose, n2, then depends on the number of doses that remain in the
trial. Let K2 ⊆ {1, ..., k1} be the set of experimental doses that remain in the trial for
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testing in stage 2 with k2 = |K2|. The selection procedure we propose in this chapter
allows considering any of the k1 doses in stage 1 to continue to stage 2 so that there are 2k1
possible sets of doses that we could choose. To reduce the set of doses to be considered, the
search may be restricted to sets of adjacent doses. Also, in practice at the phase III stage,
the number of experimental doses is fewer so that the possible set of doses to be considered
could be lower. Let x2j and t2j , j ∈ {0} ∪ K2 with j = 0 corresponding to the control
treatment, respectively denote the number of successes and toxicities on dose j in stage 2.
At the end of stage 2, the efficacy data x2 = ({x2j}), j ∈ {0}∪K2 can be used to construct
a set of p-values p2,J corresponding to the closure set of p-values p1,J constructed using the
stage 1 data.
By utilizing the method described in Section 4.4, the two sets of p-values from the
two stages can be used to test whether there is an effective dose among the k2 doses that
proceed to the second stage. Given stage 1 data we want to determine the set K2 which
will be most likely to lead us to finding at least one effective and safe dose at the end of
stage 2 using the predictive power. In the next section, given stage 1 data, for each potential
set of doses K2 to test in stage 2, we develop an expression for the probability at least one
of the doses in K2 will be concluded effective and safe after stage 2 (conditional power).
This probability is the sum of probabilities of different stage 2 outcomes for which at least
one dose will be concluded effective and safe. The predictive power, which is the expected
value of the conditional power, is given in Section 5.3.
5.2 Conditional power
As described above, in this section, assuming that stage 2 data have a distribution which
depends on a fixed parameter vector, we develop an expression for the probability of con-
cluding at least one of the k2 doses in the potential set of doses K2 to be tested in stage 2 is
effective given the results of stage 1. The expression is obtained by summing probabilities
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of outcomes for which we will find at least one effective dose after stage 2 given stage 1
data. To incorporate the safety measure, we multiply this probability by an indicator vari-
able that doses that are effective are safe. We will refer to this probability as the penalized
(combined) conditional power. Since the conditional power is a summation of probabilities
of stage 2 data, we need to determine the distribution of stage 2 data. The distribution of
stage 2 data is given in the next subsection. In Section 5.2.2, we give the probability of
stage 2 data for which at least one dose will be concluded effective. This probability is
penalized for toxicity in Section 5.2.4.
5.2.1 Distribution of second stage data
Let f(x2, t2; θ) denote the distribution of stage 2 data where θ is the vector of parameters
giving the dose-response curves for efficacy and toxicity. To give the form of θ, suppose
a study patient is administered a dose level d. The outcome for efficacy will be either a
successful treatment or a treatment failure and the probability of the successful treatment
will be denoted by pE(d). The toxicity outcome will be categorized as either toxic or non-
toxic and the probability of a toxic outcome will be denoted by pT (d). We propose two
logistic models for the outcomes;
pE(d) =
exp(αE + βE log d)
1 + exp(αE + βE log d)
(5.1)
and
pT (d) =
exp(αT + βT log d)
1 + exp(αT + βT log d)
(5.2)
so that stage 2 data (x2, t2) would depend on the probability vector θ = (αE , βE, αT , βT )′.
Although we propose a logit link, other link functions may be used. For the logistic dose-
response models (5.1) and (5.2), we have taken the dose in the log scale as in common in
drug development but a different linear predictor may also be used. Assuming the outcomes
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are independent, then the probability of x20 successes and t20 toxicities in the control group
and x2j successes and t2j toxicities in the experimental dose j, j ∈ K2 is
f(x2, t2; θ) = fB(x20;n2, pE0)fB(t20;n2, pT0)
∏
j∈K2
fB(x2j ;n2, pEj)fB(t2j ;n2, pTj),
where fB(x2j ;n2, pEj) and fB(t2j ;n2, pTj), j ∈ {0}∪K2 are binomial mass functions with
parameter vectors (n2, pEj) and (n2, pTj ) respectively. The parameters pEj and pTj , j ∈ K2
are respectively points on the dose-response curves (5.1) and (5.2) corresponding to dose
level j. If the control treatment is a dose level of the experimental drug, pE0 and pT0 are also
points on the dose response curves (5.1) and (5.2). Otherwise, for example, an estimate of
pE0 is obtained by maximizing the likelihood
l(pE0 |x10, n1) =
(
n1
x10
)
px10E0 (1− pE0)n1−x10 .
5.2.2 Expressions for conditional power
After obtaining the distribution of stage 2 data, the next step in obtaining the conditional
power involves determining stage 2 data for which the final hypothesis will be significant
given the results of stage 1. Given stage 1 data x1, the p-value p1,J corresponding to an
intersection hypothesis HJ in the closure set H can be considered fixed. The final hy-
pothesis test for the intersection hypothesis HJ will be significant at level α if and only
if C(p1,J , p2,J) ≤ α. The inequality can be rearranged to determine the maximum value
of p2,J such that the null hypothesis HJ is rejected at the end of stage 2. For example if
the combination test of choice is the inverse normal combination given by equation (4.3),
rearranging the inequality, the final hypothesis test will be significant if and only if
p2,J ≤ 1− Φ
{
Φ−1(1− α)− w1Φ−1(1− p1,J)
w2
}
. (5.3)
Let l ≤ |J | be the number of experimental doses in hypothesis HJ at stage 2. Then using
the Bonferroni adjusted p-value, p2,J = min(1, l × minj∈J{p2,j}), where p2,j is the p-
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value obtained from testing the pairwise null hypothesis Hj at the second stage. Since
p2,J = min(1, l×minj∈J{p2,j}), inequality (5.3) holds if and only if
l ×min
j∈J
{p2,j} ≤ 1− Φ
{
Φ−1(1− α)− w1Φ−1(1− p1,J)
w2
}
since, as the right hand side (RHS) is less than 1, we so cannot have 1 ≤ RHS. Dividing
both sides of the above inequality by l, then hypothesis HJ is rejected after stage 2 if and
only if
min
j∈J
{p2,j} ≤
(
1− Φ
{
Φ−1(1− α)− w1Φ−1(1− p1,J)
w2
})/
l. (5.4)
Note that if inequality (5.4) holds, then it means that for some pairwise hypothesis Hj
(j ∈ J), p2,j is less than the RHS of inequality (5.4). Thus hypothesis HJ will be rejected
at the end stage 2 if and only if
p2,j ≤
(
1− Φ
{
Φ−1(1− α)− w1Φ−1(1− p1,J)
w2
})/
l for some j ∈ J. (5.5)
The RHS of inequality (5.5) could be viewed as the “level of testing” for hypothesis HJ at
stage 2.
For each possible number of successes in the control treatment (x20), the minimum
number of successes required in either of the l doses such that inequality (5.5) holds can be
obtained. We will denote this minimum number of successes by Bx20(p1,J) where the nota-
tion reflects dependency on x20 and the stage 1 p-value p1,J for the intersection hypothesis
HJ . The next subsection focusses on obtaining Bx20(p1,J). Hypothesis HJ will be rejected
for the set of stage 2 data x2 such that x2j ≥ Bx20(p1,J) for some j ∈ J . To conclude that
an experimental dose j is more effective than the control treatment, we need to determine
the set of stage 2 data x2 for which all hypotheses HJ with j ∈ J are all rejected. We de-
note the set of x2 for which this is true by R(p1,j), j ∈ K2. The probability of concluding
dose j is more effective than the control after stage 2 analysis is obtained by summing the
probabilities of all outcomes in R(p1,j).
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The form of R(p1,j) depends on the number of doses that continue to the second
stage. For example, suppose k1 = 4 with a single treatment continuing, say K2 = {1}. To
conclude that dose 1 is effective all the hypotheses H1234, H123, H124, H134, H12, H13, H14
and H1 need to be rejected. Since only dose 1 proceeds to the second stage, the intersection
hypotheses H1234, H123, H124, H134, H12, H13 and H14 simplify to the pairwise hypothesis
H1 because no data are available for the other doses at stage 2 but the tests are carried
out at different levels determined by inequality (5.5). The minimum number of successes
at dose 1 (x21) for a given number of successes in the control treatment (x20) required to
reject all hypotheses HJ for J ⊆ {1, 2, 3, 4} with 1 ∈ J could be obtained and is given by
Bx20(max{p1,J}). We take max{p1,J} since the RHS of inequality (5.5) decreases when
p1,J increases. Dose 1 would then be concluded to be more effective than the control
treatment at the end of stage 2 if
x21 ≥ Bx20(max{p1,J})
for all J with 1 ∈ J . The probability of concluding dose 1 is more effective than the control
treatment at the end of stage 2 is then given by
∑
R(p1,1)
f(x2; θ) =
n2∑
x20=0
{
fB(x20;n2, pE0)
n2∑
x21=B
fB(x21;n2, pE1)
}
, (5.6)
where fB(x2j ;n2, pEj) (j = 0, 1) is the probability mass function of the binomial random
variable X2j with parameter vector (n2, pEj ), B = Bx20(max{p1,J}) and R(p1,1) denotes
the set of x2 for which dose 1 is rejected after stage 2.
Suppose from an initial four experimental doses at stage 1, dose 1 and dose 2 pro-
ceed to stage 2, that is, k1 = 4 and K2 = {1, 2}. In order to make inference on the
effectiveness of dose 1 using the closure principle, the null hypotheses H1234, H123, H124,
H134, H12, H13, H14 and H1 are tested. On the other hand, the null hypothesesH1234, H123,
H124, H234, H12, H23, H24 and H2 are tested in order to make inference on dose 2. Since
no data are available for doses 3 and 4, tests for hypotheses H134, H13, H14 and H1 which
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are included in H1 but not in H2 are performed using only the test for H1 but at different
levels. The minimum x21 required to reject all these hypotheses which we denote by B1 is
obtained by evaluatingBx20(max{p1,J}) for J ⊆ {1, 3, 4}with 1 ∈ J . Similarly, only dose
2 data are available for hypothesesH234, H23, H24 andH2 which are included inH2 but not
in H1. The minimum x22 required to reject all these hypotheses which we denote by B2 is
obtained by evaluating Bx20(max{p1,J}) for J ⊆ {2, 3, 4} with 2 ∈ J . On the other hand,
only dose 1 and dose 2 data are available at stage 2 for hypotheses H1234, H123, H124 and
H12 and hence their test is performed using only the test for H12. The minimum number of
successes required in either dose 1 or 2 to reject all these hypotheses which we denote by
B12 is obtained by evaluating Bx20(max{p1,J}) for J ⊆ {1, 2, 3, 4} with {1, 2} ∈ J .
Assuming dose 1 and dose 2 are interchangeable, there are three possible configu-
rations for B1, B2 and B12 namely;
(i) B1 < B2 < B12 (ii) B12 < B1 < B2 and (iii) B1 < B12 < B2.
The expression for conditional power for each of these scenarios is different. From left to
right, Figure 5.1 shows configurations (i) to (iii) for a given realization x20. The partitions
marked by 1, 2 and 12 respectively represent the realization of the number of successes in
the experimental doses for which only dose 1, only dose 2 and for which both dose 1 and 2
are concluded to be effective for a given number of successes in the control treatment. The
probability of concluding at least one of the experimental doses is effective is obtained by
summing all the probabilities of all outcomes in the partitions marked by 1, 2 and 12. For
example, for configuration (i), the probability of concluding dose 1 or dose 2 is effective
after stage 2 is
∑
R(p1,1)
f(x2; θ) +
∑
R(p1,2)
f(x2; θ) +
∑
R(p1,12)
f(x2; θ), (5.7)
where R(p1,1), R(p1,2) and R(p1,12) respectively denote the set of stage 2 data given the
stage 1 data for which after stage 2 only dose 1 would be effective, only dose 2 would be
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Figure 5.1: Configuration of the minimum number of successes. The x-axes are the number
of successes in dose 1 (x21) and y-axes the number of successes in dose 2 (x22).
effective and when both dose 1 and 2 would be effective so that
∑
R(p1,1)
f(x2; θ) =
n2∑
x20=0
fB(x20;n2, pE0)
{
n2∑
x21=B12
B2∑
x22=0
fB(x21;n2, pE1)fB(x22;n2, pE2)
}
,
∑
R(p1,2)
f(x2; θ) =
n2∑
x20=0
fB(x20;n2, pE0)
{
B1∑
x21=0
n2∑
x22=B12
fB(x21;n2, pE1)fB(x22;n2, pE2)
}
and
∑
R(p1,12)
f(x2; θ) =
n2∑
x20=0
fB(x20;n2, pE0)
{
n2∑
x21=B12
n2∑
x22=B2
fB(x21;n2, pE1)fB(x22;n2, pE2)
}
+
n2∑
x20=0
fB(x20;n2, pE0)
{
B12∑
x21=B1
n2∑
x22=B12
fB(x21;n2, pE1)fB(x22;n2, pE2)
}
,
where fB(x2j ;n2, pEj), j = 0, 1, 2, is the probability mass function of the binomial ran-
dom variable X2j with parameters n2 and pEj .
Expressions (5.6) and (5.7) are respectively the combined conditional power when
K2 = {1} and K2 = {1, 2}. The expressions also give the conditional power for taking
K2 = {1} or K2 = {1, 2} for any value of k1 ≥ 2 and similar expressions can be obtained
for any K2 = {i} and K2 = {i, j} for any i, j ∈ {1, ..., k1}. The Bonferroni adjusted p-
values have been used to obtain the expressions for conditional power. The ˇSidak adjusted
p-values similarly lead to simple expressions for conditional power. For Simes adjusted
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p-values, it is not possible to obtain a single inequality such as the one resulting from
Bonferroni adjusted p-values given by inequality (5.5) for composite hypotheses. However,
it is still possible to obtain expressions for conditional power using this test but this becomes
less straightforward as the value of k2 increases.
We have given the expressions for when up to two doses proceed to stage 2 but using
the same principles, expressions can be obtained for k2 > 2. In practice, it would be rare
to proceed to stage 2 with many experimental doses.
5.2.3 Obtaining the minimum number of successes
In this sub-section, we illustrate how to obtain Bx20(p1,J), the minimum number of suc-
cesses required in either of the l experimental doses in J such that the null hypothesis HJ
is rejected at the end of stage 2. The left hand side of inequality (5.5) is the p-value from
testing the null hypothesis Hj , j ∈ J at stage 2. If a chi-squared test is used to test the null
hypothesis Hj with j ∈ J , the critical chi-squared value χ2c corresponding to the level of
the test (RHS of inequality (5.5)) can be determined. The null hypothesis Hj is rejected if
and only if the observed chi-square value
2n2(x20 − x2j)2
(x20 + x2j){2n2 − (x20 + x2j)} ≥ χ
2
c .
Rearranging the expression, the null hypothesis is rejected for superiority if and only if
x2j ≥ U + V
(2n2 + χ2c)
= Bx20(p1,J)
where
U = −{χ2c(x20 − n2)− 2n2x20} and V =
√
n2χ2c{n2χ2c + 8x20(n2 − x20)}.
Although we focus here on the χ2 test, the value of Bx20(p1,J) can be evaluated for any
other test statistic that can be used for making inference on binary data.
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5.2.4 Penalizing for toxicity
Toxicity has not been incorporated in the conditional power expressions (5.6) and (5.7).
Suppose a dose will be rejected for toxicity if the probability of toxicity exceeds some
predetermined level γ. Then the probability that a dose is demonstrated to be both safe and
effective is the product of the conditional power given by expression (5.6) and the indicator
I(pT1 ≤ γ). If more than one experimental dose proceeds to the second stage the different
disjoint events for which we conclude at least one of the experimental doses in stage 2 is
effective are multiplied by different indicators. For example if K2 = {1, 2}, there are three
disjoint events for which we conclude there is an effective dose. These are; only dose 1 is
effective, only dose 2 effective and both dose 1 and 2 are effective. The respective indicators
with which the probability of these events are multiplied are I(pT1 ≤ γ), I(pT2 ≤ γ) and
I(pT1 ≤ γ, pT2 ≤ γ).
5.3 Predictive power
The conditional power expressions obtained in Section 5.2 assume a fixed value of the
parameter vector θ. Suppose that θ is given some prior distribution with density pi0(θ). The
posterior distribution of θ given the data observed at the end of the first stage is given by
Bayes’ theorem to be equal to
pi(θ|x1, t1, n1) = l(θ|x1, t1, n1)pi0(θ)∫
l(θ|x1, t1, n1)pi0(θ)dθ ,
where l(θ|x1, t1, n1) is the likelihood function of θ given the observed data (x1, t1, n1) from
the k1 doses of the experimental treatment observed at the end of the first stage. Assuming
the number of successes and toxicities at each dose level are independent,
l(θ|x1, t1, n1) =
k1∏
j=1
(
n1
x1j
)
p
x1j
Ej
(1− pEj )n1−x1j
(
n1
t1j
)
p
t1j
Tj
(1− pTj )n1−t1j ,
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where pEj and pTj are respectively the probabilities of success and toxicity at dose j. The
predictive power is then obtained by evaluating the posterior mean of the conditional power,
that is, the predictive power is given by∫
Θ
(CPθ)pi(θ|x1, t1, n1)dθ, (5.8)
where CPθ denotes the conditional power. For example if K2 = {1, 2}, the penalized
predictive power is given by∫
Θ
[I(pT1 ≤ γ) · A1 + I(pT2 ≤ γ) · A2 + I(pT1 ≤ γ, pT2 ≤ γ) ·A12] pi(θ|x1, t1, n1)dθ,
where
AJ =
∑
R(p1,J )
f(x2; θ), J ∈ {1, 2, 12}
andR(p1,1),R(p1,2) andR(p1,12) respectively denote the set of stage 2 data given the stage
1 data for which after stage 2 only dose 1 would be effective, only dose 2 would be effective
and when both dose 1 and 2 would be effective as described above.
The penalized predictive power depends on the choice of the doses selected to con-
tinue to stage 2 as these affect the number of patients per arm, n2, the rejection region,
R(p1), which probabilities pEj enter the density f(x2; θ) and which probabilities pTj enter
the penalty. We wish to make a choice of doses to continue on the basis of x1 and t1 to
make the penalized predictive power as large as possible.
5.3.1 Distribution of the unknown parameters
We propose obtaining the prior beliefs on the dose-response curves for efficacy and toxicity
separately using the technique of Bedrick et al. (1996) as was described in Section 2.2.2.
This requires eliciting beta prior distributions at two dose levels d−1 and d0 for each dose-
response curve since each dose-response curve is defined by two parameters. We assume
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the beta prior distributions at each dose level can be elicited as was described in Section
2.2.1 using the contribution by Thall and Simon (1994) and Lindley and Phillips (1976).
Suppose for the probability of success, pEj = pE(dj) at dose j (j = −1, 0), the elicited
prior distribution is Beta(x1j , y1j). Then assuming that the probabilities of success are re-
lated to the dose levels according to the logistic model (5.1) and using the prior distribution
given by equation (2.6), the prior distribution for (αE , βE)
pi0(αE, βE) =
0∏
j=−1
p
x1j
Ej
(1− pEj)y1j
B(x1j , y1j)
∣∣∣∣log
(
d−1
d0
)∣∣∣∣ , (5.9)
where B is the beta function and
pEj =
exp(αE + βE log dj)
1 + exp(αE + βE log dj)
, j = −1, 0.
Similarly suppose a beta prior distribution Beta(pTj ; t1j , u1j) is elicited for the probability
of toxicity, pTj = pT (dj) at dose j (j = −1, 0), then assuming logistic dose-response (5.2)
for the probabilities of toxicity, the prior distribution of (αT , βT )
pi0(αT , βT ) =
0∏
j=−1
p
t1j
Tj
(1− pTj)u1j
B(t1j , u1j)
∣∣∣∣log
(
d−1
d0
)∣∣∣∣ , (5.10)
where B is the beta function and
pTj =
exp(αT + βT log dj)
1 + exp(αT + βT log dj)
, j = −1, 0.
As in Section 5.1, let x1j denote the number of successfully treated patients and
y1j = n1 − x1j the number of patients that are not treated successfully at stage 1 after
treatment with dose j (j = 1, ..., k1). After observation of the stage 1 data, using equation
(2.7), the updated distribution (posterior distribution) of (αE , βE) is
pi(αE, βE|x1, n1) ∝
k1∏
j=−1
p
x1j
Ej
(1− pEj)y1j , (5.11)
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where
pEj =
exp(αE + βE log dj)
1 + exp(αE + βE log dj)
, j = −1, 0, 1, ..., k1.
Similarly let t1j denote the number of patients that experience toxicity at stage 1 and u1j =
n1−t1j the number of patients that do not experience toxicity, then the posterior distribution
of
pi(αT , βT |t1, n1) ∝
k1∏
j=−1
p
t1j
Tj
(1− pTj )u1j , (5.12)
where
pTj =
exp(αT + βT log dj)
1 + exp(αT + βT log dj)
, j = −1, 0, 1, ..., k1.
If the control treatment is a lower dose of the same drug as the experimental treat-
ments, data from the control group are used in updating the prior distributions of (αE, βE)
and (αT , βT ). If it is a different drug, a beta prior distribution Beta(pE0 ; a0, b0) for the prob-
ability of successful treatment at control treatment which is conjugate for the likelihood
function
l(pE0|x10, n1) =
(
n1
x10
)
px10E0 (1− pE0)n1−x10
is elicited. The parameters a0 and b0 are elicited as explained in Section 2.2.1. The resulting
posterior has a beta distribution Beta(pE0 ; a0 + x10, b0 + n1 − x10).
5.4 Summarizing the dose selection procedure
In Chapter 4, we introduced seamless phase II/III clinical trials and described the challenges
in these trials. One of the challenges of seamless phase II/III clinical trials is how to analyse
these trials without inflating type I error rates. In Chapter 4, we described in detail an
analysis method given in Bauer and Kieser (1999), Hommel (2001) and Bretz et al. (2006).
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When several doses are to be tested with the possibility of dropping some doses after stage
1, this analysis allows selection of any combination of doses to continue to stage 2 with a
final analysis that strongly controls the FWER.
The second challenge of seamless phase II/III is how best to select the doses that
are tested in stage 2. In the previous sections of this chapter, we have proposed a procedure
for selecting the doses to test in stage 2 of a seamless phase II/III clinical trials assuming
the analysis described in Bauer and Kieser (1999), Hommel (2001) and Bretz et al. (2006).
The doses are selected by calculating the predictive power of each set of doses that may be
tested in stage 2 using the knowledge of this analysis and stage 1 while also incorporating
the prior knowledge through prior distributions, and proposing to test in stage 2 the set of
doses with the highest predictive power.
In more detail, before the seamless phase II/III clinical trial, prior distributions given
by equations (5.9) and (5.10) for the parameters that define the dose-response curves for
the probability efficacy and for the probability of toxicity are elicited. After stage 1, stage
1 efficacy and toxicity data are used to update prior distributions of the parameters for the
efficacy and toxicity dose-response curves using equations (5.11) and (5.12). In addition
to using the stage I data to update prior distribution, stage 1 efficacy data are used to ob-
tain all intersection hypotheses p-values pJ (J ⊆ {1, ..., k1}), where k1 is the number of
experimental doses in stage 1.
The stage 1 p-values are required to obtain expressions for conditional power, the
conditional probability of concluding at least one of the experimental doses that is tested
in stage 2 is efficacious and safe given stage 1 data. The expressions for conditional power
are obtained for each potential set of doses that may be tested in stage 2. For example, if
the number of experimental doses at stage 1 is 3, and can only proceed with a single dose
or consecutive pairs of doses, then 5 expressions for conditional power are obtained. The
5 expressions for conditional power correspond to the single experimental doses 1, 2 and
3, and the consecutive pairs doses 1 and 2 and doses 2 and 3. For proceeding with the
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single doses, the conditional powers have the form given by expression (5.6) multiplied
by probability of safety described in Section 5.2.4. For continuing with two experimental
doses, the conditional powers have the form given by expression (5.7) multiplied by prob-
abilities of safety as described in Section 5.2.4. Expressions (5.6) and (5.7) are expressions
for probability of all data for which we conclude at least one of the experimental doses is
more efficacious than control. Stage 1 p-values enter these expressions by determining the
minimum successes using equation (5.5). Equation (5.5) also requires the weights w1 and
w2, and the level of the test α to be pre-defined. A typical level for one-sided tests is 0.025.
The weights w1 and w2 could be chosen proportional to the pairwise comparisons sample
sizes (that is patients treated in each treatment arm) as was demonstrated using the example
given at the end of Section 4.4.
The posterior distribution is then used to obtain the expected value of the conditional
powers using equation (5.8). This is the predictive power. For example, using the example
given in the previous paragraph, 5 predictive power values corresponding to proceeding to
single doses 1, 2 and 3 and the consecutive pairs doses 1 and 2 and doses 2 and 3 will be
obtained. The predictive power values are compared to choose the set of doses to test in
stage 2. The set of doses with the highest predictive power is chosen for testing in stage 2.
The final analysis does not include the prior knowledge. The prior distributions are
only used to plan stage 2.
5.5 Comparing the dose selection procedure with existing
methods
In this section, we explicitly discuss the features of the dose selection developed above in
comparison with the existing methods. The features described in detail in this section are
generally attractive. Before describing the attractive features, in this paragraph, we briefly
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mention the features of the dose selection developed in this chapter that may be improved
while also giving the thesis sections in which these features are described in more detail.
The first feature that may be improved concerns how the association between efficacy and
toxicity is modeled. The association between efficacy and toxicity is not modeled explicitly
and the details of how the association between efficacy and toxicity are given in Section 5.6.
Also, we have assumed some known dose-response curves (5.1) and (5.2) respectively for
efficacy and toxicity. However, there may be uncertainty in the form of the dose-response
curves and it would be desirable to include this uncertainty in the dose selection procedure.
Bretz et al. (2005) and Klingenberg (2009) have proposed methods that include model
uncertainty while estimating the minimum effective dose. In Section 7.2, we have described
how the ideas in Klingenberg (2009) could be borrowed to include model uncertainty in the
dose selection procedure.
Some of the key attractive features of this procedure are that it: (1) allows for the
dose-response relationships by using the logistic models (5.1) and (5.2) respectively to
model the probability of efficacy and toxicity, (2) as described in Section 5.3, uses the
Bayesian tools by defining some prior distributions for the parameters that enter the prob-
ability of concluding at least one of the doses that is tested in stage 2 is effective and safe,
and (3) explicitly includes safety by including the probability of concluding that the doses
that are concluded effective after stage 2 are also safe as described in Section 5.2.4. In the
light of these features, we explain why this new procedure is different from the existing
methods and why the new procedure is expected to perform better.
The method proposed by Stallard and Todd (2003) selects among the experimental
treatments (doses) tested in stage 1, the best performing treatment (dose) in terms of its
efficacious level compared to the control treatment. If more than one dose is selected, it
is not guaranteed the type I error rates are controlled at the desired level. This restriction
also applies to the method proposed by Thall et al. (1988). Our procedure does not have
this restriction because the analysis assumed allows for any decision rule without inflating
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type I error rates. The simulation results presented in the next chapter show under some
scenarios, it is often better to choose two doses so that it is better to have a procedure that
allows continuing with more than a single dose. Further, unlike Stallard and Todd (2003)
and Thall et al. (1988), with this procedure the prior knowledge about the experimental
doses and the control treatment is formally used in planning stage 2.
Stallard and Todd (2003), Thall et al. (1988), Schmidli et al. (2007) and Zuber et al.
(2006) would be adequate if the experimental treatments are distinct treatments. However,
when the treatments are different doses of the same drug, then these methods do not exploit
the dose-response relationship which is expected when the treatments are different doses of
the same drug. The simulation results presented in the next chapter show the dose selection
developed in this chapter capture the dose-response relationships.
Finally, we have explicitly included safety in the dose selection procedure. It is
likely the methods proposed by Thall et al. (1988), Schaid et al. (1990) and Stallard and
Todd (2003) require a lot effort to include safety. It may be easy to incorporate safety in
the methods proposed by Schmidli et al. (2007) and Zuber et al. (2006) but these authors
have not done this.
5.6 Remarks on the dose selection procedure
The method of Bedrick et al. (1996) of eliciting prior distributions for the dose-response
curves parameters assumes that the beta prior distributions elicited at dose levels d−1 and
d0 are independent. This assumption simplifies the mathematics but as noted in Whitehead
et al. (2006), it has the undesired consequences that it is possible for βE < 0 or βT <
0 when it is believed that βE ≥ 0 and βT ≥ 0. This is because assuming the elicited
beta distributions at dose levels d−1 and d0 are independent, for example implies that the
probability that the probability of efficacy at dose level d−1 is higher than the probability of
efficacy at dose level d0 for d−1 < d0 is not zero even when it is believed efficacy improves
5.6. REMARKS ON THE DOSE SELECTION PROCEDURE 97
with dose level. This in turn means it is possible to have βE < 0 when it is believed
βE ≥ 0. To partly address this problem the beta prior distributions are elicited at locations
that are far from each other. Also as in Whitehead et al. (2006), since we are interested in
the posterior means of the conditional powers associated with continuing with different set
of doses, negative parameter values for the slope parameters will not have undesired effects
on the predictive power. Further, since we obtain the posterior distributions by updating the
prior distributions using all the phase II clinical trial data, for the posterior distributions,
the slope parameters are unlikely to be negative when the slope parameters are actually
positive.
The use of conditional efficacy and toxicity models (5.1) and (5.2) may raise concern
about the association between efficacy and safety. At each dose level, we are assuming
independence between the probabilities of efficacy and toxicity to obtain the predictive
power. However, because we are using more than one experimental dose, this does not
imply marginal independence between efficacy and toxicity. To demonstrate this, using
odds ratio as a measure of the association, first we give the expression for the odds ratio and
then give the implied odds ratio for some scenarios. As above, let pEj and pTj respectively
denote the probability of efficacy and of toxicity at dose j (j = 1, ..., k1). Further let pRj
denote the probability of a patient being randomized to dose j (j = 1, ..., k1). Using law
of total probability, the marginal probabilities of efficacy (pE) and toxicity (pT ) and the
probability of efficacy and toxicity (pET ) assuming independence of safety and efficacy at
each dose level are expressed as:
pT =
k1∑
j=1
pTjpRj , pE =
k1∑
j=1
pEjpRj and pET =
k1∑
j=1
pEjpTj · pRj
so that the marginal odds ratio is given by
pET (1− pE − pT + pET )
(pT − pET )(pE − pET ) . (5.13)
To give examples of some implied odds ratio, we use the three scenarios used to assess the
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effect probability of efficacy in the next chapter. We refer to the three scenarios as the refer-
ence scenario, Scenario 2 and Scenario 3. The dose-response curves for the three scenarios
are given in Figure 5.2. In the three scenarios, the dose-response curve for the probability
of toxicity is the same with (αT , βT ) = (−2.5782, 0.1621) and is given by the continuous
line (—). The three scenarios differ in the parameter vector (αE, βE). For the reference sce-
nario, the parameter vector (αE, βE) = (−1.4867, 0.2720) and the dose-response curve is
given by the dashed line (- - -). In Scenario 2, (αE , βE) = (−2.6226, 0.3187) and the dose-
response curve is given by the dotted line (· · ·). For Scenario 3, (αE , βE) = (−0.8473, 0)
and the dose-response curve is given by the dashed and dotted line (· - · - ·).
Assuming a new drug is tested at the marked dose levels on the x-axis of Figure 5.2,
that is dose levels 10.5mg, 35mg, 87.5mg, 262.5mg, 700.0mg and 1050.0mg, the marginal
odds ratios for reference scenario, Scenario 2 and Scenario 3 respectively are 1.13, 1.14
and 1.0. In Scenario 3 the probability of toxicity increases with dose level and probability
of efficacy does not change with the dose level so that an odds ratio of 1 would not be a
bad assumption. Scenario 2 has a higher odds ratio than the reference scenario which is
what we would desire. This is made possible since we assume some dose-response curves.
The marginal odds ratio expression (5.13) holds even when probabilities of efficacy and
toxicity are not modelled using some dose-response curves. Modelling the probabilities at
each dose level independently may result in instances where the marginal odds ratio for
Scenario 2 is less than the odds ratio for the reference scenario. By using different dose
levels, as would be expected, we observed that the modelled odds ratios for the reference
scenario and Scenario 2 are higher when: (1) patients are allocated to more dose levels, and
(2) the experimental dose level are further apart.
To conclude, by modelling the probabilities of efficacy and the probabilities of tox-
icity as described above, we assume that the probability of efficacy is independent of the
probability of toxicity given dose subject to a given marginal odds ratio. The marginal
odds ratio is induced by assuming some dose-response curves for the probabilities of ef-
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Dose (mg)
p(d
)
10.5 35.0 87.5 262.5 700.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Toxicity
Reference Scenario
Scenario 2
Scenario 3
Figure 5.2: Different scenarios of dose response curves used to give examples of implied
marginal associations.
ficacy and of toxicity. Thus, although we assume independence at each dose level, there
is a restriction of the values the probabilities of efficacy and of toxicity can take. If there
is correlation between efficacy and toxicity, we reduce the set of values probabilities of
efficacy and of toxicity can take at each dose level so that the independence assumption
is less strong compared to modelling outcomes (efficacy and toxicity) at each dose level
independent and also outcomes at a dose level independent of the outcomes in other dose
levels.
Chapter 6
Simulation studies
In Chapter 5, we have described how the doses continuing from the first stage of a seamless
phase II/III clinical trial may be chosen and how a final analysis may be conducted to allow
for this without inflating type I error rates. In this chapter, the performance of the selection
procedure is investigated using simulation studies. Different scenarios for the underlying
true probabilities of toxicity and efficacy using the different doses are considered. For
each of these scenarios, 1000 studies were simulated in order to obtain the probabilities of
continuing to stage 2 with each of the potential doses.
6.1 Simulation model parameter values
The simulation studies are based on the trial described by Whitehead et al. (2006). We as-
sume that the new drug is tested at dose levels 10.5mg, 35.0mg, 87.5mg, 262.5mg, 700.0mg
and 1050.0mg plus a control. To conform with the previous chapters, we simply refer to
the experimental doses in increasing dose levels as dose 1, dose 2, dose 3, dose 4, dose 5
and dose 6. Further, in all simulation studies, we assume that γ, the accepted maximum
probability of toxicity, is 0.2. The control treatment is assumed to be a different drug from
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the experimental drug with the true probability of efficacy for the control treatment taken
to be 0.3. For the dose-response curve parameters, the true parameter values for (αE , βE)
and (αT , βT ) corresponding to dose-response curves (5.1) and (5.2) are assumed to be (-
1.4867, 0.2720) and (-2.5782, 0.1621) respectively. We refer to this set of parameter values
for (αE , βE) and (αT , βT ) as the reference scenario. With these parameter values, all doses
are acceptably safe and dose 1 is as efficacious as the control treatment while all the other
experimental doses are more efficacious than the control treatment.
To explore the effect of efficacy, two more scenarios are compared to the reference
scenario. We will refer to them as efficacy Scenario 2 and efficacy Scenario 3. The two sce-
narios have the same value for the true parameter vector (αT , βT ) as the reference scenario
but differ from the reference scenario in the value of the parameter vector (αE, βE). The
probabilities of efficacy and toxicity at each experimental dose level for the two scenarios
and the reference scenario are given in Table 6.1 while the dose-response curves for the two
scenarios and the reference scenario are given in the left panel of Figure 6.1. The marked
points on the x-axis correspond to the experimental doses. As the linear predictor of the
dose-response curves are on the natural log dose scale, doses are plotted on the log scale
in Figure 6.1, so that the higher doses are closer to each other on the x-axis. The continu-
ous line (—) shows the toxicity dose-response curve for the reference scenario. The same
toxicity dose-response curve will be used for the efficacy Scenario 2 and efficacy Scenario
3. As already described above, the dose-response curves shows that all the experimental
doses are acceptably safe since the probability of toxicity in all cases is less than 0.2. The
dashed line (- - -) gives the efficacy dose-response curve for the reference scenario. In this
scenario, dose 1 is as efficacious as the control while doses 2 to 6 are more efficacious than
the control. The dotted line (· · ·) gives the efficacy dose-response curve for the efficacy
Scenario 2 for which (αE , βE) = (−2.6226, 0.3187). In this scenario only doses 5 and 6
are more efficacious compared to control. The dashed and dotted line (· - · - ·) gives the
efficacy Scenario 3 with (αE , βE) = (−0.8473, 0). In this scenario, all the experimental
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Figure 6.1: Underlying true dose-response curves. The left panel shows different scenarios
for efficacy while the right panel shows different scenarios for toxicity.
doses have the same efficacy level as the control treatment. For each of these three scenar-
ios, 1000 studies were simulated and in each case predictive power calculated to determine
the dose(s) that continue to stage 2. The simulation results are given in Section 6.5.
We also wish to explore the effect of true toxicity on the proposed dose selection
procedure. To do this, two more scenarios that will be compared to the reference scenario
will be considered. We will refer to them as toxicity Scenario 2 and toxicity Scenario 3.
The dose-response curves for the probability of efficacy for the toxicity Scenario 2 and
the toxicity Scenario 3 have the same parameter vector (αE , βE) as the reference scenario.
However, the dose-response curves for the probability of toxicities for the two scenarios
are different from the reference scenario. Table 6.2 gives the probabilities of efficacy and
toxicity at each experimental dose level for the reference scenario and the toxicity Scenario
2 and the toxicity Scenario 3 while Figure 6.1 (right panel) gives the dose-response curves
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Table 6.1: Probabilities of efficacy and toxicity at tested dose levels for the three scenarios
used to assess effect of efficacy
Dose levels (mg)
Scenario (Outcome) 10.5 35.0 87.5 262.5 700.0 1050
All Scenarios (Toxicity) 0.10 0.12 0.14 0.16 0.18 0.19
Reference Scenario (Efficacy) 0.30 0.37 0.43 0.51 0.57 0.60
Scenario 2 (Efficacy) 0.13 0.18 0.23 0.23 0.37 0.40
Scenario 3 (Efficacy) 0.30 0.30 0.30 0.30 0.30 0.30
for the reference scenario and the toxicity Scenario 2 and the toxicity Scenario 3. The
continuous line (—) shows the efficacy dose-response curve for the reference scenario.
The same dose-response curve for efficacy will be used to simulate studies for toxicity
Scenario 2 and 3. The dashed line (- - -) gives the toxicity dose-response curve for the
reference scenario for which all doses are acceptably safe. The dotted line (· · ·) and the
dashed and dotted line (· - · - ·) respectively give the toxicity dose-response curves for the
toxicity Scenario 2 and toxicity Scenario 3. For the toxicity Scenario 2 (· · ·), (αT , βT ) =
(−2.6728, 0.2023). In this scenario dose 5 is nearly safe (probability of toxicity is 0.206)
and dose 6 is unacceptably toxic while the other doses are acceptably safe. On the other
hand, for the toxicity Scenario 3 (· - · - ·), (αT , βT ) = (−2.9523, 0.3211) so that doses 1
to 3 are acceptably safe while the other experimental doses would be considered too toxic.
A further two sets of 1000 studies for each of these two new scenarios were simulated
and predictive powers evaluated to determine the dose(s) that continue to stage 2. The
simulation results for these scenarios are also given in Section 6.5.
In all the simulation studies, it will be assumed that n1, the number of patients tested
at each dose at stage 1 is 20 and the total number of patients available for testing at stage
2 is 400 such that n2, the number of patients allocated to each treatment arm at stage 2
is 400/(k2 + 1), where k2 is the number of the number of doses chosen to be tested in
the second stage. We will demonstrate the method for clinical trials in which up to 2 ex-
perimental doses are included with the control in stage 2, that is k2 = 1 or k2 = 2. We
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Table 6.2: Probabilities of efficacy and toxicity at tested dose levels for the three scenarios
used to assess effect of toxicity
Dose levels (mg)
Scenario (Outcome) 10.5 35.0 87.5 262.5 700.0 1050
All Scenarios (Efficacy) 0.30 0.37 0.43 0.51 0.57 0.60
Reference Scenario (Toxicity) 0.10 0.12 0.14 0.16 0.18 0.19
Scenario 2 (Toxicity) 0.10 0.12 0.15 0.18 0.206 0.22
Scenario 3 (Toxicity) 0.10 0.14 0.18 0.24 0.30 0.33
will also restrict testing consecutive experimental doses so that we will not consider for
example a stage 2 trial with dose 1 and dose 3. The restriction to consecutive experimental
and considering k2 ≤ 2 is not a limitation of the selection procedure. The selection pro-
cedure can be extended to consider k2 > 2 but the expressions for the conditional power
would involve summing over more dimensions which is computational expensive. Further,
including non-consecutive experimental doses increases the sets to be compared increasing
the computation time.
6.2 Prior distributions
As described in Section 5.3, to evaluate the predictive power, beta prior distributions for
the probability of efficacy using the control treatment and for the probabilities of efficacy
and toxicities at two dose levels of the new drug are required. To determine the parameter
values for the beta prior distributions, we examined the beta curves and the 90% credible
interval width as described in Section 2.2 while also considering what would be typical of
the prior distributions elicited in practice. In all the simulation studies, the predictive power
is evaluated assuming a beta prior distribution Beta(12, 28) for the probability of efficacy
using the control treatment.
Beta prior distributions for probabilities of successful treatment and probabilities of
toxicity are defined at dose levels 10.50mg and 5000mg. Figure 6.2 shows the densities
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Figure 6.2: Elicited prior densities. Row 1 and 2 give the prior distributions for efficacy and
toxicity respectively. Columns 1 and 2 correspond to prior distributions at dose 10.50mg
and 5000mg respectively. Column 3 gives the resulting joint prior distributions.
of the elicited prior distributions. Rows 1 and 2 respectively give the prior distributions
for the efficacy and toxicity models. Columns 1 and 2 respectively give the beta prior
distributions at dose levels 10.50mg and 5000mg whose parameter values are given in
the legends. Column 3 is the resulting joint prior distributions of the intercept and slope
parameters obtained as described in Section 2.2.2.
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6.3 Computational details
The predictive power was defined in Section 5.3 as the expected value of the conditional
power using the posterior distribution. Evaluating this expectation has two complexities:
(1) the integral in equation (5.8) cannot be given in closed form, and (2) the expression
for CP in equation (5.7) requires calculation of an expectation that involves summing over
more than one dimension. To overcome the first complexity, we used numerical quadra-
ture to integrate over the parameter space. In the rest of this section, we describe how we
avoided more than one summation using the normal approximation to the binomial distri-
bution.
Examples of the form of the conditional power are given by expressions (5.6) and
(5.7). These expressions entail summing over possible values in the control treatment and
over outcomes in the experimental doses for which at least one dose is concluded to be
better than control. These summations are computationally expensive so that to make it
feasible to evaluate the predictive power for the simulation studies, some approximations
are needed. Expression (5.6) is given by
n2∑
x20=0
{(
n2
x20
)
px20E0 (1− pE0)n2−x20
n2∑
x21=B
(
n2
x21
)
px21E1 (1− pE1)n2−x21
}
, (6.1)
where B = Bx20(max{p1,J}) is the minimum number of successes in dose 1 required to
conclude that dose 1 is better than control after stage 2. This expression requires sum-
ming over a grid of possible number of successes in the control treatment (x20) and for
each possible value of x20, summing over the number of successes in dose 1 (x21) from
Bx20(max{p1,J}) to n2. To reduce the computation time, the latter summation is ap-
proximated using the normal approximation to the binomial distribution. Suppose the
probability of successful treatment with dose 1 is pE1 so that the number of successes
at stage 2 (x21) is Bin(n2, pE1). The number of successes (x21) is approximately normal
6.3. COMPUTATIONAL DETAILS 107
N(n2pE1 , n2pE1(1− pE1)) so that using the properties of the normal distribution
Prob(X21 ≥ x21) = 1− Prob(X21 < x21)
≃ 1− Φ
{
x21 − n2pE1√
n2pE1(1− pE1)
}
,
where Φ is the standard normal distribution function. Hence, to reduce the computation
time for evaluating expression (6.1), the following approximation is used
n2∑
x21=B
(
n2
x21
)
px21E1 (1− pE1)n2−x21 = 1− Φ
{
B − n2pE1√
n2pE1(1− pE1)
}
.
On the other hand, expression (5.7) has summations of the form
n2∑
x20=0
{
fB(x20;n2, pE0)
{
n2∑
x21=B12
B2∑
x22=0
fB(x21;n2, pE1)fB(x22;n2, pE2)
}}
, (6.2)
where fB(x20;n2, pE0), fB(x21;n2, pE1) and fB(x22;n2, pE2) are respectively probability
mass functions of Bin(x20;n2, pE0), Bin(x21;n2, pE1) and Bin(x22;n2, pE2) and B12 and
B2 are quantities that depend on x20 and stage 1 results. The normal approximation to the
binomial distribution in expression (6.2) is used for the term{
n2∑
x21=B12
B2∑
x22=0
fB(x21;n2, pE1)fB(x22;n2, pE2)
}
.
Since conditional on pE1 and pE2 , the number of successes in dose 1 (x21) and dose 2 (x22)
are independent, then the above expression could be re-expressed as{
n2∑
x21=B12
fB(x21;n2, pE1)
B2∑
x22=0
fB(x22;n2, pE2)
}
,
which using the normal approximation to the binomial distribution as described above can
be approximated by(
1− Φ
{
B12 − n2pE1√
n2pE1(1− pE1)
})(
Φ
{
B2 − n2pE2√
n2pE2(1− pE2)
})
.
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These approximations reduced the computation time for evaluating the predictive
powers associated with continuing to stage 2 with a single dose and two consecutive doses
in a single simulation study from a few days to a few minutes on a personal computer using
the R package. For each scenario, 1000 simulation studies were used and it takes about
three days to simulate and evaluate predictive powers for the 1000 simulation studies.
6.4 Explanation of how results will be obtained
In the previous sections of this chapter, we have described the scenarios (based on true pa-
rameter values) we will use to investigate the operating characteristics of the dose selection
procedure, the total sample sizes at each stage that will be used in the simulation studies
(120 for stage 1 and 400 for stage 2), prior distributions that will be used to calculate the
predictive powers and the computational details. Also, we explained that in the simulation
results we present in this chapter, we can proceed to stage 2 with single experimental doses
1, 2, 3, 4, 5 and 6 or pairs of consecutive experimental doses, that is, doses 1 and 2, doses
2 and 3, doses 3 and 4, doses 4 and 5, and doses 5 and 6. In this section, we describe how
we obtained the simulation results given in this chapter.
For each scenario, 1000 simulation studies will be carried out. In each simulation
study, stage 1 data are simulated using the underlying true parameter values. The stage 1
data consist of the number of successes from 20 simulated patients per experimental dose
and the control treatment. Using the stage 1 data, stage 1 p-values for all intersection hy-
potheses p1,J , J ⊆ {1, ..., 6} are obtained. Given these p-values, for each potential set
of doses that may be tested in stage 2, that is, the single doses and consecutive pairs of
consecutive doses, we obtain the expressions for conditional power as described in Section
5.2. Thus there will be 11 separate expressions for conditional power corresponding to the
6 experimental doses and 5 pairs of consecutive doses. For the single doses, the condi-
tional powers have the form given by expression (5.6) multiplied by probability of safety
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described in Section 5.2.4. For pairs of consecutive doses, the conditional powers have the
form given by expression (5.7) multiplied by probabilities of safety as described in Section
5.2.4. To obtain the expressions for conditional power, we need to define the weights and
level of the tests given in inequality (5.3). The hypotheses are tested at level 2.5% and the
squares of the weights are proportional to the total sample sizes, that is, w1 =
√
120/520
and w2 =
√
400/520.
The next step in the dose selection is obtaining the predictive power. To obtain
the predictive power, we need the distribution of the parameters in the expressions for
conditional power. The parameters are given by the dose response curves and the prior
distributions of these parameters are given in Section 6.2. The prior distribution are updated
using the stage 1 data to obtain the posterior distributions of the dose response curves
parameters using equations (5.11) and (5.12). The posterior distributions are used to obtain
the expected value of each of the 11 expressions for conditional power described in the
previous paragraph. This is the predictive power. The 11 predictive power values are
compared to choose the set of doses to test in stage 2. The set of doses with the highest
predictive power is proposed for testing in stage 2. This is repeated for the 1000 simulated
studies. To obtain the simulated probability of selecting each potential set of doses, the
number of times this set is proposed for testing in stage 2 is divided by 1000.
6.5 Comparing results for different scenarios
Figure 6.3 shows histograms of the simulated probabilities of continuing to stage 2 with
each dose and consecutive pair of doses. Each histogram corresponds to one of the sce-
narios described in Section 6.1 and is based on a 1000 simulation studies. On the x-axis,
the notation di, i ∈ {1, ..., 6} means dose i is selected for testing at stage 2 while dij with
i, j ∈ {1, ..., 6} means both doses i and j are selected for testing at stage 2. The selected
set of doses has the highest predictive power among the potential doses or pair of doses
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Figure 6.3: Histograms of set of doses with highest predictive power. Row 1 explores
different scenarios for efficacy. In (a), only dose 1 is ineffective, in (b) only doses 5 and
6 are effective and in (c), all doses are ineffective. Row 2 explores different scenarios for
toxicity. In (d), all doses are safe, in (e) dose 6 is toxic and in (f), doses 4 to 6 are toxic.
considered for testing at stage 2. The y-axis gives the proportion for which the doses on the
x-axis are selected out of the total 1000 simulation studies. The bars have been partitioned
into simulation studies whose maximum predictive power of potential doses to test in stage
2 is above 0.7 (shaded parts) and studies whose maximum predictive power is less than
0.7 (striped parts). The latter represent trials in which it is unlikely that any dose would
continue to the second stage because the probability of a successful trial, that is, a trial that
is going to identify a safe and efficacious dose, is low.
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Row 1 of Figure 6.3 corresponds to the results comparing different scenarios for
efficacy (the dose-response curves for these scenarios were given in Figure 6.1, left panel).
The same true dose-response curve for probabilities of toxicity (reference scenario toxi-
city dose-response curve) is used in these scenarios. As shown in Table 6.1 Row 3, the
respective true probabilities of toxic outcomes for these scenarios at doses 1 to 6 are 0.10,
0.12, 0.14, 0.16, 0.18 and 0.19. In panel (a), the reference scenario for dose-response for
efficacy is used. The respective true probabilities of efficacy at doses 1 to 6 for this scenario
are given in Table 6.1 Row 4 and are 0.30, 0.37, 0.43, 0.51, 0.57 and 0.60. Thus all the
experimental doses are safe and doses 5 and 6 do not differ much in terms of efficacy. Dose
4 is considerably less efficacious than doses 5 and 6 but also considerably safer than doses
5 and 6. Based on all simulation studies (shaded and striped parts), dose 5 or 6 is selected
for testing at stage 2 with probability of about 0.6. Dose 4 or one of the higher doses is
among the selected doses for testing at stage 2 with probability of over 0.9. When only
the simulation studies whose predictive power greater than 0.7 are considered (607 studies
out of 1000), dose 5 or 6 would be tested in stage 2 with probability above 0.65 and dose
4 or 5 or 6 would be tested in stage 2 with probability above 0.96. Panel (b) gives results
for efficacy Scenario 2. The respective probabilities of efficacy for this scenario are given
in Table 6.1 Row 5 and are 0.13, 0.18, 0.23, 0.30, 0.37 and 0.40 so that in comparison to
the control treatment, dose 4 is not better, dose 5 and 6 are more efficacious while doses 1
to 3 are less efficacious. In this scenario, the desired dose for testing at stage 2 would be
dose 6. In the simulation studies, this dose alone is selected with probability above 0.75.
Doses 5 or 6, which are the only dose levels efficacious than the control, are selected for
testing at stage 2 with probability of above 0.90. Sets which include only doses that are less
efficacious than the control treatment, that is doses 1 to 3, are selected with probability of
about 0.01. In panel (c), the probabilities of efficacy are the same among all the experimen-
tal doses and the control treatment. As would be desired the predictive power for almost
all the simulated studies is less than or equal to 0.7. In this scenario dose 1 would be the
112 CHAPTER 6. SIMULATION STUDIES
most desired because it is the least toxic. However dose 6 alone has the highest probabil-
ity of being tested in stage 2. The selection procedure may be driven more by the prior
distribution since the prior belief is that the efficacy improves with dose level. In the next
section, more simulations based on the same scenario for dose response curves but different
prior distributions support this view. With stronger prior belief, dose 1 is selected with less
probability and when the prior belief is weak, dose 1 is selected with higher probability.
A distinctive difference between results in panel (a) and panels (b) and (c) is that
in (a) continuing with more than one dose has higher probability than in (b) and (c). This
may be explained by the true probabilities of efficacy of the experimental doses. In panels
(b) and (c), the probability of efficacy is low and hence the (predictive) power of potential
doses will be lower so that it would be preferable to allocate the available patients to the
control and to only one dose of the new drug. Further comparing results in panel (a) to
the results in panel (b), in panel (a), the probabilities of selecting the doses increase to
selecting both dose 4 and 5 and then drops for continuing with dose 5 or 6 or both dose
5 and 6. On the other hand, in panel (b), the probability of selecting doses increase with
dose level with dose 6 selected with the highest probability. This may be explained by
the probabilities of efficacy and toxicity. In panel (a), the probabilities of efficacy are high
so that the probability of obtaining a significant result in a trial that includes dose 4 and
dose 5 is as high as a trial that includes either dose 5 only, dose 6 only or both dose 5 and
dose 6. However, since testing both dose 4 and 5 involves testing safer doses, this set is
selected with higher probability. In panel (b), the probabilities of efficacy are low so that
the probability of obtaining a significant result in a trial with higher dose levels is higher so
that dose 6 is selected with highest probability since it is also safe.
Row 2 of Figure 6.3 corresponds to the results comparing different scenarios for
toxicity (the dose-response curves for these scenarios were given in Figure 6.1, right panel).
As shown in Table 6.2 Row 3, for all these scenarios the respective true probabilities of
efficacy at doses 1 to 6 are 0.30, 0.37, 0.43, 0.51, 0.57 and 0.60. Results in panel (d)
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are the same as in panel (a) but on a different vertical scale to facilitate comparison of
results in panels (e) and (f). Panel (e) gives results of toxicity Scenario 2 and as shown
in Table 6.2 Row 5, the true probabilities of toxicity for this scenario at tested dose levels
in increasing order are 0.10, 0.12, 0.15, 0.18, 0.206 and 0.220. Hence the prior belief
(mean) underestimates the level of toxicity. Based on all simulation studies, dose 6 alone
whose true proportion of toxicity is well above 0.20, the accepted proportion of toxicity,
is selected for testing at stage 2 with probability less than 0.10. Dose 4 which would be
the desired dose for testing in stage 2 is among the selected doses with probability of about
0.70. When only simulation studies with maximum predictive power greater than 0.7 are
considered (483 studies out of 1000), dose 6 is selected with probability less than 0.02 while
dose 4 is among the selected doses with probability above 0.80. Dose 5 which is nearly safe
is selected with probability 0.05. Both dose 5 (nearly safe) and dose 6 (toxic) are selected
for testing in stage 2 with probability 0.08. Panel (f) gives results for toxicity Scenario 3
and as shown in Table 6.2 Row 6, the true probabilities of toxicity for this scenario at the
tested dose levels in increasing order are 0.10, 0.14, 0.18, 0.24, 0.30 and 0.33. The desired
dose is dose 3. When only simulation studies with predictive power greater than 0.7 are
considered, dose 3 is among the set selected for testing in stage 2 with probability 0.79.
Dose 4 or both dose 4 and 5 which are all toxic are selected with a high probability of 0.18.
We could not find an explanation to this high probability rather than chance.
Comparing the results in Row 2, we observe that the proportion of simulation studies
with predictive power above 0.7 decreases from panel (d) to panel (f). This is because
the probabilities of toxicity for doses 2 to 6 which are more efficacious than the control
treatment increase from panel (d) to (f) so that from panel (d) to (f) lower doses which are
less effective than the higher doses would be desired for testing in stage 2. The difference
in panels (d) and (e) is particularly interesting. Although in both panels testing both dose
4 and dose 5 has the highest probability, testing either dose 5, dose 6 or both dose 5 and
dose 6 is selected with lower probability in panel (e). When only studies with predictive
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power above 0.7 are considered, the probability of continuing with either of these doses
is even lower. Further we observe that dose 1 is selected with very low probability in the
three scenarios so that even though higher doses are selected with lower probability when
they are considered too toxic, the selection procedure still does not favour dose 1 which is
not efficacious.
6.6 Comparing results for different prior distributions
The results discussed in the last section were obtained using the prior distributions pre-
sented in Figure 6.2. We refer to these sets of prior distributions as the middle weight prior
belief. In order to assess the effect of prior distribution weight, we consider two more sets
of prior distributions. In the second set of the prior distributions, Beta prior distributions
at dose levels 10.50mg and 5000mg for the efficacy model have parameter vectors (18, 42)
and (18, 7.71) respectively. For the toxicity model the Beta prior distributions have pa-
rameter vectors (9, 81) and (10.2, 30.6) at dose levels 10.50mg and 5000mg respectively.
These beta distributions have the same prior means as the middle weight belief but smaller
variance. From left, the first and the second contour plots in Figure 6.4 respectively give
the resulting joint prior distribution of the slope and intercept for the efficacy and toxicity
model. We refer to this set of prior belief as the most informative prior belief. The third set
of the prior distribution is less informative and we refer to this set as the least informative
prior belief. For the least informative prior belief, for both efficacy and toxicity the beta
distributions at both dose 10.50mg and 5000mg are assigned parameter vector (1, 1) (that
is Beta(1, 1) which is equivalent to the Uniform(0,1)). The resulting joint prior distribution
for the intercept and the slope parameters is given by the contour in the right panel of Figure
6.4. Note that the scale for this contour plot is different from the scales of the other contour
plots in Figure 6.4 and in Figure 6.2 with its contours spread wider along the intercept and
slope parameters.
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Figure 6.4: Contour plots for more informative and less informative prior densities.
We chose to demonstrate the effect of the prior distributions using the reference
scenario (all doses safe, dose 1 as efficacious as control treatment and doses 2 to 6 more
efficacious than the control) and efficacy Scenario 2 (all doses safe and equally as effica-
cious as the control treatment). Figure 6.5 gives the results using the different sets of prior
distributions. Row 1 and Row 2 respectively correspond to the reference scenario and effi-
cacy Scenario 2. Columns 1 to 3 respectively correspond to the most informative, middle
weight and least informative prior distributions. For the reference scenario (Row 1), using
the three sets of the prior distribution, probability of testing both dose 4 and dose 5 at stage
2 is highest. However the relative frequency decreases as the prior distributions become
less informative. As the prior belief becomes less informative lower, higher doses are se-
lected with higher probability. For example, the frequency of dose 6 increases as the prior
distributions become less informative. The frequency, however, has a larger contribution
from the simulation studies whose predictive power is less than 0.7 (striped parts).
For efficacy Scenario 2 (Row 2), when the prior distributions have higher weight
(panel (d)), higher doses are selected for testing at stage 2 with higher probability with
dose 6 selected with the highest probability. This is driven by the prior distribution in
which higher doses are considered more efficacious compared to the lower doses. In panel
(e), the prior distributions have lesser weight compared to panel (d) but the prior belief
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Figure 6.5: Histograms of set of doses with highest predictive power. From left to right the
prior beliefs are less informative.
is still that higher doses are more efficacious so that dose 6 is selected with the highest
probability. However, in panel (e), dose 1 is selected with higher probability compared to
panel (d) as would be expected. In panel (f), the prior distributions used in obtaining the
predictive power, assumed there is no difference between lower and higher doses. Further,
the prior distribution had least weight with beta parameters having values (1,1) so that the
selection probability compared to results in panels (e) and (f), puts more weight on stage
1 data. As expected, dose 1 is selected for testing at stage 2 with the highest probability
because it is the safest and is not inferior compared to doses 2 to 6. Dose 6 has the second
highest probability of selection. This may be explained by the stage 1 efficacy data. The
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stage 1 data may suggest either a positive or a negative slope for probability of efficacy. A
positive slope will favour dose 6 resulting into dose 6 selected more compared to doses 2
to 5.
6.7 Summary findings from the simulation results
In the previous sections of this chapter, we have presented simulation results under several
scenarios. In this section, we summarize the key characteristics from these results while
also pointing the advantage of the dose selection procedure as exhibited by the results.
First, we observed that, as desired, when the second stage is not adequately powered in
terms of probabilities of efficacy, the candidate sets with a single treatment are selected for
testing at stage 2 with higher probability compared to candidate sets with two experimental
doses. This is the case of the scenario whose results are given in Figure 6.3 (b). However,
under scenarios where some experimental doses are highly efficacious and safe, such as the
scenario whose results are given in Figure 6.3 (d), it is often better to test two experimental
doses at stage 2. Thus the new dose selection is advantageous than the methods that allow
only to proceed with one experimental dose.
Secondly, when all the experimental doses are acceptably safe but toxicity increases
with dose level and the second stage sample size is such that it powers (based on proba-
bilities of efficacy) the lower doses enough so that the difference in power of highest dose
levels and some lower dose levels is not large, lower dose levels are selected with higher
probability because they are safer to administer to patients. The results given in Figure 6.3
(d) are from such a scenario. Also, the inclusion of safety in the dose selection procedure
avoids selecting unsafe doses although they may be more efficacious. For example, for
the results given in Figure 6.3 (e), dose 6 is unsafe and thus compared to results in Figure
6.3 (d) in which all experimental doses are safe, it is selected with lower probability and
when it is selected, the predictive power is low as in most cases the predictive is less than
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0.70. The same trend, as shown in Figure 6.3 (f), is observed when doses 4 to 6 are unsafe.
Thus new dose selection procedure is advantageous than the previous procedures that do
not explicitly include safety.
The results for all scenarios captured the dose-response relationships. For example,
in Figure 6.3 (b), the probability of selection increases with dose. The same is observed
from Figure 6.3 (f) where the probability of selection increases with dose and then de-
creases with dose when doses 4 or higher, which are unsafe and which become less safe
with increase in dose, are selected for testing in stage 2. The use of dose-response also
captures the probabilities of efficacy and toxicity well. For example, in Figure 6.3 (d),
there is huge increase in probability of selection from when only dose 3 is selected to when
both doses 3 and 4 are selected. Probability of efficacy in control 0.3 while probabilities
of efficacy at doses 3 and 4 are respectively 0.37 and 0.43 so that it may be that it is only
when dose 4 or higher doses are selected that the probability of concluding efficacy is high.
Finally, the results for a scenario where the experimental doses of the new drug are
not better than the control treatment, that is for the scenario whose results are given in 6.3
(c), the selected doses to test in stage follow the profile of the prior distribution but the
predictive power is low so that the trial is unlikely to proceed to stage 2.
Chapter 7
Further work
In Chapter 5, we have developed a new method for selecting doses that continue from
a phase II stage to a phase III stage of a seamless phase II/III clinical trial. The work
focussed on binary outcomes at both stages, assumes the data are generated using some
known generalized linear model and that there are only two stages. These features lead to
three new research questions that can extend the work described in Chapter 5: (1) can the
work be extended to include more than 2 stages with monitoring boundaries, (2) can the
dose selection procedure be extended to include model uncertainty and can the outcomes be
modelled using models that are not in the family of generalized linear models, and (3) can
the work be extended to include other endpoints or a change of endpoint. In this chapter,
we describe the direction we are taking to answer these questions. For the first question, we
will describe ongoing recent work. For the second and third questions, we will summarise
some works that have answered similar questions in different contexts that may be relevant.
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7.1 Extending to more than two stages with monitoring
In Chapter 5, we assumed that there is no early stopping at end of phase II stage and that
in the phase III stage, there will be no monitoring. However, as described in Sections
3.3.1 and 3.4.2, the investigators may wish stop the trial after the phase II stage and to also
monitor the phase III data for among other reasons, ethical considerations. In this section,
we give the progress made on exploring how a seamless phase II/III clinical trials with a
single monitoring in the phase III stage so that the seamless phase II/III clinical trial will
have 3 stages; the phase II stage and two phase III stages, may be planned. We will assume
that there are no opportunities for adaptation in the phase III stage and we present the
simple case of proceeding with one experimental dose into the phase III stage. In Section
3.3.1, we explained that clinical trials may stopped early either for overwhelming evidence
of efficacy, futility or both. In Section 7.1.1, we will describe an example of how p-values
using the combination tests may be adjusted when there are opportunities to stop early for
overwhelming evidence of efficacy or for futility. We will set the notation of the seamless
phase II/III clinical trial of interest in Section 7.1.2. In Section 7.1.3, given the stage 1 data,
we will describe how to obtain the expression for the conditional power, the probability of
concluding at least one of the experimental doses that continue to the phase III stage is
effective after stage 2 or after stage 3. Finally, in Section 7.1.4, we define the predictive
power for a trial with opportunities to stop early.
7.1.1 Combined p-value with opportunity to stop early
Let H be a null hypothesis of interest that is tested at two stages. Let p1 and p2 respectively
denote stage 1 and stage 2 p-values. Suppose that at stage 1 the null hypothesis H will be
rejected if p1 ≤ α1 and is accepted if p1 > α0, where 0 ≤ α1 < α < α0 ≤ 1. Assuming p1
and p2 are independent and uniform[0,1] underH , in Section 4.2.2, we gave the expression
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for type I error rate as
α1 +
∫ α0
α1
∫ 1
0
1[C(p1,p2)≤c]dp2dp1, (7.1)
where C(p1, p2) is some combination function of the p-values such as the Fisher’s combi-
nation function given by equation (4.2) and the inverse normal function given by equation
(4.3), c is the stage 2 critical value obtained by solving expression (7.1) for overall type I
error rate α, and 1[C(p1,p2)≤c] equals 1 if C(p1, p2) ≤ c and equals 0 otherwise. In the previ-
ous chapters, we assumed that we do not have opportunities to stop early so that expression
(7.1) simplifies to ∫ 1
0
∫ 1
0
1[C(p1,p2)≤c]dp2dp1. (7.2)
In this subsection, we consider seamless phase II/III clinical trials with opportunities to stop
early for overwhelming evidence or futility. The values of α1 and α0 can be determined
using the group sequential methods (Brannath et al., 2002) such as the alpha spending
function of Lan and DeMets (1983).
Let q(p1, p2) denote the adjusted combined p-value. For expression (7.2), since
there are no opportunities to stop early, q(p1, p2) = C(p1, p2). To control type I error rate
defined by expression (7.1), Brannath et al. (2002) propose adjusting the combined p-values
as follows
q(p1, p2) =


p1 if p1 ≤ α1 or p1 > α0
α1 +
∫ α0
α1
∫ 1
0
1[C(x,y)≤C(p1,p2)]dydx otherwise.
(7.3)
For the Fisher’s combination function given by expression (4.2), solving expression (7.3)
gives the combined p-value as
q(p1, p2) =


p1 if p1 ≤ α1 or p1 > α0
α1 + p1.p2[lnα0 − lnα1] if p1 ∈ (α1, α0] and p1.p2 ≤ α1
p1.p2 + p1.p2[lnα0 − ln(p1.p2)] if p1 ∈ (α1, α0] and p1.p2 ≥ α1.
(7.4)
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For the normal combination method, there is no closed solution to expression (7.3) so that
numerical integration methods are required.
The type I error rate expression (7.1) was obtained by evaluating the following def-
inition of type I error for a two stage trial
ProbH [p1 ≤ α1] + ProbH [C(p1, p2) ≤ c, α1 < p1 ≤ α0].
Extending this to a trial with three stages (3 stage trial), let αs0 and αs1 (s = 1, 2) respec-
tively denote the futility boundary and rejection boundary at stage s so that the trial stops at
stage s for futility if the adjusted p-value is greater than αs0 and for efficacy if the adjusted
combined p-value is less or equal to αs1. Let ps (s = 1, 2, 3) denote the stage s p-value,
then for a 3 stage trial, the type I error is given by
ProbH [p1 ≤ α11] + ProbH [C(p1, p2) ≤ cα21 , α11 < p1 ≤ α10] +
ProbH [c(p1, p2, p3) ≤ c, α11 < p1 ≤ α10, cα21 < C(p1, p2) ≤ cα20 ],
where cα21 and cα20 are respectively the critical values for efficacy and futility. Following
Brannath et al. (2002), the combined p-value for a 3 stage seamless phase II/III clinical trial
may be given by
q(p1, p2, p3) =


p1, if trial stops at stage 1
α11 +
∫ α10
α11
∫ 1
0 1[C(x,y)≤C(p1,p2)]dydx, if trial stops at stage 2
α21 +
∫ α10
α11
∫ 1
0
∫ 1
0
1[cα21<C(x,y)≤cα20 ]
1[C(x,y,z)≤C(p1,p2,p3)]dzdydx, otherwise.
(7.5)
In equation (7.5), the trial stops in stage 1 if p1 ≤ α11 or p1 > α10 and in stage 2 if
C(p1, p2) ≤ cα21 or C(p1, p2) > cα20 . In general, numerical methods may be required to
evaluate equation (7.5).
7.1.2 Notation and setting of interest
As in Chapter 5, suppose k1 experimental doses are compared to the control treatment
at stage 1 so that the null hypotheses of interest are H1 : θ0 = θ1, ..., Hk1 : θ0 =
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θk1 where θj, j ∈ {0, 1, ..., k1} is a measure of the effectiveness of dose j, with j = 0
corresponding to the control treatment. If the closure principle is to be used to control the
FWER associated with comparing the k1 experimental doses to the control treatment, all
the intersection hypotheses HJ , J ⊆ {1, ..., k1} are constructed. We assume n1 patients
are allocated to each dose j, j ∈ {0, 1, ..., k1} at stage 1 and we respectively denote the
number of successes and toxicities in dose j after stage 1 by x1j and t1j . The probabilities
of efficacy and toxicity at dose j will respectively be denoted by pEj and pTj . The efficacy
data x1 = (x10, x11, ..., x1k1) can be used to obtain the stage 1 p-values p1,J (J ⊆ {1, ..., k1}
corresponding to the constructed intersection hypotheses HJ .
Let K2 ⊆ {1, ..., k1} be the set of experimental doses that remain in the trial for
testing in stage 2 with k2 = |K2|. We assume that there is no adaptation after stage 2 so
that if the trial does not stop after stage 2, all the experimental doses tested at stage 2 and
control continue to stage 3. Let n2 and n3 respectively denote the total sample sizes at
stage 2 and stage 3. We assume that the total stage 2 and stage 3 sample sizes are fixed so
that the number of patients allocated to dose j, j ∈ {0} ∪ K2 with j = 0 corresponding
to the control treatment at stage s (s = 2, 3) is ns/k2. At stage s (s = 2, 3), let xsj and
tsj, j ∈ {0} ∪ K2 with j = 0 corresponding to the control treatment, respectively denote
the number of successes and toxicities on dose j. At the end of stage s (s = 2, 3), the
efficacy data xs = ({xsj}) (j ∈ {0} ∪ K2) can be used to construct a set of p-values ps,J
corresponding to stage 1 p-values p1,J constructed using the stage 1 data.
7.1.3 Conditional power
From the setting above, ps,J denotes stage s (s = 1, 2, 3) p-value obtained from testing
hypothesis HJ , J ⊆ {1, ..., k1}. Given the stage 1 p-value p1,J for hypothesis HJ , as in
inequality (5.3), using the adjusted p-value q(p1,J , p2,J , p3,J) given by equation (7.5), we
can obtain the minimum value of stage 2 p-value p2,J so that hypothesis HJ is rejected at
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the end of stage 2. If a Bonferroni adjustment is used to obtain the p-value for hypothesis
HJ , the minimum p-value testing the pairwise hypothesis comparing the control treatment
to the experimental doses contained in the hypothesis HJ can be obtained as described for
inequality (5.5). Subsequently, as was described in detail in Section 5.2.2, for each possible
number of successes in the control arm at stage 2, x20, we can obtain the configurations of
data such that at least one experimental dose is concluded effective after stage 2.
Suppose we continue to stage 2 with a single experimental dose i, i ∈ {1, ..., k1}. In
Section 5.2.2, for each possible x20, we denoted the minimum number of successes required
at experimental dose i at stage 2, x2i so that dose i is concluded effective at stage 2 by
Bx20(max{p1,J}) for all J with i ∈ J . For a 3 stage seamless phase II/III clinical trial, for
each x20, we are also interested in determining the minimum number of successes required
in dose i so that the trial does not stop at stage 2 with acceptance of the null hypothesis
of no treatment difference. This number is obtained similarly to Bx20(max{p1,J}). To
differentiate between the notation for the two numbers, we denote the minimum number
of successes required to stop the trial at stage 2 for efficacy by BRx20(max{p1,J}) and the
minimum number of successes required to avoid stopping the trial at stage 2 for acceptance
of the null hypothesis by BAx20(max{p1,J}). Thus the expression for the probability of
concluding dose i (i ∈ {1, ..., , k1}) is more effective than the control treatment at stage 2
is
n2∑
x20=0
{
fB(x20;n2, pE0)
n2∑
x2i=B
fB(x2i;n2, pEi)
}
, (7.6)
where fB(x2j ;n2, pEj) (j = 0, i) is the probability mass function of the binomial random
variableX2j with parameter vector (n2, pEj), B = BRx20(max{p1,J}) for all J ⊆ {1, ..., k1}
with i ∈ J .
If the trial does not stop at stage 2, for all possible data in stage 2 for which we
do not stop at stage 2 and for each possible number of successes with control treatment at
stage 3, x30 we can obtain the minimum number of successes required in dose i at stage 3
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so that dose i is concluded effective after stage 3. Let us denote this minimum number of
successes by Bx30(x2,max{p1,J}), where notation reflects number of successes in control
treatment x30, the stage 2 data x2 and stage 1 data max{p1,J}. Then the probability that
dose i is concluded not futile after stage 2 and effective after stage 3 is given by
n2∑
x20=0
{
fB(x20;n2, pE0)
B−1∑
x2i=A
(
fB(x2i;n2, pEi)
n3∑
x30=0
[
fB(x30;n3, pE0)
n3∑
x3i=C
fB(x3i;n3, pEi)
])}
,(7.7)
where fB(x2j ;n2, pEj) (j = 0, i) is as defined above, fB(x3j ;n3, pEj) (j = 0, i) is the prob-
ability mass function of the binomial random variableX3j with parameter vector (n3, pEj),
A = BAx20(max{p1,J}), B = BRx20(max{p1,J}) and C = Bx30(x2,max{p1,J}). Expres-
sion (7.7) contains many summations which would make its evaluation computationally
expensive so that some approximation may be required. As an alternative, we will explore
whether it is easier to use the efficient score statistics described in Section 4.2.1.
The conditional power, the expression for probability of concluding dose i is effec-
tive at stage 2 or at stage 3 given stage 1 data is given by summing expressions (7.6) and
(7.7). The probability of concluding dose i is effective and safe is obtained by multiplying
expressions (7.6) and (7.7) by the indicator that dose i is safe. For example, if an exper-
imental dose is considered safe if its probability of toxicity is less than or equal to some
value γ, expressions (7.6) and (7.7) are multiplied by the indicator I(pTi ≤ γ). We will
denote the conditional power by CPθ where θ is a vector of parameters in the conditional
power.
7.1.4 Predictive power
The probabilities of efficacy and toxicity, pEj and pTj that enter the conditional power are
respectively given by the dose-response models (5.1) and (5.2) so that θ = (αE, βE , αT , βT )′.
As in Section 5.3, the predictive power may be obtained by evaluating the posterior mean
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of the conditional power, that is, the predictive power is given by∫
Θ
(CPθ)pi(θ|x1, t1, n1)dθ, (7.8)
where pi(θ|x1, t1, n1) is the posterior mean of θ given the stage 1 data (x1, t1, n1) obtained
as described in Section 5.3.1. To improve the predictive power given by expression (7.8),
we will investigate how feasible it is to update the distribution of θ with second stage data
(x2, t2) so that the parameter values that enter part of the conditional power that includes
stage 3 data reflect the knowledge gained in stage 2. This is unlikely to be an easy task but
has the advantage of reducing the uncertainty (variance) of the parameter values.
7.2 Uncertainty in the dose-response curves
In Chapter 5, we assumed that the probabilities of efficacy and of toxicity can be modelled
by generalized linear models of known form. However, the investigators may be uncertain
about the dose-response curve so that they would want to consider several models. Klin-
genberg (2009) has proposed a method for estimating the maximum estimated dose (MED)
that incorporates model uncertainty. He proposes including all dose-response curves that
significantly reflect the dose-response signal from the data to estimate the MED by getting
the weighted average of the MEDs from these dose-response models. In future work, we
intend to consider including model uncertainty by obtaining the predictive power possibly
by averaging the predictive power obtained using different models similar to the proposal
of Klingenberg (2009) of estimating the MED.
Klingenberg (2009) gives several dose-response curves in the generalized linear
model family that result into different dose-response shapes such as probabilities increasing
and then dropping. However, these models may not capture the dose-response profile ade-
quately so that further work needs to develop models that are outside the generalized linear
models family. Yin et al. (2006) have proposed models that do not specify any parametric
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form for the dose-response curve. Rather they model probabilities so that it is possible
to induce some relationship such as probability of toxicity increasing with dose level. In
particular, they assume that the probability of toxicity increases with dose because most
investigators assume a monotonically increasing relationship between toxicity and dose.
They do not enforce any ordering for the probability of efficacy since for certain therapy,
probability of efficacy may decrease with dose.
In detail, let pTj be the probability of toxicity at experimental dose j (j = 1, ..., k1),
Yin et al. (2006) model the probabilities of toxicity as follows
φj =


log
pTj
1−pTj
if j = 1
log
(
pTj
1−pTj
− pTj−1
1−pTj−1
)
for j = 2, ..., k1
so that
pTj =


exp(φj)
1+exp(φj)
if j = 1
exp(φ1)+...+exp(φj)
1+exp(φ1)+...+exp(φj) for j = 2, ..., k1.
(7.9)
Modelling probability of toxicity using equation (7.9) ensures that
pj−1 < pj , j = 2, ..., k1,
that is, probability of toxicity increases with dose as required because the terms exp(φj)
are positive. To define the model of efficacy, let pEj be the probability of efficacy at ex-
perimental dose j (j = 1, ..., k1). Yin et al. (2006) model the probabilities of efficacy as
follows
ψj =


log
pEj
1−pEj
if j = 1
log
(
pEj
1−pEj
)
− log
(
pEj−1
1−pEj−1
)
for j = 2, ..., k1
so that
pEj =


exp(ψ1)
1+exp(ψ1) if j = 1
exp(ψ1+...+ψj)
1+exp(ψ1+...+ψj)
for j = 2, ..., k1.
(7.10)
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Expression (7.10) does not impose any order for the probability of efficacy. For further
work on model uncertainty, we will study characteristics of fitting models given by expres-
sions (7.9) and (7.10) and consider including these models in the candidate set of models so
as to capture dose-response relationships not described by the generalized linear models.
7.3 Change of endpoints
The dose selection procedure developed in Chapter 5 focussed on binary outcomes both
at phase II and phase III stage. Posch et al. (2005) present such a trial where in both
stage 1 and stage 2 of a seamless phase II/III clinical trial, binary outcomes are considered.
However, for some therapies as Inoue et al. (2002) explain, the primary outcome in the
phase II study is a binary outcome which is used to plan a phase III study whose primary
outcome is a time to an event outcome. Hence, it would be practically important to design
seamless phase II/III clinical trials with change of primary endpoint from a binary endpoint
to a survival outcome.
Inoue et al. (2002) propose a fully Bayesian seamless phase II/III clinical trial by
using Bayesian tools to plan a trial and make inference from the observed data. Here we just
describe how the binary outcomes are included in the inference. Let Y and T respectively
denote the binary outcome and the survival time. Inoue et al. (2002) assume there will be
censoring after time U and that the binary outcome is observed after time t0 < U . If the
survival time for a patient is less than t0, Y is not observed, that is, Y is observed if T ∗ ≥ t0,
where T ∗ = min(T, U). Using the law of total probability, they write the distribution of T
as follows
f(t) = f(t|T < t0)Prob(T < t0) + f(t|T ≥ t0)Prob(T ≥ t0). (7.11)
Since Y is observed for T ≥ t0, Inoue et al. (2002) use it to learn about the distribution of
T in the second part of equation (7.11). Thus they incorporate Y in the second piece of the
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distribution of T , that is in the second part of RHS of equation (7.11), using the law of total
probability to result in the following mixture distribution
f(t) = f(t|T < t0)Prob(T < t0) +
1∑
y=0
f(t|T ≥ t0, Y = y)piyProb(T ≥ t0), (7.12)
where piy = Prob(Y = y|T ≥ t0). LetW be the indicator that Y is observed or equivalently
the indicator T ≥ t0, Inoue et al. (2002) assume T = T0(1−W ) + (T1 + t0)W , where T0
and T1 are latent survival times with T0 following a distribution f0 not depending on Y and
T1 following the mixture distribution
∑1
y=0 fypiy. Hence expression (7.12) may be written
as
f(t) = {f0(t)}1−W
{
F0(t0)
1∑
y=0
fy(t− t0)piy
}W
=


f0(t) if t < t0
F0(t0)
∑1
y=0 fy(t− t0)piy if t ≥ t0,
where F0(t) = Prob(T0 > t) is the survival function corresponding to f0. The inference is
then made using the distribution of T defined above.
Schmidli et al. (2007) do not consider change of endpoint but they propose a seam-
less phase II/III design that utilize binary and survival outcomes techniques. Schmidli
et al. (2007) consider survival outcomes with right censoring. At both stage 1 and stage
2, survival or censoring time and the binary outcome that denotes whether the outcome of
interest (the outcome that gives survival time) are recorded. Suppose the right censoring
time is U . The analysis is based on the binary outcomes, that is, comparing the number
of events that occur within the censoring time U . To determine the distribution of stage 2
data, the probability of an event of interest is considered Bernoulli(1 − S(U ; θj)), where
θj are the parameters of the survival function S(t) which enter the stage 2 data distribution
when treatment (dose) j is considered for testing at stage 2. At the time of planning the
phase III stage, some of the phase II stage patients will not have an event and will not have
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reached the censoring time U . If the phase III stage planning is done at time t0 < U for
a patient, the probability of an event for this patient in the remaining follow-up time is
(1− S(U ; θj))− (1− S(t0; θj)) = S(t0; θj)− S(U ; θj).
Both the work of Schmidli et al. (2007) and Inoue et al. (2002) consider survival
outcome up to some censoring time U . Schmidli et al. (2007) do not incorporate the sur-
vival time in the analysis but incorporate it the planning by assuming that the probability of
a survival event between time 0 and censoring time U depends on some survival functions.
Inoue et al. (2002) use the survival outcome to make inference but the distribution of the
survival time T is a mixture of distributions for different outcomes of the binary outcomes.
The two approaches underline the complexity of having two endpoints. However, the ideas
in these articles in which the authors use one outcome to determine another outcome and the
technique of surrogate endpoints which we have not yet studied, may offer a starting point
for further work on designing seamless phase II/III clinical trials with change of endpoints.
Chapter 8
Discussion and conclusions
The work in this thesis was based on seamless phase II/III clinical trials. Seamless phase
II/III clinical trials are carried out in two stages; the phase II stage (stage 1) and the phase
III stage (stage 2). After collecting stage 1 data, an interim analysis is done so that there
are opportunities to adapt the trial based on stage 1 results. Possible adaptations in clinical
trials are sample size re-estimation for example as described by Friede and Kieser (2006),
sub-population selection for example as proposed by Zuber et al. (2006) and treatment
selection for example as proposed by Thall et al. (1988), Schaid et al. (1990), Stallard and
Todd (2003), and Schmidli et al. (2007). Our work also focussed on treatment selection in
seamless phase II/III clinical trials but include features that are not included in the above
works on treatment selection.
Most work for treatment selection in phase II/III trials consider candidate treatments
which are distinct treatments. In this thesis, we have considered candidate treatments which
are different doses of the same drug. To incorporate this, we have proposed some dose-
response curves to estimate the probabilities of efficacy and toxicity at the experimental
doses to inform the planning of the phase III stage so that dose selection is based on data
observed over the entire experimental dose range in the phase II stage. This is similar to
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dose-finding phase I studies where it is common to allocate patients to the experimental
doses assuming some dose-response curves. For example, O’Quigley et al. (1990) pro-
posed an exponential curve for a safety model while Whitehead et al. (2006) have proposed
logistic models for both safety and efficacy outcomes. The work in dose-finding phase I
studies generally does not focus on hypotheses testing. However, in phase II/III clinical
trials hypotheses testing is done and the dose selection procedure should be made such that
the type I error is not inflated. The flexible two stage hypothesis tests we assume will be
used to analyze data from the two stages of the seamless phase II/III trials allow the use of
the dose-response curves and also the prior knowledge about dose-response curves without
inflating type I error rates.
Both efficacy and toxicity have been considered explicitly in early clinical trials. For
example Whitehead et al. (2006) have proposed a design applicable to phase I/II clinical
trials. However, safety is often not explicitly included in the dose-selection procedure for
doses to be tested in phase III. For example, at the planning stage, the dose selection pro-
cedure may determine the (predictive) probability that the candidate sets will be concluded
effective after stage 2 and a separate decision is made on whether the promising doses are
safe for further experimentation. The dose-selection procedure that we have proposed con-
siders both the efficacy and the safety of potential doses explicitly. Rather than only focus
on the probability that the dose will be concluded effective after phase III stage, the pro-
cedure uses the joint probability that the dose will be concluded effective and safe by not
exceeding some threshold safety level.
The penalty for safety was considered based on the distribution of probability of
toxicity rather than the distribution of the number of patients who would experience a toxic
outcome at stage 2. This option was preferred for two reasons. If the penalty considered
the probability that the number of patients treated in an experimental dose does not exceed
(γ × n2), where γ is the maximum probability of toxicity that can be tolerated and n2 is
the number of patients randomized to each treatment arm in stage 2, then larger samples
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will be penalized more when the true probability of toxicity is greater than γ and less when
the true probability of toxicity is less than γ. The second reason is that, in practice, safety
data are monitored as the trial continues so that the safety of the drug is evaluated before
all patients have been treated.
In Chapter 6, to study the characteristics of the dose selection procedure, we re-
stricted the doses to be considered for testing at phase III stage to consecutive doses. How-
ever, as described in Sections 5.2.2 and 6.1, this does not reflect a limitation to the dose
selection procedure developed in Chapter 5. The restriction reduces the sets of doses to be
considered for testing in the phase III stage and hence reduces the computation time. Also
continuing with nonconsecutive doses seems practically implausible. However, in some
scenarios it may be reasonable to consider nonconsecutive doses. To demonstrate when it
may be desirable to consider proceeding with non-consecutive doses, consider three doses,
say dose 1, dose 2 and dose 3. Suppose the efficacy dose response curve is such that the
probabilities of efficacy at dose 1 and dose 2 differ very little and the probability of efficacy
at dose 3 is considerably higher than at dose 2. Then if the safety dose response curve is
such that the probabilities of toxicity at consecutive doses are considerably different, then
it would be desirable to proceed to phase III stage with dose 1 and dose 3 rather than with
doses 2 and 3.
We have assumed that efficacy and toxicity are independent given the dose level.
In Section 5.6, we showed by using the conditional efficacy and toxicity models (5.1) and
(5.2), we do not assume marginal independence and that the modelled association between
probabilities of efficacy and toxicity are reasonable. Alternatively the association between
efficacy and safety may be modelled explicitly by introducing a parameter for association.
For example, Yin et al. (2006) include parameters for the odds ratio at each dose to model
the association between efficacy and toxicity. This is likely to capture association better
but would introduce complexity in obtaining the joint distribution of the parameters in the
model and increase the computation time, and we do not think this would make much
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difference on the choice of doses to continue to stage 2.
To summarise, in this thesis, we have proposed a new method for dose selection
in seamless phase II/III clinical trials. The method enables rational choice of doses to
continue to stage 2 while: (1) allowing for the final analysis, (2) incorporating the stage 1
data profile, and (3) incorporating the prior knowledge.
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